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Through the current trend for bioprospecting, marine organisms - particularly algae - are 
becoming increasingly known for their osteogenic potential. Such organisms may provide 
novel treatment options for osteoporosis and other musculoskeletal conditions, helping to 
address their large healthcare burden and the limitations of current therapies. This study 
focused on screening for marine-organism derived osteogenic (promoting bone formation) 
activity, using extracts produced from a wide range of taxonomic groups sourced from the 
west coast of Ireland.  
Initial work detailed the in vitro methods used and their development, such as cell choice and 
optimisation of key assays included throughout the study. Subsequently, once a robust 
methodology was established, a large screen of extracts (supplied by the Marine Institute, 
Galway) was conducted. Initially, this involved testing extracts, produced from a 
DCM/methanol extraction and reconstituted in DMSO or ethanol, for cytotoxicity, 
proliferation and differentiation effects on a human foetal osteoblast (hFOB) cell line. Various 
small scale effects were seen for extracts dissolved in both solvents, along with some 
pronounced cytotoxicity and significant decreases in proliferation and differentiation. 
However, neither extract set notably promoted measures of cell activity and thus extracts 
left over from the original DCM/methanol extraction were also tested. These residues were 
treated by water or alkaline extraction to produce ‘powder extracts’, many of which - despite 
their fairly substantial processing – caused large significant promotions of hFOB proliferation. 
Interestingly, many of the most promising powder extracts were derived from algal sample 
material, particularly those from Rhodophyta.  
Screening work served to identify a promising concentration range to test with powder 
extracts, allowing more focused in vitro testing using human bone marrow derived stromal 
cells (hBMSCs). These primary cells give a better indication of cell response within the human 
body and are therefore more informative than hFOBs used for initial screening work. Powder 
extracts caused substantial promotions of hBMSC activity measures, including proliferation, 
differentiation and mineralisation. Taking powder extracts from the epiphytic red algal 
species Plocamium lyngbyanum as an example, increases compared to control of 
approximately 120% were seen for hBMSC proliferation, +100% for differentiation and 
+200% for mineralisation. In addition to in vitro testing, promising powder extracts were also 
tested in vivo using an operculum area (measuring bone growth) and caudal fin regeneration 
system. Operculum area system results were highly promising, showing large operculum area 
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increases with powder extract treatment. With P. lyngbyanum , increases of between 50 and 
60% were seen over a 3 day growth period, indicating good in vivo potential and supporting 
results seen in vitro. Comparatively, caudal fin regeneration system results were less 
promising, with little significant variation in measures of osteogenesis, regeneration or bone 
mineral density. This is most likely due to differences between extract preparation and 
exposure method between the two systems and is something that will be addressed in future 
work.  
Overall, this study details a substantial screening effort for osteogenic activity in marine-
organism derived extracts, of which powder extracts showed the most potential. Within this 
group, red algae were particularly active, showing an excellent ability to promote osteogenic 
activity in vitro and in vivo. This may indicate that activity will also be maintained in humans, 
helping to promote bone growth in those suffering from conditions such as osteoporosis; 
allowing increases in bone mineral density, a better quality of life and reduced costs for NHS 
services. Future work should focus on elucidating the exact bioactive component of each 
extract and its mechanism of effect.  
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Bone is a bioceramic composite tissue comprised of a basic mineralized collagen fibril unit 
(Olszta et al. 2007), and is both formed and maintained through the diverse interactions of a 
group of cells (Jilka 2003). Bone fulfils many important roles, aiding motility by serving as 
attachment points for muscle and acting as a mineral store (Harada & Rodan 2003; Huiskes 
2000). Clinically, skeletal damage can present a diverse range of treatment challenges, 
ranging from complex fractures (Stufkens et al. 2011) to pathological bone disorders such as 
osteoporosis (Alghamdi, van den Beucken & J. a. Jansen 2014), though all centre around the 
need for stimulation of bone repair (increased osteogenesis). The aim of this project is to 
identify new osteogenic treatments derived from marine sources. To accomplish this we will 
screen extracts, derived from marine organisms collected off the west coast of Ireland, for 
their ability to enhance the proliferation and differentiation of osteogenic precursor cells. 
These organisms were chosen partly to increase the potential/utilisation of Irish marine 
resources and partly due to previous indications of osteogenic activity from marine organism 
(see section 1.3 for more detail).  
 
1.1 Bone structure 
1.1.1 Basic macrostructure  
Bone tissue is comprised of both organic and inorganic material organised at the 
macrostructural level into two main types; cortical and cancellous bone. Cortical bone is both 
hard and dense, forming the outer layer of the tissue as well as the entire shaft of long bones 
(the diaphysis). Cancellous bone on the other hand is located within this shell, towards the 
articular end of long bones (epiphysis), and has a honeycomb-like structure made up of 
interconnecting rods and plates of bone, known as trabeculae (Rho et al. 1998). Cancellous 
tissue is highly porous, with the intervening space between thin trabeculae filled with either 
red (containing haematopoietic stem cells) or yellow (adipocytes) bone marrow. Cortical 
bone also houses bone marrow at its centre, in an area known as the medullary cavity.  
At a nanostructural level the organic component of bone is approximately 90% comprised of 
the fibrous protein collagen type I. Additionally, there are a number of non-collagenous 
proteins present in the extracellular matrix (ECM) (Ravindran & George 2014; Ingram et al. 
1993), which carry out a variety of functions. The non-organic component is comprised of the 




small, thin crystals either in, or upon, collagen fibrils (Weiner & Wagner 1998). This creates 
the mineralized collagen fibril unit, comprised of three helically wound polypeptide chains 
with both water and crystals also present within gap regions of the structure (Olszta et al. 
2007). Individual fibrils associate with each other to form bundles of fibres, which are then 
organised into arrays (figure 1.1). Bone is anisotropic, as collagen fibres are laid down in the 
direction of mechanical loading (Fan et al. 2002), with most healthy adult tissue in the form 
of lamellar bone. Lamellar bone can be thought of as having a plywood like structure, with 
parallel fibril arrays arranged in layers of alternating thickness, each of which at a 30o angle 
to the original (Weiner et al. 1999). As a result, bone generally has excellent mechanical 
properties, though these vary depending upon the bone in question, between 
cortical/cancellous bone and with the age of the person (Rho et al. 1998). In general, bones 
have a high compressive strength and whilst brittle are supported by significant elasticity, 
helping them bear the load of the body and protect vital organs. Further remodelling occurs 
in cortical bone to produce structures known as osteons, formed of concentric rings of 
lamellae around a central, or haversian, channel, which functions as a blood vessel (Olszta et 










1.1.2 Bone at the cellular level; remodelling and the basic multicellular unit 
Bone is a dynamic tissue that is constantly being broken down and reformed in a process 
known as bone turnover or remodelling, ensuring the skeleton remains strong and able to 
cope with its mechanical load (Martin & Seeman 2008). This process is important for mineral 
homeostasis, particularly calcium for which bone is the only reserve (Heaney 2002); as well 
as for healing after damage, such as from fractures or microdamage (Lee et al. 2002). Bone 






remodelling is dependent on a number of different cell types, particularly osteoclasts and 
osteoblasts. Osteoclasts are multinucleated giant cells which function to break down bone 
tissue in a process known as resorption (Boyle et al. 2003). Alternatively, osteoblasts, with a 
morphology almost identical to that of fibroblasts, are the cells responsible for bone 
formation (Ducy et al. 2000). Both of these work together to maintain bone structure and to 
carry out the process of remodelling. A number of other cell types, including bone lining cells, 
osteocytes, osteomacs and T lymphocytes (see figure 1.3) also aid bone maintenance, 
functioning together with osteoblasts and osteoclasts in a group known as the basic 
multicellular unit (BMU) (Kular et al. 2012).  
 
1.1.2.1 Osteoclasts 
Osteoclasts are located on both periosteal and endosteal surfaces and are formed, in a 
process known as osteoclastogenesis, through the fusion of mononuclear macrophages or 
monocytes, derived from hematopoietic stem cells (Boyle et al. 2003). Osteoclastogenesis, 
and therefore also the degree of resorption, is stimulated by two main chemical factors; 
macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor 
kappa B ligand (RANKL) (Raggatt & Partridge 2010). The importance of these cytokines in 
stimulating intracellular signalling pathways was originally demonstrated in mouse model 
studies. Groups including Kong et al. (1999) and Yoshida et al. (1990) showed that genetic 
disruption of the Csf-1 and Tnfs11 genes (responsible for M-CSF and RANKL production 
respectively) resulted in osteoclast deficiency and a tendency towards an osteopetrotic 
(increased density/hardening of 
bones) phenotype.  
As shown in figure 1.2, upon 
maturation osteoclasts can exist 
in two functional states: a non-
polarised motile state, in which 
they migrate to the resorption 
site, and a resorptive state. 
Resorptive state osteoclasts are 
polarised and have specific 
membrane domains, such as an 
organelle free sealing zone 
separating the acidic environment 
Figure 1.2: a simplified representation of osteoclast and 
osteoblast development. Stromal stem cells can interact 
with hematopoietic stem cells to promote osteoclast 
formation. This figure highlights the morphological 
differences between precursors and the mature cell 





required for resorption from the rest of the cell (Kular et al. 2012). In addition to this 
compartmentalization there is conspicuous folding of the plasma membrane in the mature 
cell, creating a ruffled border. This membrane functions to produce a microenvironment 
between the cell and bone surface and to transport acidifying vesicles and ions (Teitelbaum 
2000). These subsequently lower the extracellular pH to 4.5, leading to dissolution of the 
hydroxyapatitie mineral phase of bone beneath the cell. Consequently, the organic collagen 
phase of bone is broken down by the secretion of the lysosomal protease cathepsin K (Gowen 
et al. 1999).  This creates a lacunae/resorption pit on the bone surface and is part of the first 
phase of bone remodelling, termed the initiation phase (Raisz 1999). Figure 1.3 shows the 
BMU in the process of remodelling for both cortical and cancellous bone. Here, the initiation 
phase of remodelling involves osteoclast precursor recruitment, from hematopoietic stem 
cells associated with the bone marrow/blood supply, and their subsequent differentiation to 
















(Sims & Martin 2014) 
Figure 1.3: the basic multicellular unit, located within both trabecular/cancellous bone as well as 
cortical bone. Vascularization and bone marrow are key in both cases, supplying hematopoietic 
precursors which form osteoclasts and MSCs which develop into osteoblasts. These osteoblasts 
may then form bone lining cells or osteocytes. T cells and macrophages are also derived from blood 







1.1.2.2 Osteoblasts  
The second stage of bone remodelling, the reversal phase, is characterised by decreased 
bone resorption and osteoclast apoptosis, whilst the activity of osteoblasts starts to increase. 
Osteoblasts are the cells responsible for bone formation and have a morphology almost 
identical to fibroblasts (Ducy 2000), although mature osteoblasts are cuboidal in shape and 
have a well-developed Golgi apparatus and rough endoplasmic reticulum. These cells are 
derived from mesenchymal stem cells (MSC) present within bone marrow, and have a lineage 
which involves pre-osteoblast commitment and differentiation to the mature osteoblast 
form, culminating with the formation of an osteocyte, bone lining cell or eventual apoptosis, 











Osteoblast differentiation is facilitated by the transcription factor core-binding factor subunit 
alpha-1 (Cbfa1), also known as runt-related transcription factor 2 (Runx-2). Runx-2 is known 
as the master regulator of osteoblast differentiation and is one of the only osteoblast specific 
transcripts (Harada & Rodan 2003; Ducy et al. 1997; Ducy 2000). A number of signalling 
pathways are known to phosphorylate/activate the Runx-2 transcription factor [see section 
1.1.3.1] (Franceschi et al. 2003), the importance of which has also been demonstrated in mice 
mutation studies. Such work showed that mice deficient in Cbfa1 have an absence of both 
osteoblasts and bone, dying shortly after birth (Komori et al. 1997; Otto et al. 1997); whilst 
forced expression of the transcription factor can induce osteoblast gene expression in non-
osteoblastic cells (Ducy et al. 1997). 
 
Figure 1.4: the osteogenic lineage 
from a mesenchymal stem cell 
(MSC). Included are adipocytes 
and support cells which MSCs can 
also form. Also shown are the 
three potential fates of mature 
osteoblasts: lining cell/osteocyte 
formation and cell death. Figure 






Once osteoblast precursors are recruited to the area of remodelling and have differentiated 
to the mature form, the process of bone formation and mineralisation can begin; the 
termination phase.  
The formation of new mineralised bone tissue during remodelling is different to bone 
formation during foetal development, which occurs by intramembranous or endochondral 
ossification. Intramembranous ossification involves the direct development of mesenchymal 
cells into osteoblasts which then form bones including the mandible, clavicle and cranial 
vault; whilst endochondral ossification involves the transformation of a cartilage template 
(formed by chondrocytes) into bone, after vascularisation (de Crombrugghe et al. 2001; Ducy 
2000). In the remodelling process - after the maximum depth of resorption has been achieved 
- osteoblasts congregate at the base of the pit. These osteoblasts then begin to secrete an 
organic matrix, laying down type I collagen fibrils and other non-collagenous proteins to 
produce a layer of un-mineralised tissue (Kular et al. 2012), known as osteoid. Shortly after 
the start of collagen deposition, around day 13 of the remodelling process (Globus et al. 
1998), mineralisation begins. Though the exact mechanism remains unclear, mineralisation 
is known to be regulated by osteoblasts predominantly through secreted factors (Matsuo & 
Irie 2008). For example, crystal formation may be facilitated by ‘nucleators’ such as bone 
sialoprotein (BSP), whilst the membrane associated enzyme alkaline phosphatase (ALP) is 
thought to play a role through regulating phosphorylation of proteins like BSP (Mackie 2003). 
Both BSP and ALP are markers of osteoblast differentiation (figure 1.5) and are upregulated 
at the site of bone formation, with collagen synthesis slowly decreasing and being replaced 
by enhanced mineralisation as the pit becomes filled with osteoid. This eventually results in 
the formation of new mineralised bone tissue, over a period of around 150 days (Kular et al. 







 Figure 1.5: sequential changes in cell markers at different stages along the osteoblast lineage, 





1.1.2.3 Osteocytes, bone lining cells, osteomacs and T lymphocytes 
The remainder of the BMU is made up of cells which support osteoclast and osteoblast 
function. For example, during the termination phase individual osteoblasts become 
entombed within the osteoid, to become osteocytes. Osteocytes are a long-lived, terminally 
differentiated form of osteoblast, which eventually undergo apoptosis (Kular et al. 2012) or 
are digested during resorption (Hadjidakis & Androulakis 2006). They are believed to act as 
mechanosensors due to their extensive connections with each other and cells at the bone 
surface through long filipodial processes, and their ability to influence cellular activity beyond 
their localised area (Hadjidakis & Androulakis 2006). There is increasing evidence that 
osteocytes aid the initiation of remodelling, as microdamage-induced apoptosis of these cells 
correlates with an increase in RANKL (Tatsumi et al. 2007).   
Bone lining cells are also terminally differentiated osteoblasts but their role is much less clear. 
These quiescent cells line most bone surfaces that are not being remodelled, whilst in 
remodelling areas they relocate to form a canopy (as in figure 1.3), creating a 
microenvironment which enhances the localization of factors necessary for remodelling 
(Hauge et al. 2001). Osteomacs - macrophages present on endosteal/periosteal surfaces - 
form a similar canopy, though on a smaller scale, by covering mature osteoblasts. The 
function of this may again be to provide factors for the support of osteoblast mineralisation, 
which they are known to regulate (Chang et al. 2008), or to produce a coupling signal. Finally, 
T and B lymphocytes are also able to influence the activity of the BMU, particularly that of 









The three stages of bone remodelling, initiation, transition and termination, are represented 
in figure 1.6. Whilst the cells of the BMU have specific roles in remodelling they are also 
known to impact the activity of each other, through the production of cytokines, growth 
factors and other molecules e.g.  production of RANKL by osteocytes and T lymphocytes, 
serving to stimulate osteoclast activity.    
A good example of both direct and indirect interactions is the effect of osteoclasts on 
osteoblast recruitment and function, which serves to stimulate the transition phase of bone 
remodelling. Changes in topography through lacunae production can stimulate osteoblast 
activity (Gray et al. 1996), as may recognition of localised factors such as Tartrate-resistant 
acid phosphatase (TRAP), a marker of osteoclast activity and an important modulator of both 
collagen degradation and its synthesis by osteoblasts (Roberts et al. 2007). The resorption 
action of osteoclasts also serves to release factors that are stored in the bone matrix, 
originally laid down by osteoblasts during bone formation. These factors, for instance bone 
morphogenetic proteins (BMPs) and insulin like growth factors (IGFs), alter cell signalling to 
stimulate the differentiation of bone forming cells (Sims & Martin 2014; Kular et al. 2012; 
Matsuo & Irie 2008). In terms of direct interactions a number of regulatory coupling factors 
have been identified, for example Sphingosine 1-phosphate (S1P) (Ryu et al. 2006), Ephrin B2 
and EphB4 (Martin et al. 2010) and semaphorin 4D (Negishi-Koga et al. 2011). Coupling 
Figure 1.6: representation showing the three phases of bone remodelling: initiation, transition and 
termination. Osteoclasts (red) resorb bone, stimulated by RANKL (arrow) produced by osteoblasts. 
Osteoblasts (blue) secret new bone, or osteoid. Regulatory factors can either be liberated from 
existing bone (triangles), be secreted (hexagons) or be coupling factors needing direct cell to cell 






involves a membrane bound molecule on one cell binding to a receptor on another, through 
direct cell to cell contact, bringing about changes in activity. Taking Sphingosine 1-phosphate 
as an example, this signalling sphingolipid is expressed by osteoclasts and subsequently binds 
to its receptor on osteoblasts. This serves to increase osteoblast RANKL production and 
survival, as well as the migration of precursors for both cell types (Sims & Martin 2014; Kular 
et al. 2012; Ryu et al. 2006).  
 
1.1.3 Major signalling pathways 
Direct interactions and regulatory factors produced or liberated by cells, bring about their 
effects through intracellular signalling pathways. When understanding the response of 
osteoblasts and osteoclasts to specific factors or bioactives there are a few major signalling 
pathways that are useful to understand.  
 
1.1.3.1 Osteoblast Wnt-β-catenin pathway 
Wnts are a group of highly conserved glycoprotein growth factors that activate cell surface 
receptors, thus stimulating intracellular signalling pathways controlling a range of cellular 
processes (Gordon & Nusse 2006). In osteoblasts Wnt operates through the “canonical” 
pathway, meaning it impacts β-catenin levels. In the absence of Wnt, β-catenin is held in a 
destruction complex comprised of the proteins Axin, adenomatous polyposis coli (APC) and 
the enzyme glycogen synthase kinase 3β (GSK3β). GSK3β phosphorylates β-catenin causing 
its ubiquitination and subsequent proteasomal degradation, keeping cytoplasmic levels of β-
catenin low. However, if present, Wnt will bind to the co-receptor complex formed of a 
frizzled protein and the low density lipoprotein receptor related protein (LRP) 5/6. 
Consequently, Dishevelled protein is activated which inhibits GSK3β action; causing an 
increase in β-catenin levels, which ultimately activates lymphoid enhancer-binding factor 
(LEF) and T-cell factor (TCF) transcription factors (Hoeppner et al. 2009). These cause changes 
in gene expression that help to promote the early commitment of progenitor cells to the 
osteoblast lineage, as opposed to chondrocyte development (Day et al. 2005). The 
importance of the Wnt-β-catenin pathway has been demonstrated through 
mutation/knockout studies, which showed LRP5/6 to be important in maintaining bone mass 
and strength (Ai et al. 2005; Gong et al. 2001), whilst β-catenin influences osteoblast 





Major inhibitors of this pathway include the proteins Dickkopf-1 (DKK-1) and sclerostin (Lin 
et al. 2009), which bind to LRP5/6 meaning Wnt is unable to associate with the receptors. 
Furthermore, secreted Frizzled-related proteins interact with Wnts directly or bind to Frizzled 
proteins to inhibit signalling (Hoeppner et al. 2009).  
 
1.1.3.2 Osteoblast - Bone Morphogenetic Proteins 
As stated BMPs are one of the best known bioactives used in the treatment of skeletal 
conditions. These dimeric growth factors are part of the transforming growth factor β (TGFβ) 
superfamily and have a variety of roles in cellular functioning (Cao & Chen 2005). Specifically 
in terms of skeletal development, BMP -2, 4, 6, 7 and 9 are known to induce ALP activity in 
preosteoblastic cell lines, increase osteocalcin levels (another late stage protein marker of 
differentiation) and enhance mineralisation (Cheng et al. 2003). Moreover, mice respond 
with increased bone formation after localised calvarial injections of BMP-2 (Chen et al. 1997), 
whilst transgenic mice with a dominant-negative form of BMP 1-b show reduced postnatal 
bone formation (Zhao et al. 2002).  
The effects of BMPs are transduced through an intracellular signalling pathway, which starts 
with the binding of the growth factor to serine/threonine kinase receptors, termed type I and 
type II. Different BMPs bind to the two receptors, which are both necessary for signal 
transduction as the type II receptor transphosphorylates the type 1 receptor (Miyazono 
1999). Subsequently, intracellular signalling is facilitated by Smad proteins, with Smads 1, 5 
and 8 activated by the receptor. These can then form a heteromeric complex with Smad 4, 
which translocates to the nucleus where it activates gene transcription (Miyazono 1999; 
Kawabata et al. 1998). Regulation of the BMP pathway can be both intracellular; through 
Smads 6 and 7 which inhibit the pathway by binding to the type I receptor, and extracellular; 
through Noggin and chordin molecules which form complexes with BMPs (stopping them 


















(Lissenberg-Thunnissen et al. 2011) 
 
 
1.1.3.3 Mitogen Activated Protein Kinase pathway 
The mitogen activated protein kinase pathway (MAPK) involves the sequential activation of 
a series of protein kinases broadly including MAPKKK, MAPKK and MAPK which can be one 
of four main classes: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase, p-
38 MAPKs and ERK5 (Hu et al. 2003). C-Jun N-terminal kinases are involved in stress 
responses and p38 MAPKs in multiple cellular processes, whilst ERKs make up the classic and 
best studied pathway influencing proliferation/differentiation.  
Various growth factors and cytokines act as activators for the ERK pathway, binding to the 
extracellular portion of receptor tyrosine kinases (RTKs) which subsequently become 
phosphorylated. This leads to the binding of growth factor receptor bound protein 2 (GRB2) 
to the RTK and subsequent binding of son of sevenless protein (SOS) and a GDP binding Ras 
protein. The latter is catalysed to produce GTP before leaving the complex to bind to the 
Figure 1.7: 1. BMP binds to receptor II, 2. Receptor II forms a complex with receptor I leading to its 
phosphorylation. 3. Smads 1, 5 and 8 are then phosphorylated and form a complex with Smad 4 
which translocates to the nucleus to influence gene transcription. This signalling pathway is 
regulat d in a number of w ys, including 4. Extracellular inhibitors such as noggin and chordin, 5. 
Receptor inhibitors, 6. Pseudoreceptors and intracellular inhibitors such as 7. Smads 6 and 7. Figure 






effector protein B-Raf (Zhang & Liu 2002). B-Raf subsequently activates MEK 1/2 which in 
turn activates ERK 1/2, a complex which then translocates to the nucleus to influence gene 
transcription. In osteoblasts the activation of this pathway is dependent on the ECM binding 
to β1 subunit containing integrins on preosteoblasts, or regulated through fibroblast growth 
factor 2 (FGF2) (Bokui et al. 2008). Ultimately, the action of the ERK pathway in osteoblasts 
is to accelerate differentiation and aid bone development.  
Whilst the ERK class is the best known pathway example, all classes of MAPKs have important 
roles in regulating gene transcription and cell development. For example, p38 MAPKs are 
activated along with ERKs during osteoblast differentiation, and when inhibited lead to 
decreases in mineralisation and ALP activity (Hu et al. 2003). Furthermore, it is not always 
possible to separate out the actions of the different classes as they often show simultaneous 
activation, as with ERK 1/2 and JNK 1/2/3 after cytokine stimulation (Bokui et al. 2008). This 
is also the case for the other osteoblast signalling pathways mentioned in this section, as 
there is the potential for multiple pathways to be activated at any one time as a result of one 
or more stimulating factors. For example, multiple signalling pathways are known to 
converge on the Runx2 transcription factor, including MAPK and BMP pathways (Franceschi 
et al. 2003), to regulate its expression.   
 
1.1.3.4 Osteoclast  
As previously stated osteoclast differentiation is largely facilitated by M-CSF and RANKL. M-
CSF cytokines bind to the c-Fms receptor on early osteoclast precursors, facilitating the 
survival (Teitelbaum 2000) and proliferation of these cells (Neve et al. 2011; Matsumoto et 
al. 2000). M-CSF is produced by both osteoblasts and stromal cells and, like many of the 
cytokines discussed so far, operates through multiple pathways (Kular et al. 2012). These 
include the ERK1/2 pathway and the P13K/Akt pathway (Ross 2006). P13K/Akt serves to 
degrade or block cell cycle inhibitors such as cyclin D1 and p27/p130, enhancing the 
proliferation of osteoclast precursors (Ross 2006).     
RANKL is a transmembrane protein which is part of the tumour necrosis factor (TNF) 
superfamily. It is expressed by osteoblasts, T-cells and endothelial cells, and is released in 
soluble form through proteolysis (Boyle et al. 2003; Teitelbaum 2000). RANKL supports 
osteoclast differentiation through a variety of different intracellular signalling pathways 
depending on the TNFR-associated cytoplasmic factors (TRAFs) involved. These pathways 




latter as an example, the adaptor protein TRAF6 is phosphorylated upon the binding of 
RANKL to RANK, causing a transduction cascade. This cascade leads to the association of IκB 
kinase (IKK)α, IKKβ and IKKγ to make the IKK enzyme complex, which subsequently 
phosphorylates IκB leading to its ubiquitination and protesomal degradation (Otero et al. 
2010). IκB normally acts to hold NF-κB in a complex preventing its translocation to the 
nucleus, though once degraded NF-κB is free to regulate gene expression. The importance of 
this transcription factor is demonstrated by mutagenesis of its p50/p52 component, which 
causes osteopetrosis in mice attributed to a lack of mature osteoclasts (Franzoso et al. 1997). 
Osteopetrosis is also the outcome from mutagenesis of the cFos component of the 
transcription factor activator protein 1 (AP-1), also stimulated initially by TRAF6 (Grigoriadis 
et al. 1994).  
Whilst p50/p52 subunit proteins and the proto-oncogene cFos are no doubt important for 
osteoclast development, they are not the sole outcomes of RANKL stimulation. Depending 
on the pathway in question there are a variety of consequences, including increased 
expression of genes coding for TRAP and cathepsin K during p38 stimulation (Boyle et al. 
2003). One particularly important associated transcription factor is the nuclear factor of 
activated T-cells cytoplasmic (NFATc1), which is a key osteoclast regulator supporting 
osteoclastogenesis even in those precursors lacking c-Fos (Matsuo et al. 2004).  NF-κB and c-
Jun are known to interact with NFAT (Zhao et al. 2010), whilst p38 signalling enhances 
NFATc1 expression downstream of c-Fos (Huang et al. 2006). In addition to this NFATc1 is 
also upregulated through intracellular calcium signals, via the ITAM pathway which works co-
operatively with RANKL (Zhao et al. 2010).  
The importance of RANKL in osteoclast development means it is a good target for the 
endogenous control of bone resorption. This is mainly mediated through osteoprotegerin 
(OPG), a soluble glycoprotein which acts as a decoy receptor, binding to RANKL and thereby 
preventing its association with RANK, as in figure 1.8 (Hadjidakis & Androulakis 2006). OPG 
is mainly produced by osteoblasts and is therefore another example of the coupling between 
these two cell types. Osteoblasts appear to show sequential changes in the ratio of RANKL to 
OPG expression, supporting the transition between different phases of bone remodelling 









1.2 Clinical Applications  
Treatment for bone defects is highly variable, though in general bone regenerative medicine 
has a triad of key features: a cellular component, a scaffold for tissue growth and the 
inclusion of bioactive/growth factors (Ringe et al. 2002). Where the bone is significantly 
damaged or absent a biocompatible scaffold is often required for tissue growth, whilst the 
importance of the cellular component has already been discussed. On the other hand, 
bioactive factors are a promising area of study, though are the least developed in terms of 
clinical usage (Kanakaris et al. 2009). The term ‘bioactive’ is incredibly broad, referring to a 
compound or substance which is able to elicit a biological effect. However, in this work the 
term will be limited to natural products derived from organisms, specifically focusing on 
marine sources (Gudbjarnason 1999). Bioactives range in structure from small proteins, like 
the more widely used BMPs (Gomes et al. 2012; Kawabata et al. 1998), to extracellular 
calcium ions (Nakade et al. 2001). These factors can be present naturally in the body, as with 
the previous examples, be supplied at increased concentration or be exogenous in their 
origin (Xiao et al. 2002), the latter being the focus of this study.  
 
Figure 1.8: the major factors impacting upon osteoclastogenesis. M-CSF and RANKL bind to 
receptors of macrophages to induce their commitment to the osteoclast phenotype. Each of these 
factors are secreted by stromal cells/osteoblasts which also produce OPG, which binds to RANKL 
thus stopping its association with the receptor. PTH can increase expression of RANKL and M-CSF, 
but can also blunt their expression too. Also shown is the mature osteoclast phenotype polarised 






Various clinical issues are associated with bone tissue, the most common including fracture 
repair and pathological conditions such as osteoporosis, osteopetrosis and Paget’s disease of 
bone. In addition to those with specific conditions, the elderly population also constitutes a 
large treatment group, due to the overall decrease in the structural integrity of bone in later 
life (Riggs et al. 1998).  
 
1.2.1 Fracture 
Trauma can result in bone fractures which tend to heal within 6 to 8 weeks following injury. 
However, complex fractures, or those presenting in patients with pre-existing conditions like 
osteoporosis (Charissoux et al. 2013), are much more difficult to treat. Even straightforward 
fractures may not heal within the expected timeframe, presenting delayed union if healing is 
not observed after 4 months and non-union after 6 months. The accepted rate of delayed 
and non-union is between 5-10%, though in long bone fractures these rates are often higher 
(Tzioupis & Giannoudis 2007). Providing more effective fracture treatment options is 
therefore necessary, reducing morbidity and mortality for patients and lowering healthcare 
costs (Charissoux et al. 2013).  
Current treatment for situations of mal and non-union involve augments to stimulate bone 
healing, the gold standard autograft (bone from the patient), allograft (donor bone), 
demineralised bone matrix (DBM) or synthetic graft material. In graft situations, it is not just 
a scaffold for growth which is important, but also the inclusion of a cellular population 
sufficient to promote healing (Gómez-Barrena et al. 2014). The success of autograft 
compared to other treatments can be attributed to this, as the graft material already contains 
an immunologically compatible cellular component to support bone formation (Hoffman et 
al. 2013). However, the collection of bone from patients can cause morbidity at the donor 
site, increase healing times or may not be suitable for those who are frail (Clarke et al. 2011). 
It is for these reasons that alternate sources like allograft are used, though healing with this 
material is often delayed compared to autograft treatment (Hoffman et al. 2013) (Hoffman 
et al. 2013). Similarly, synthetic grafts designed to have high biocompatibility, such as calcium 
phosphate ceramics, have lower efficacies compared to autograft (Clarke et al. 2011) and 
poorer mechanical integrity (Rezwan et al. 2006). One way of improving outcomes is to 
supplement the material with a cellular component. Taking coral grafts as an example, 
inclusion of bone marrow cells was shown to increase bone surface area compared to 




included for comparison. In a study that did include autograft groups, ankle fusion rates in 
the ankle using MSC supplemented allograft (Anderson et al. 2014), were still lower though 
not to a significant degree.  
Bioactives are another option to increase fracture healing and improve the outcomes of graft 
operations, with the most widely used being that of BMPs. These endogenous growth factors 
are known to be osteoinductive, stimulating bone formation. Currently BMP-2 and BMP-7 
are available for clinical application both in the US (Kanakaris et al. 2009) and UK (Giannoudis 
& Tzioupis 2005). However, whilst their use is becoming more common, trials are still being 
conducted to assess their effectiveness. BMP treatment appears to aid healing in clinical trials 
(Kanakaris et al. 2009; Zimmermann et al. 2009), though the impact and reliability of these 
and similar studies is often limited by small and/or unequal sample sizes as well as poor 
experimental design; problems also present in many earlier trials (Garrison et al. 2007). 
Controversy around the effectiveness of BMPs is enhanced both by their expense (Garrison 
et al. 2007) and the complex nature of fracture treatment, with outcome success variable 
between individuals, gender, age groups and the type of bone being treated. However, it 
appears likely that the use of BMPs will increase with cheaper production methods and 
optimisation of their application to different fracture types (Lissenberg-Thunnissen et al. 
2011). Furthermore, despite the controversy surrounding their effectiveness, the consensus 
appears to be that BMPs show promise in enhancing bone repair. This highlights the 
importance of investigating other sources of bioactives in the search for similar and even 
more effective compounds.    
 
1.2.2 Osteoporosis 
As with many pathological bone conditions osteoporosis stems from a breakdown in the 
regulation of bone remodelling and therefore unbalanced functioning of the BMU. The World 
Health Organisation (WHO) defines osteoporosis as a bone mineral density 2.5 or more 
standard deviations below the average value of the young (female) reference (Kanis et al. 
1994). Based on the WHOs definition it is estimated that 30% of postmenopausal women 
(PMW) suffer from the disease, a percentage which increases with age (Kanis et al. 1994). 
Osteoporosis is characterised by a decrease in bone mass attributed to increased bone 
resorption by osteoclasts and reduced bone formation by osteoblasts. This decrease in bone 
mass is accompanied by degradation of the bone microarchitecture and increased fracture 




of life; particularly PMW, a trait strongly associated with decreasing estrogen levels (Riggs et 
al. 1998; Albright et al. 1941). This is explained at the cellular level through estrogen receptor 
alpha signalling, which increases osteoclast activity and causes shorter osteoblast lifespans 
(Alghamdi, van den Beucken & J. A. Jansen 2014). Additionally, osteoporosis effects bone 
healing, not only through disrupting the regulation of growth factors and cytokines (Pacifici 
1996) but also through impacting MSCs, which show a poorer growth rate in PMW (Marco et 
al. 2005).  
As with any large scale disease estimations, suggestions on affected populations and 
associated costs vary between studies and location. However, one recent and comprehensive 
systematic review aimed to assess the global burden attributed to low BMD, and found that 
that the number of deaths and disability adjusted life years (DALYs) increased from 1990 to 
2010. This represents an almost doubling of the total global burden from 0.12 to 0.21% 
(Sànchez-Riera et al. 2014). Furthermore, a recent report estimated that the economic 
burden of osteoporosis was €37.4 billion for Europe (27 countries) as a whole in 2010, with 
the UK making up a significant €5.4 billion of this total (Hernlund et al. 2013). This is 
particularly daunting considering the prevalence of the condition in aged populations, 
coupled with estimations that by 2030 20% of Europeans and 30% of the US population will 
be over 65 (Christensen et al. 2009). It is therefore in the best interests of patients, 
governments and health services to develop the most effective treatments possible. 
Currently available therapies are numerous, ranging from physical exercise programmes to 
pharmacological treatments (Khajuria et al. 2011). However, all current treatments present 
implementation and efficacy issues, for instance the cost and numerous side effects 
associated with hormone therapy (Khajuria et al. 2011). It would therefore be beneficial to 
develop an effective bioactive to aid bone healing and/or manage bone maintenance in later 
life; allowing for improved healing times and a better quality of life.  
 
Currently available pharmacological treatments of osteoporosis are mostly anti-resorptive 
agents (e.g. bisphosphonates) which inhibit the action of osteoclasts and so preserve 
remaining bone mass (Poole & Compston 2006). Comparatively there has been little 
development of anabolic agents, which increase bone formation and aid bone mass recovery 
through osteoblast stimulation (Canalis et al. 2007). Currently, the only available anabolic 
agent is parathyroid hormone (PTH), which stimulates various osteoblast signalling pathways 




though the cost of 1 months medication is roughly 10 times greater than alternatives (Lau et 
al. 2012) and is currently tightly regulated by the National Institute for health Care and 
Excellence (NICE). To address these limitations novel and recent research on anabolic agents 
has been conducted, such as the work of Negishi-Koga et al. (2011) on semaphorin 4D, a 
molecule expressed by osteoclasts. Semaphorin 4D was shown to bind to its osteoblast 
receptor, Plexin-B1, resulting in suppression of IGF-1 signalling and osteoblast motility. 
Negishi-Koga et al. showed that bone formation could be increased both through gene 
knockout and use of Semaphorin 4D specific antibodies, making this molecule a promising 
target for developing an anabolic osteoporosis treatment. Such research is promising and 
serves to highlight the need for more focused anabolic studies.  
 
1.2.3 Osteopetrosis and Paget’s disease of bone 
Osteopetrosis, commonly called ‘marble bone disease’, is a rare and heritable disease 
characterised by increased bone density (Stark & Savarirayan 2009). It is caused by mutations 
in 10 genes (accounting for 70% of cases) which alter the differentiation and function of 
osteoclasts to reduce bone resorption (Stark & Savarirayan 2009). No effective remedy 
currently exists for this condition, though specialist fracture treatment (Farfán et al. 2015) 
and calcium/vitamin D supplementation are common. Paget’s disease of bone (PDB) is also 
characterised by abnormal osteoclast activity (Kular et al. 2012); accompanied by hyperactive 
and irregular bone formation by osteoblasts, resulting in poor quality tissue. As with 
osteopetrosis the cause of PDB is thought to be genetic, though the exact source of the 
disease is unknown (White & Rushbrook 2013). However, unlike osteopetrosis the disease 





1.3 Marine bioactives; their pathways, effects and potential 
As mentioned, bioactive factors are the least developed member of the triad in terms of 
clinical application. This is no doubt influenced by the vast array of potential sources of these 
factors, e.g. from plant, animal or marine organism sources. Whilst there has been significant 
effort to identify potential bioactives, research is often constrained by the time and cost 
implications of exploratory work, not to mention conservational and yield issues which raise 
feasibility concerns (Proksch et al. 2003). For example, in a recent natural product review 
(Blunt et al. 2017) it was highlighted that a secondary metabolite isolated from the sponge 
Spirastrella mollis had an extremely low yield, limiting its identification and future use. The 
overall dearth of research does imply that novel work may identify potential new and 
possibly efficacious treatments for the clinical issues previously discussed. Marine organisms 
are a particularly promising area to search for such compounds, as they are exposed to an 
extreme range of environmental variables (i.e. nutrient, light and temperature levels) which 
act as a catalyst for specialization and adaptation (Jha & Zi-rong 2004; Smith et al. 2010). 
Furthermore, the difficulties and costs associated with exploiting this huge reserve of 
organisms means they have been even less well-studied than terrestrial taxa. Currently, 
marine bioactives can be easily sourced from commercial by-products, such as fish and 
shellfish remains (Harnedy & Fitzgerald 2013). In terms of our focus on invertebrates, by-
product levels are much lower and whilst dedicated work on single species has been 
conducted, studies are still limited in number and understanding – see table 1.1 for overview 









Genus and species General description Extract?  
Undaria pinnatifida Brown algae Fucoidan 
Ascophyllum nodosum Brown algae Fucoidan (low molecular 
weight) 
Sargassum horneri  Brown algae Raw extract 
Laminaria japonica  Brown algae Fucoidan  
Sargassum siliquastrum Brown algae Sargachromanol G 
Sargassum thunbergii Brown algae Quinone derivatives 
Hizikia fusiforme Brown algae Water by-product 
Cladophora rupestris Green algae Crude extract 
Codium fragile Green algae Crude extract 
Laurencia undulata Red algae Floridoside 
Lithothamnion corallioides Calcareous red algae Aquamin 
Nannochloropsis oculata  Microalgae  Peptide 
Alteromonas infernus Prokaryote Polysaccharide  
Symploca sp.  Cyanobacterium  Largazole (depsipeptide) 
Millepora dichotoma  Hydrocoral Bioactive material 
Porites lutea Stony coral Bioactive material  
Porites lutea Stony coral Biomatrix 
Synularia polydactyla Alcyonarian coral Proteins 
Xenia elongate Soft coral Coral cells 
Montipora digitata  Hard coral Coral cells 
Stichopus japonicus  Sea cucumber  Fucan sulfate 
Haliotis discus hannai Abalone Digested intestines 
Haliotis laevigata Abalone Perlucin protein 
-- Mussels  Adhesive protein 
Crassostrea gigas Oyster Protein 
Nacre (water soluble 
matrix) 
Pinctada maxima  Pearl oyster Individual proteins. 
Low molecular weight 
molecules.  
Pteria martensii Pearl oyster Nacre (water soluble 
matrix) 
Pinctada margaritifera Oyster Proteinase inhibitor. 
Proteins. 
Nacre (water soluble 
matrix). 
Pinctada fucata Akoya pearl oyster Pinctada fucata mantle 
gene 3. 
Protein p10 and other 
novel proteins. 
Table 1.1: the genus, species, general description and extract type of key invertebrates that have 
been tested for their impact on bone cells or tissue. This is not an exhaustive list but demonstrates 
the range of taxa investigated within this field, many of which are referred to in the text. Numerous 
other marine species have had their molecular components determined, many of which show 
similarity to human skeletal proteins/growth factors (as discussed by Green et al. 2013). However, 







1.3.1 Current marine bioactive research 
1.3.1.1 Algae 
One group of marine invertebrates which show promise as a source of bioactives is algae, 
particularly macroalgaes. Within the algal group, fucoidan is one of the best studied extracts. 
Fucoidans are highly sulfated and fucose-rich polymers, found as a heavily branched and 
relatively high yield form in brown macroalgae and a more linear form in echinoderms (Fitton 
2011). These marine polymers are multifunctional, with a range of therapeutic uses from 
anti-inflammatories and anti-virals (Fitton 2011).  
In terms of its effects on bone tissue it appears that the extract has both an anti-resorptive 
and osteogenic potential. Fucoidan extracted from the sea cucumber Stichopus japonicus has 
been shown to inhibit osteoclastogenesis (Kariya et al. 2004), whilst work by Kim et al. (2014) 
demonstrated the same; though with respect to brown algae extracts added to bone marrow 
macrophage cultures. This reduction in osteoclast differentiation was attributed to inhibition 
of RANKL dependent MAPKs and down-regulation of c-Fos and NFATc1 transcription factors. 
However, the precise molecular mechanism through which this inhibition occurs is yet to be 
elucidated, which is a common limitation to studies on this polysaccharide. Despite this, it is 
speculated that fucoidan binds to either RANKL or RANK to inhibit intracellular signalling, an 
action which may be facilitated by its sulphated regions (Kim et al. 2014). 
With respect to osteogenic potential, low molecular weight (LMW) fucoidan can promote 
osteoblast proliferation in vitro. This was measured as increases in the presence of osteoblast 
markers including ALP and type 1 collagen in 3D (S. Igondjo Tchen Changotade et al. 2008) 
and 2D culture (Y.-D. Cho et al. 2009; S Igondjo Tchen Changotade et al. 2008). The in vitro 
potential of fucoidan was also demonstrated in work by Pereira et al. (2014), whereby extract 
treatment increased osteogenic differentiation as measured by ALP, osteopontin, Runx2 and 
calcium deposit formation in adipose tissue-derived stem cells ADSCs. However, one 
limitation of current published studies is a lack of in vivo testing, which may simply be a 
function of the early developmental stage of much of this work. Pereira et al. (2014) did make 
efforts to address this, through use of coated biphasic calcium phosphate implants in mice, 
though no significant effect of fucoidan coating on bone formation was observed. This may 
indicate that fucoidan would be better applied to stimulate ex vivo osteogenic differentiation 
before in vivo re-implantation, though more testing is required to confirm this. Alternatively, 
it may be that the drug delivery method is important, and that direct injections or coupling 




To date the most comprehensive study completed on fucoidan is that of Kim et al. (2015), 
which aimed to elucidate the complex mechanism by which the extract stimulates MSC 
differentiation into osteoblasts. ALP, mRNA levels of multiple other markers and alizarin red-
S (AR-S) staining was used to determine osteoblast differentiation and mineralisation, whilst 
western blotting was also conducted, including antibodies for various intracellular signalling 
pathway proteins. The results indicated that BMP2-Smad 1/5/8 signalling was responsible for 
stimulating osteoblast differentiation through activation of ERK and JNK pathways.  
Whilst fucoidan is one of the better known bioactives there are other marine algae extracts 
which also have an effect on bone homeostasis. Extracts from the brown algae Sargassum 
horneri are known to stimulate osteoblastogenesis and inhibit osteoclastogenesis in vitro in 
preosteoblastic and monocyte cell lines (M Yamaguchi & Matsumoto 2012). Similar in vitro 
work was conducted using rat femoral tissues, which demonstrated the ability of S. horneri 
extracts to increase their bone calcium content (Uchiyama et al. 2004) and inhibit bone 
resorption (Uchiyama & Yamaguchi 2002). Such work complements in vivo tests, which 
indicate that S. horneri extracts have a preventative effect on bone loss in streptozotocin-
diabetic rats (Uchiyama & Yamaguchi 2003). Furthermore, there has even been a basic 
human trial investigating the effect of oral intake of the algae on bone metabolic markers 
(Matsumoto et al. 2008). Despite being limited by very small sample sizes, this study reported 
an inhibitory effect of the extract on bone resorption, as determined by decreased levels of 
circulating resorption markers such as TRAP, and is one of the few human trial studies 
conducted for any marine based compound. As with fucoidan, the main limitation to the S. 
horneri body of work lies in identifying the active component of the extract, which appears 
to be different for bone stimulation and suppression of resorption (Uchiyama et al. 2004). 
Another brown algae extract which has been tested both in vitro and in vivo is Hizikia 
fusiforme (Jeong et al. 2016). Specifically, this study tested a hot water by-product of the 
algae which contained high polysaccharide levels and was shown to stimulate ALP activity 
and BMP-2 levels in mouse myoblast C2C12 cells. Furthermore, in vivo stimulations of 
skeletal activity were confirmed in zebrafish, ovariectomized mice and mouse calvaria bones 
(Jeong et al. 2016). A final brown algae based study investigated quinone derivatives from 
Sargassum thunbergii, finding that treatment with a crude extract containing these 
derivatives was able to enhance osteoblast differentiation (Kim et al. 2016). 
In addition to Phaeophycae, green and red algae also show examples of extracts which are 
able to stimulate osteogenic activity. For example, extracts from two marine green 




activity. These extracts were enriched in phenolic compounds and able to stimulate 
mineralogenic activity of a fish bone-derived cell line, as well as 1.5 fold increases in 
operculum area of juvenile zebrafish (Surget et al. 2017). Floridoside is the best example of 
a red algae derived osteogenic bioactive. This glycerol glycoside metabolite of Laurencia 
undulata (amongst other red algae) is known to promote differentiation of osteoblast D1 
cells, as well as increasing ALP levels, mineralisation and expression of factors including type 
I collagen, Runx-2 and Osterix (Ryu et al. 2015). 
The studies discussed appear to indicate that algae may be a promising reserve of bioactive 
compounds, whilst the ease of sourcing these inshore and shallow water eukaryotes makes 
them a likely commercial source. However, it is apparent that more in vivo studies are 
needed, as well as a focus on the mechanism of resorption inhibition and the active molecular 
component of algal extracts.   
 
1.3.1.2 Aquamin   
Aquamin is a food supplement derived from the red algae Lithothamnion corallioides, and 
contains calcium, magnesium and 72 other trace minerals (Gorman et al. 2011). Though an 
algae, L. coralloides has been included separately here due to its calcareous skeleton which 
distinguishes it from the previously discussed non-mineralised algal species. L. corallioides is 
normally found on muddy or sandy substrates at less than 20m depth, in aggregations of 
unattached algae known as maerl beds (Wilson et al. 2004). It is from these beds, with a wide 
European (including western Irish and British shores) and more northern distribution, that 
maerl is collected before it is ground into the commercial product known as aquamin. 
Currently, aquamin is solely licenced to and produced by Marigot Limited (Marigot, Cork, 
Ireland).  
Mineralising organisms like L. corallioides are an obvious choice when searching for extracts 
to promote bone health due to their structural similarities, tendency to contain similar key 
molecules (David W Green et al. 2013) and high mineral content. The latter is the theoretical 
basis of aquamin, as there are well established links between BMD and the intake of minerals 
such as calcium, magnesium and zinc (Palacios 2006).  From a cellular perspective O’Gorman 
et al. (2012) investigated the ability of aquamin to enhance the mineralisation of a pre-
osteoblastic cell line. Mineralisation did increase, though only at the latest time point (day 
28), whilst other markers of osteoblast activity, for instance proliferation measures, did not 




enhanced when vitamin D is included with aquamin treatment, as compared to levels in 
osteoblast cultures treated with only aquamin or control solutions (Widaa et al. 2014). These 
studies appear to indicate aquamin has potential to increase mineralisation, though further 
work is needed.  
Aquamin was tested in vivo by inclusion in the food of mice given a western style diet, which 
is known to detrimentally impact bone strength and mineralization (Aslam et al. 2010). 
Aquamin was shown to negate diet related bone defects, further supporting its potential to 
enhance mineralisation. Alternatively, the supplement may be acting by increasing bone 
turnover rather than mineralisation, as supplementation studies on horses showed enhanced 
levels of osteocalcin and type I collagen relative to limestone controls (Nielsen et al. 2010).  
Interestingly, despite a lack of more basic studies, two randomised control trials have been 
conducted, aimed at assessing the efficacy of aquamin supplementation in treating knee 
osteoarthritis (Frestedt et al. 2009; Frestedt et al. 2008). These studies reported 
improvements in outcome measures of mean walking distance and range of motion for 
aquamin treatment compared to controls. However, these results are questionable due to 
the short study periods (12 weeks), lack of long term follow up and small sample sizes used. 
Overall, further in vitro and in vivo studies are required before the true potential of aquamin 
supplementation becomes apparent. However, irrespective of its treatment prospects L. 
corallioides is unlikely to be a long term resource, as it has a slow growth rate (1mm) and is 




Another calcareous based extract, and one which is supported by a considerable body of 
research, is nacre. Nacre, also known as mother of pearl, is the lustrous aragonitic inner layer 
found on molluscan shells in taxa such as mussels and abalone. Like bone, nacre has both 
inorganic and organic components, with an organic shell matrix comprised of proteins, 
glycoproteins and polysaccharides which then serve as a template for calcium carbonate 
mineralisation (Marie et al. 2009). 
Research on nacre has been conducted since the early 1990’s, with initial in vitro work 
demonstrating its capacity to stimulate the mineralisation of human osteoblasts (Silve et al. 
1992). The most interesting of these early studies investigated the ability of nacre to aid bone 




the blood of patients before being injected into the defect site of eight middle-aged female 
patients. The results showed no evidence of toxic effect and also demonstrated enhanced 
mineralisation and good biodissolution of nacre within the area of injection (Westbroek & 
Marin 1998). Since this early work there has been a surge of research effort including in vitro 
and in vivo studies, as well as those specifically focusing on the proteins and mechanisms 
involved in enhancing cellular activity; making nacre an excellent case study of bioactive 
research.   
A good example of the in vitro work conducted used water soluble matrix (WSM) extracted 
from the oyster Pinctada fucata (Chaturvedi et al. 2013). This study demonstrated both the 
ability of nacre to enhance osteoblast differentiation (increased Col-I, osteocalcin and ALP 
expression) and its ability to scavenge free radicals, suggesting an antioxidant potential that 
may also support bone regeneration.  WSM has also been shown to increase BMD in an 
ovariectomized mouse model of osteoporosis (Kim et al. 2012), in part attributed to 
increased Runx2 and Fos-related antigen-1 expression as a result of JNK pathway stimulation 
in osteoblasts. Furthermore, the extract suppressed actin ring formation and RANKL- induced 
up-regulation of c-Fos and NFATc1 in osteoclasts.  Other In vivo work showed nacre implants 
into rat femurs supported new bone formation, implant/bone fusion and increased 
expression of numerous markers indicative of increased BMU action (Liao et al. 2002). 
As the osteogenic potential of nacre is well established numerous studies have worked 
towards identifying active components within the extract. At a basic level, nacre WSM is 
known to be made up of a variety of fractions, containing amino acids of varying size and 
composition (Almeida et al. 2000). Moreover, numerous proteins have been identified within 
the nacre of different species, many of which are thought to have roles in regulating bone 
tissue. For example, proteomic nacre analysis of the oyster Crassostrea gigas found four 
novel proteins thought to aid in shell mineralization; with structures homologous to 
endogenous human proteins also with roles in osteogenesis (Oliveira et al. 2012). Novel 
single proteins have also been identified, for example p10  (Zhang et al. 2006), P60 (Lao et al. 
2007) and PFMG3 (Wang et al. 2011b), all sourced from the pearl oyster Pinctada fucata. All 
three of these studies demonstrated the proteins’ ability to enhance the crystallisation of 
calcium carbonate in vitro. Each also established their ability to enhance the differentiation 
of osteoblast cell lines through various marker assays, though the work of Wang et al. (2011) 
was the most comprehensive. Additionally, nacre appears to contain proteinase inhibitors of 
varying molecular weights, which may help to conserve proteins important for processes 




molecules, which were shown to increase osteoblast mineralisation, Col-1 expression and 
mRNA levels of Runx2 and osteopontin (Rousseau et al. 2008). Overall then, these studies 
indicate that the effect of nacre, regardless of species, is due to the interaction of a range of 
bioactive molecules present within the extract. However, the exact structure and action of 
the majority remain to be identified.   
 
1.3.1.4 Assorted taxa 
Corals, of the phylum Cnidaria and class Anthozoa, are another group which have received 
surprisingly little attention. This phylum includes mineralising species, which have a skeleton 
comprised of calcium carbonate either in the form of calcite, aragonite or a mixture of the 
two, as with the Scleractinian or stony corals (Rogers 1999). Like those taxa containing nacre, 
coral skeletons also include an organic phase, comprised of proteins, polysaccharides, lipids 
and glycosaminoglycans (David W Green et al. 2013). Marine invertebrates such as corals 
have a long evolutionary history of developing proteins and genes that govern 
biomineralisation, many of which are highly conserved and analogous to human variants 
(David W Green et al. 2013). For instance, in scleractinians both soluble and insoluble 
components of the organic matrix are known to influence calcium carbonate precipitation 
(Goffredo et al. 2011). More specifically, multiple species express BMP2/4 orthologs, which 
show specificity to murine BMP receptors despite the taxonomical distance between the two 
groups (Zoccola et al. 2009). This indicates incredible conservation of the protein sequence 
over time and suggests other proteins of skeletal importance may also be present within 
coral tissue. The presence of these bioactives is also supported by the regeneative ability of 
corals, many of which show relatively rapid skeletal repair, particularly those species living in 
shallow water, high-energy environments (Kramarsky-Winter & Loya 2000). Despite their 
significance as a potential source of bioactive molecules, research using coral extracts is 
limited. Instead, the majority of research has focused on their potential as a scaffold material 
for graft procedures, due to their structural and compositional similarities to human bone 
(Clarke et al. 2011). 
There are numerous examples of taxa and extracts that have only undergone initial 
screening, many of which show osteogenic potential. For example, the in vitro potential of 
abalone gastro-intestinal digests from Haliotis discus hannai were investigated using an 
osteoblast-like cell line (MG-63), and subsequently showed increased ALP and mineralization 




expression, thought to be a result of MAPK pathway activation. Similar results are presented 
for a range of extracts, even for microalgae byproducts (Nguyen et al. 2013) and a 
depsipeptide (largazole) sourced from cyanobacteria (Lee et al. 2011). Another interesting 
prokaryote is Alteromonas infernus, which is a deep sea species known to produce a high 
molecular weight polysaccharide. This oversulfated polysaccharide was shown to increase 
chondrogenesis in vitro, via the MAPK pathway, and may consequently be a potential therapy 
for cartilage repair (Merceron et al. 2012). Mussel adhesive proteins are also of interest as 
they are known to increase cell proliferation and osteogenic differentiation, and can be used 
to easily coat graft materials (Hong et al. 2012). This, along with their biocompatibility and 
biodegradability, makes them promising adjuncts to synthetic grafts. These preliminary 
studies, looking at various markers of cell-stimulation potential, highlight the diversity of 
marine bioactives and indicate that it is primarily research effort which determines success 
within this field.  
 
1.3.2 Challenges  
Conservation concerns are an important consideration when looking for potential bioactive 
sources. Taking corals as an example, it is well known that the world’s populations are a 
serious conservation issue (Hughes et al. 2010), with both cold and warm water species 
showing declining abundance and many listed in the convention on international trade in 
endangered species (CITES) list (Harriott 2003). Reasons for the decline are varied, including 
increasing water temperature and ocean acidification associated with climate change, as well 
as damage from trawling, dynamite fishing, aquarium stocking and various forms of 
anthropogenic pollution (Hughes et al. 2010). This, coupled with slow growth rates, long time 
to maturity and relatively limited ecological niches, means further declines in coral numbers 
are likely. The sustainability of these invertebrates as a source of bioactives is therefore 
questionable, although some species like Millepora dichotoma are more abundant and show 
promise for aquaculture production (Abramovitch-Gottlib et al. 2006). Though corals are 
perhaps an extreme example in terms of sustainability, many marine invertebrates suffer 
from low abundance or long development cycles. In these cases bacterial cultures (modified 
to express the bioactive) or synthetic production are potential solutions, though complex 
molecule structures often make this challenging (Proksch et al. 2003).  
Aquaculture may become a necessity if commercial bioactives are to be sourced from marine 




material for significant extraction (Proksch et al. 2003). In particular, secondary metabolite 
yields tend to be very low, though structural and non-metabolic proteins (like many of those 
with skeletal importance) tend to have higher yields (David W Green et al. 2013). It is not just 
a question of tissue yield but also the costs and difficulties associated with collecting enough 
quality specimens in the first place, an issue which is further complicated when sourcing deep 
sea species. Advances in technology, like the development of sophisticated remote operated 
vehicles (ROVs), is beginning to make collection of these specimens more feasible.  
From a more general perspective there are also a number of limitations to more widely 
available bioactives, growth factors and other therapies. For example, as mentioned 
previously, BMP 2/9 are currently available for clinical use in the UK and US. However, trials 
involving these bioactives have been limited to date and as a result their efficacy is still 
debated (Garrison et al. 2007), despite usage becoming more common. Alternatively, 
hormones such as teriparatide can be used to stimulate anabolic action of the BMU. Whilst 
effective, treatment courses are currently long, expensive and require daily injections, with 
any positive effects quickly lost after ceasing treatment (Black & Rosen 2016; Canalis et al. 
2007). One interesting and developing treatment option is gene therapy, which involves the 
transfer of target genes which code for proteins which stimulate bone 
formation/regeneration. This therapy has already been shown to aid bone healing, though 
there are several issues with its implementation (Balmayor & van Griensven 2015). For 
example, therapy may also stimulate the immune system which can interfere with treatment, 
whilst in rare cases tumours can form because of poor DNA integration. Furthermore, if 
viruses are used for gene transfer there are also toxicity and disease concerns that need to 
be addressed.  
 
1.3.3 Summary  
Throughout this narrative the complexity of bone, its remodelling and the myriad of effects 
bioactives can have on cells of the BMU have been introduced. Remodelling encompasses a 
host of different cellular activities in a complex series of events, which can be influenced in 
multiple ways by localised factors. For example, a bioactive may serve to stimulate the 
recruitment and commitment of MSCs to the osteoblast lineage, as with nacre powder 
(Flausse et al. 2013). Similar anabolic bioactives may increase the proliferation of progenitor 
cells leading to greater numbers of osteoblasts carrying out bone formation. Alternatively, 




mineralisation, as shown during aquamin treatment (Widaa et al. 2014). However, in addition 
to promoting osteoblast activity, a promising extract might also limit osteoclastogenesis and 
the activity of these cells. The complexity of this situation increases when using a raw, whole 
or relatively unrefined extract, as the material may contain any number of bioactives having 
different or competing effects. When working with extracts to identify novel compounds it is 
therefore important to determine their primary effects, using both in vitro and in vivo 
techniques, and if promising also clinical trials. Two of the most challenging aspects of this 
work are isolating the active compound(s) and determining the mechanism of effect, such as 
the intracellular signalling pathway being stimulated or repressed. In addition to all of these 
considerations the source taxa also needs to be sustainable, have a high abundance, produce 
large extract yields or be suitable for aquaculture.      
In this body of work a large number of extracts will be screened for their osteogeneic activity. 
This will be primarily focused on measures of human foetal osteoblast (hFOB) activity (cell 
line), with the basic screen measuring cell proliferation and ALP activity (differentiation 
measure), whilst also ensuring no cytotoxicity of potential treatments. After determining 
promising extracts a more detailed screen of osteoblast activity will be conducted, using 
human bone marrow derived stromal cells (hBMSCs). This is the best in vitro method of 
assessing osteogenic potential (David W Green et al. 2013), as cell lines are not fully 
representative of a human tissue response. Subsequent to this body of work the in vivo action 
of extracts will be determined, using zebrafish as a model for skeletal growth through a 
partnership at the University of Algarve. This diverse range of experiments will allow varying 
forms of osteogenic activity to be identified at different developmental stages, and is thus 

















Chapter 2  









Before starting any experiments, it is important to choose appropriate methods - which have 
the best chance of providing useful and reliable results. It is also crucial to properly analyse 
and optimize these methods, to ensure they are accurate, precise and therefore suitable 
choices. This chapter contains basic protocols for many in vitro techniques used throughout 
this thesis, on both a human foetal osteoblast (hFOB) cell line and human bone derived 
marrow stromal cells (hBMSCs). It also contains highlights from a significant body of 
optimisation studies for both cell types.  
Work presented here (summarised in figure 2.1) was mainly completed during year one of 
the PhD, as issues with different methods became apparent. However, some optimisation 
spanned the entire three years, whilst other assays – particularly those focusing on cell 
differentiation – were not used until later in the project. Any protocols listed in section 2.2 
are final, fully optimised versions, whilst remaining chapter sections explain how and why 
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Figure 2.1: flow diagram detailing the sections/methods discussed in this chapter. Blue colouration 





2.2 General in vitro methods 
2.2.1 XTT – cell viability 
To quantify the number of viable cells the In Vitro Toxicology Assay Kit XTT based, or ‘TOX2’ 
kit, was used (Sigma Aldrich, UK). The method is simple to perform and gives an indication of 
the cytotoxicity associated with a treatment, as well as the degree of metabolic activity.  
 
XTT (2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) is 
yellowish in colour when first added to cell solutions and through normal cell metabolism, 
mitochondrial dehydrogenases reduce the tetrazolium ring to produce a red and soluble 
formazan product (Riss et al. 2004). After incubation, absorbance in each active well can be 
measured to determine formazan levels and therefore give an indication of metabolic activity 
levels. The assay was performed according to the manufacturer’s instructions. Briefly, the 
assay substrate was reconstituted in culture medium and 40 µl, representing 20% of the total 
volume, was added to each active well on the culture plates. After incubating for 4 hours, the 
wells were thoroughly mixed and a 100 µl aliquot was transferred to a clean assay plate. 
Absorbance was read at 450 nm on a Tecan microplate reader with Magellan software 
(GENios, USA).   
 
2.2.2 Lactate dehydrogenase – cytotoxicity 
The CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega) was used to quantify the 
amount of lactate dehydrogenase present within a sample. This enzyme is constrained to the 
cytoplasm of healthy cells with preserved membranes, but is released into the culture 
medium from dead or dying cells (G. Wang et al. 2012). As such, it is a good measure of the 
cytotoxicity of a substance/treatment. This assay benefits from being able to detect low level 
cytotoxicity and is therefore suitable for use after short culture periods, such as the day 1 
time points used in this thesis.  
The assay works through a coupled enzymatic reaction which takes place over a 30-minute 
interval. Simply, those cells that are damaged release LDH, which then catalyses the 
conversion of lactate to pyruvate, via the reduction of NAD+ to NADH. Concurrently, the 
enzyme diaphorase utilises NADH and tetrazolium salt (INT) to produce NAD+ and formazan, 
a dye product which is red in colour. The amount of formazan and therefore the degree of 





In general, cells were given a 24-hour attachment period and 24 hours (or sometimes 4 days) 
of exposure to treatment, before conditioned medium was removed and LDH level quantified 
according to the manufacturer’s instructions. Firstly, 50 µl of conditioned medium was 
added, in duplicate, to test plates. Negative controls were medium and medium+vehicle. 
Positive controls were a kit control and lysate from an aliquot of a known amount of cells, 
which had been pre-treated with 10 µl lysis solution (9% v/v Triton X-100) per 100 µl cell 
media. The assay substrate was reconstituted in buffer solution and 50µl was also added to 
each well. Each test plate was then covered in foil and incubated for 30min at room 
temperature, allowing the coupled enzymatic reaction to proceed. The reaction was stopped 
by the addition of 50 µl of stop solution (1 M acetic acid) to each well, before absorbance 
was read at 492 nm.  
 
2.2.3 PicoGreen – cell proliferation 
The Quant-iT™ PicoGreen® dsDNA Assay Kit (Molecular Probes 2008) is used to quantify the 
amount of double stranded DNA (dsDNA) present within a sample. This is accomplished 
through use of a PicoGreen reagent, which stains for nucleic acids.   
Following 1, 4 and 7 days’ exposure to extracts, medium was removed and the cells were 
washed x 2 with PBS or alkaline buffer solution (5 M NaCl, 1 M Tris-Cl pH 9.5, 1 M MgCl2). 250 
µl of lysis buffer (0.2 % Triton X-100 in PBS or alkaline buffer) was added to each well which 
was then subjected to at least 1 cycle of freeze (-80°C) and thaw (+37°C). This ensured that 
cell membranes were completely lysed through ice crystal formation, therefore releasing all 
dsDNA into solution. Sample wells were then mixed and 50 µl of each lysate was added to 
black assay plates in duplicate. A standard curve of 1 mg DNA/ml, 100 ng/ml, 10 ng/ml, 1 
ng/ml and 0 ng/ml was added in duplicate to each assay plate. Finally, 50 µl of PicoGreen 
reagent was added to all wells and fluorescence levels were read at excitation 480 nm, 
emission 520 nm.    
 
2.2.4 Crystal violet – cell proliferation  
Crystal violet (CV) stains for adhered cells by binding to DNA and proteins, and was used in 
this thesis to measure cell proliferation (Feoktistova et al. 2016). Cells were cultured in test 
plates for either 1, 4 or 7 days before the assay was completed. Culture medium was first 
removed by aspiration. Subsequently, cells were fixed through a 30-minute incubation at 





PBS). This fixative was then removed, test wells were washed 2x with dH2O and left to air dry. 
Cell monolayers were stained for 30 minutes at room temperature using 100 µl of CV solution 
per well (at 0.1% concentration, in dH2O and filtered before use). After staining, the CV was 
removed, the monolayer was washed 2x with dH2O and air dried. Finally, this dye was 
extracted from monolayers by the addition of 100 µl of 1 M acidified methanol (1 ml of 1 M 
HCl per 100 ml methanol). Plates were read at 585 nm and blanked on acidified methanol.  
 
2.2.5 Alkaline phosphatase – cell differentiation 
Alkaline phosphatase (ALP) is an enzyme produced by osteoblasts, which catalyses the 
conversion of p-nitrophenyl phosphate to p-nitrophenyl, which is yellow in colour. This colour 
change can then be quantified giving an indication of alkaline phosphatase activity and 
therefore cell differentiation. Briefly, cells were grown for 7, 14 and 21 days, before being 
washed with an alkaline buffer solution (5 M NaCl, 1 M Tris-Cl pH 9.5, 1 M MgCl2). Cells were 
then lysed by addition of 250 µl of buffer - containing 0.2% Triton X-100 - and left to gently 
mix for 20 minutes on ice, before being stored at -80°C. Upon defrosting, 50 µl from each 
well was added to a test plate in duplicate. 200 µl of conditioned medium, consisting of 
alkaline buffer solution (Sigma-Aldrich, UK) and p-nitrophenyl phosphate substrate (1 mg/ml; 
Sigma-Aldrich, UK), was added to each well. Each test plate was then covered in foil and 
incubated for 30 minutes at 37°C, allowing the coupled enzymatic reaction to proceed. The 
reaction was stopped by the addition of 50 µl of stop solution (3 M NaOH) to each well before 
absorbance was read at 450 nm. Finally, ALP readings were normalised to DNA concentration 
in the same lysate, determined via PicoGreen assay, to account for variances in cell number.  
 
2.2.6 Mineralisation – cell differentiation 
Mineralisation is a feature of mature osteoblasts, as the cells produce factors which control 
mineral production (Matsuo & Irie 2008). To detect this, cells were cultured in osteogenic 
supplemented media for either 7, 14, 21 and 28 days (in 24 well plates, first coated with 
excess 0.1mg/ml Poly-L-lysine [70,000-150,000 molecular weight] solution). Subsequently, 
they were washed 3x with PBS (1 ml) and fixed with 4% PFA for 1 hour at room temperature. 
Fixative was then removed and wells washed 3x with MiliQ water (1 ml). 40 mM alizarin red 
S, adjusted to pH 4.2 using ammonia hydroxide, was then added to each well (0.5 ml). Plates 
were left to stain at room temperature for 15 minutes, with gentle agitation on an orbital 





MiliQ water, before being left to air dry. Finally, wells were de-stained using a solution of 10% 
cetylpyridinium chloride in sodium phosphate (pH 7). A 100 µl aliquot of each treatment was 
collected, transferred to a 96 well plate and then used for measuring absorbance at 550 nm.  
 
2.3 Human foetal osteoblast cell line 
2.3.1 Choice of cell line 
Many experiments within this thesis, particularly preliminary ones, were conducted on the 
hFOB 1.19 (ATCC® CRL-11372™, Virginia, US) cell line. This cell line was originally established 
from biopsies of a spontaneous miscarriage, by transfection of primary cultures with a gene 
coding for a temperature sensitive mutant (tsA58) of the SV40 large T antigen (Harris et al. 
1995). These cells were also transfected with a gene coding for neomycin (G418) resistance, 
resulting in a cell line that could be positively selected for by culturing with antibiotics; in this 
case geneticin, which would otherwise disrupt ribosome action and protein synthesis. hFOBs 
were shown to proliferate rapidly at the permissive temperature of 33.5°C, whereas at 39°C, 
division was greatly reduced and cell differentiation increased. Osteoblast phenotype was 
also confirmed through expression of osteonectin, osteopontin, bone sialoprotein, type I 
collagen, alkaline phosphatase and the osteoblast specific transcript osteocalcin (Harris et al. 
1995). Further characterization showed that hFOBs had anomalies in only 1-2 chromosomes, 
were able to form extracellular matrix in vitro and were capable of in vivo bone growth in a 
mouse model (Subramaniam et al. 2002).  
Since their characterization, hFOBs have been used for a variety of different applications, 
such as evaluating the mechanism of established bone regulators, like BMP-2 and TGF-β 
(Eichner et al. 2002), as well as anti-resorptive bisphosphonates (Reinholz et al. 2000).  
Furthermore, hFOBs have been used to assess more novel treatments, like the osteogenic 
potential of plant derived Osthole (Kuo et al. 2005) and Myricetin (Hsu et al. 2007), as well 
as marine organism inspired scaffolds for tissue growth (Clarke et al. 2016). Myricetin (a 
flavonoid compound) is a particularly interesting example, as it was tested on both MG-63 
and hFOB cells to compare their responses (Hsu et al. 2007). Both cell types were almost 
identical in their response to myricetin, with broad trends always maintained and only slight 
differences in values between the two.  
As discussed, hFOBs benefit from expressing key osteoblast markers, in vivo bone growth 
capability and limited chromosomal damage even after multiple passages. However, it should 





osteosarcoma, could have also been chosen  (Billiau et al. 1977). MG-63 cells show a 
sequential profile of osteoblast marker expression (Quarles et al. 2009), though proliferation 
and alkaline phosphatase activity is not very representative of bone cell cultures (Clover & 
Gowen 1994). Furthermore, MG-63 cells have a greater number of chromosome 
abnormalities than hFOBs (Subramaniam et al. 2002). Another option as cell choice was 
MC3T3-E1 (Sudo et al. 1983), a clonal osteogenic cell line derived from mouse calvaria, which 
shows mineralization potential and is frequently used in studies within this field. A review of 
in vitro osteoblast cell lines, not including hFOBs, highlights that each line has its own distinct 
advantages and disadvantages (Czekanska 2012). For example, MG-63 cells show no 
interspecies differences compared to MC3T3-E1, though have inconsistent levels of cell 
mineralisation. Furthermore, the MC3T3-E1 cell line is known to contain different subclones, 
which vary greatly in their mineralisation potential (Wang et al. 1999). As such, compared to 
the other cell lines available hFOBs were a good choice for in vitro screening, though no cell 
line can ever fully replace the use of primary cells (see section 2.6 b for further discussion). 
However, there are disadvantages to using primary cells in that they are more difficult to 
source and can only be used for a limited number of passages; therefore, hBMSCs were saved 
for testing those extracts with definite osteogenic potential.  
 
2.3.2 Culturing hFOBs 
2.3.2.1 Flask culturing 
For normal cell growth, hFOBs were cultured in DMEM/HAM F12 (Sigma-Aldrich, 11039-021) 
medium containing 10% foetal bovine serum (FBS, PAA and Sigma-Aldrich after October 2016 
– F7524, Lot 094M3341, UK), 2 mM L-glutamine (M11-004, PAA, UK) and 0.3 mg/ml of the 
selective antibody Geneticin (10131027, Gibco, UK). To encourage cell differentiation this 
media was supplemented with 50 µM ascorbate-2-phosphate and 10 µM β-
glycerophosphate. Cells were cultured in standard T75 flasks, kept in a humidified incubator 
which was set at 33°C with a 5% CO2 concentration. During culturing medium was replaced 
twice weekly. When cells reached between 75-80% confluency they were split in a ratio not 
exceeding 1:4, using 0.25% trypsin/EDTA (Gibco, UK) and a 2-minute incubation period to 







2.3.2.2 Plate culturing 
Cells were used for experiments when approximately 80% confluency was reached in flasks. 
Cells were detached [as in 2.3.2.1], homogenised, an aliquot taken for counting and the 
remainder spun in an ALC 4218 centrifuge (Thermo Scientific, UK) for 10 minutes at 439 g. To 
count, cells were stained with trypan blue solution (Sigma-Aldrich, T8154) in a 1:2 ratio and 
counted using a Neubauer haemocytometer. Finally, cells were resuspended at the correct 
density and 200 µl of this cell solution was transferred to each well of a 96 well plate.  
After plating out cells were always given a 24-hour attachment period, before media was 




Cryopreservation was also performed at 80% confluency. Cells were detached, counted with 
a neubauer haemocytometer and then added to the correct volume of cryopreservation 
solution (8-parts FBS, 1-part DMSO, 1-part complete hFOB media), to give a solution of 
approximately 1 million cells/ml. 1 ml of this solution was then added to each 
cryopreservation tube (Sial 0659, Sigma-Aldrich, UK), and cooled at a rate of 1 degree per 
minute until -80°C was reached. Cryopreservation tubes were then transferred to liquid 
nitrogen storage. 
 
2.3.3 Optimisation of seeding density 
Figure 2.2 shows some recurrent trends between treatments at different cell densities and 
time points. In general, addition of 0.1% DMSO to culture medium appears to cause a small 
increase in proliferation, except at the 0.5x104 cells/cm2 density at day 7, and 1x104 cells/cm2 
at day 1. Treatments are more variable in their trends, though MR-05 frequently promoted 
increased dsDNA concentration (see chapter 3 for more detail). In terms of cell density, 1x104 
cells/cm2 had decreased dsDNA concentration compared to 5x104 cells/cm2, as expected, 
though the two lower densities were more comparable - particularly at days 4 and 7. Most 
importantly, by day 7 values from the 50,000 cells/cm2 density were above the maximum 
value of the standard curve, and have therefore been excluded from figure 2.2 C). Based on 

































Figure 2.2: results from a PicoGreen assay conducted on hFOBs at day 1 [A)], day 4 [B)] and day 7 [C)]  
(after an initial 24-hour attachment period). Cells were cultured at three different densities: 0.5x104, 
1x104 and 5x104 cells/cm2. Controls for both plain media and DMSO are included as well as three test 





2.4 Solvent toxicity 
2.4.1 DMSO and ethanol 
 
Extracts supplied for this project were originally produced by a DCM/MeOH extraction of 
sample material by the MI (see chapter 3 for full description) and were supplied as a 
concentrated oily residue. DMSO was chosen to reconstitute these extracts during initial 
experiments because of its universal use and ability to dissolve a wide range of compounds 
(Kolář et al. 2002). DMSO is an organic, polar and aprotic solvent, with a large dielectric 
constant and dipole moments – traits which make it a highly efficient solvent. During early 
work DMSO concentration was limited to 0.1% dissolved in culture medium, as at higher 
concentrations it can induce changes in cell morphology and membrane properties (Du et al. 
2006). However, to justify this choice and potentially raise extract concentration (and 
therefore likelihood of an effect), the impact of increased DMSO concentration was also 
investigated. Figure 2.3 indicates that 2% DMSO caused a significant increase in cell death 
compared to a complete medium control at day 1, whilst 1.5% is also slightly increased. 
Figure 2.3: Results from an LDH assay conducted on hFOBs, where two sets of cells were treated with 
DMSO (denoted DMSO set 1 and 2) and one set with a 50:50 DMSO and Tween-20 mix (denoted 
DMSO/Tween20). Concentrations included: 0.1, 0.5, 1, 1.5 and 2% diluted in complete media. Cells 
were plated at a 1x104 cells/cm2 density, given 24 hours to attach, 24 hours with treatment and then 
supernatant was collected for testing. Results are presented as the mean +/- standard deviation (n=4). 
C+ve shows the absorbance values for 100% cell death. All values are corrected for background 
absorbance by subtracting appropriate negative control values. Kit positive control confirmed the 





However, lower concentrations of 1, 0.5 and 0.1% show no apparent toxicity at this time 
point. Also, included in this figure was a 50:50 mixture of DMSO and Tween-20, to establish 
if this was a possible alternative solvent. Unfortunately, addition of Tween-20 caused 













In addition to LDH testing, a day 7 PicoGreen assay was also carried out. Figure 2.4 again 
clearly shows that Tween-20 is toxic, with no discernible dsDNA present for any Tween-20 
treatment; indicating complete cell death. On the other hand, DMSO has dsDNA present at 
all concentrations, though it is lowest at 2% and also significantly reduced at 1.5%. This 
complements cell death trends seen in figure 2.3, and suggests that high DMSO 
concentration causes a sustained increase in cell death over time. Based on these results it 
was concluded that 1% DMSO was suitable to include with cells over a 1-week experiment. 
Subsequently, a 7-day screen of 26 extracts was conducted, with each being included at a 1% 
concentration. However, (CV) had replaced PicoGreen as an assay at this point, and its results 
clearly showed a decrease in cell number with 1% DMSO, compared to plain medium 
controls. To investigate this further a smaller experiment was conducted, including controls 
and extracts at 1 and 0.5% concentrations. Results from this, presented in table 2.1, show 
that DMSO had a negative impact on cell proliferation at both 0.5 and 1% concentration, an 
Figure 2.4: Results from a day 7 PicoGreen assay conducted on hFOBs, where cells were treated with 
either DMSO (denoted D) or a 50:50 DMSO and Tween-20 mix (denoted DT). Concentrations included: 
0.1, 0.5, 1, 1.5 and 2% diluted in normal hFOB culture medium. Cells were plated at a 1x104 cells/cm2 
density, given 24 hours to attach and 7 days with treatment. Results are presented as the mean +/- 
standard deviation (n=6 for control, n=4 for treatment), *p<0.05 for treatment compared with 





issue which worsened with time. It is for this reason results from these two extract screens 
have not been included in this thesis. Furthermore, these results served to highlight a marked 
difference between PicoGreen and CV proliferation values, creating concerns with PicoGreen 








To better establish toxicity trends a second control experiment was performed, this time 
including LDH and CV assays. LDH (figure 2.5) results were like those of figure 2.3, showing 
low toxicity values for DMSO treatments that start to increase slightly at 1.5 and 2% 
concentrations; however, this time they were not significantly increased compared to the 
control. Ethanol, a polar protic solvent also with high dielectric constants and dipole 
moments, was also included in this study, as a potential replacement for DMSO if it proved 
too toxic for long term use at higher concentrations. As with DMSO, ethanol also appeared 
to show a very slight dose dependent response (figure 2.5), though all treatments had 
significantly lower cell death values than the control.   
  
DMSO concentration 
(%) Day 1 Day 4 Day 7
0.5 0 13 25
1 10 34 44
% decrease in CV proliferation 
value - solvent compared to 
plain media control
Table 2.1: the percentage decrease in CV proliferation value of DMSO treated cells 
compared to plain media controls, over days 1, 4 and 7. Included are values for cells at 0.5 















For CV (figure 2.6), day 1 proliferation values are all quite similar, though 1.5 and 2% DMSO 
did cause a small yet significant decrease compared to the control. By day 4 these decreases 
are more pronounced and a reduction in cell number was also seen with 1% concentration. 
Ethanol showed no apparent decreases in proliferation at day 4, and instead a small 
significant increase in cell proliferation at 0.1 and 0.25%. By day 7, the increase at 0.25% EtOH 
is lost, though 0.1% is still significantly increased. Furthermore, cell number in 1.5 and 2% 
EtOH are now significantly reduced compared to the control, as are DMSO concentrations of 
0.5% and above. These results are different to those of seen at day 7 with PicoGreen (figure 
2.4), as the latter only indicated that 1.5 and 2% DMSO concentrations have a negative 
impact on proliferation. Alternatively, EtOH appears to have lower cytotoxicity than DMSO 
and should therefore be suitable for inclusion with cells up to a 1% level. Overall, 
discrepancies between PicoGreen and CV proliferation values are particularly interesting, as 
they indicate CV is the more sensitive technique. Their exact cause is unclear, but may be 
caused by differences in methodology and repeatability between the tests, or a whole range 
of PicoGreen issues (see section 2.5 for discussion). However, they do clearly highlight the 
Figure 2.5: Results from an LDH assay conducted on hFOBs, treated with either DMSO or EtOH. 
Concentrations included: 0.1, 0.5, 1, 1.5 and 2% diluted in normal hFOB culture medium. Cells were 
plated at a 1x104 cells/cm2 density, given 24 hours to attach and 24 hours with treatment. Results 
are presented as the mean +/- standard deviation (n=2, duplicates). C+ve shows the absorbance 
values for 100% cell death. All values are corrected for background absorbance by subtracting 
appropriate negative control values. Kit positive control confirmed the assay worked for each test. 





importance of establishing basic experimental design (such as solvent toxicity), not just 
between cell types or time points, but also different assays.  
  
Figure 2.6: results from CV assays performed on hFOBs. Cells were plated at a 1x104 cells/cm2 density, 
given 24 hours to attach and then cultured for either 1 [A)], 4 [B)] or 7 [C)] days before being stained. 
Cells were treated with either a complete media control (C) or DMSO/EtOH, at concentrations ranging 
between 0.1 and 2% dissolved in culture media. Results are presented as the mean +/- standard 






2.4.2 Alkaline and aqueous extractions for powder extracts 
After testing for osteogenicity in extracts reconstituted in DMSO and ethanol, powder 
extracts were also screened for activity. Powder extracts were the material retained after 
original DCM/methanol extraction at the MI (see chapters 3 and 4 for a full description of 
this). These powders were supplied in dried form and were subsequently dissolved via an 
alkaline extraction using 0.1 M NaOH, before final extract solutions were neutralised via HCl 
addition to produce a saline solution. Additionally, two powder extracts were also tested 
after aqueous extraction. An alkaline extraction, whilst not common, was chosen based on 
similar work which showed it to be an efficient method to ensure a high protein yield from 
both green tea (Shen et al. 2008) and algal sample material (Harnedy & FitzGerald 2013; 
Harnedy & FitzGerald 2013). A full methodology concerning the extraction method, from 






Whilst powder extracts proved to be a very interesting source of bioactivity, one issue of 
undissolved residue material remaining in cell culture media did require optimisation during 
Figure 2.7: collage showing day 7 hBMSCs [a) b) donor: 001, passage:4; c) d) donor: 002, passage:5] 
challenged with either a control (saline 10%) or C. secundatum 350 µg/ml treatment. C. 
secundatum treatment of b) was filtered after being added to culture media, whilst d) was also 
centrifuged twice before media addition.  Images show the whole of one treatment well, from a 







the project. This residue became incorporated into cell monolayers where it was 
subsequently stained during CV assays (see section 2.5.2 for further detail on this assay), 
giving false positive cell proliferation values. To combat this, extracts were centrifuged when 
tested during hFOB screening of chapter 3, or filtered (0.22 µM, results not shown). Both of 
these methods reduced the amount of residue material that was present but did not 
completely eliminate it. Instead, a combination of two cycles of extract centrifugation and 
filtration (0.22 µM) of cell treatment media prior to use was required to eliminate residue. 
Differences between the two methods can be seen in figure 2.7, whereby C. secundatum 
treatment which was filtered and centrifuged had much less associated stained residue than 
that prepared with filtration only.  
 
2.5 Choosing an accurate, reliable method of measuring cell proliferation 
2.5.1 PicoGreen 
PicoGreen reagent is a highly sensitive nucleic acid stain, which is reported to detect much 
lower DNA quantities than other commonly used assays, such as Hoechst 33258. This assay 
is also stated to benefit from a higher fluorescence level than other traditional kits, giving 
less signal contribution from RNA and single stranded DNA contaminants. It is an established 
technique, having been in use for almost two decades (Singer et al. 1997), which along with 
its reported benefits (e.g. high sensitivity) made it a promising choice for initial work.  
Early PicoGreen results were used for preliminary tests, such as choice of cell seeding density 
(see section 2.3.3), and for determining proliferative effects of 43 marine extracts dissolved 
in DMSO (see chapter 3). These tests were informative, but also collectively highlighted 
several issues with this assay. Firstly, the standard curve used for converting fluorescence 
values to DNA concentration has a fairly limited range, with a tendency for reporting error 
values if cell seeding density or growth is too high. Extrapolation beyond the standard curve 
can be used to calculate DNA concentration, though a linear relationship cannot and should 
not be assumed. Ideally, test solutions should be diluted and a second test performed, but 
this then involves extra pipetting steps (one for diluents and one for cell solution) increasing 
error, as well as necessitating multiplication of values. Standard dilutions can be made based 
on time point length (i.e. a greater dilution with longer culture time), which generally works 
well for cell lines. However, primary cell growth shows significant patient to patient 
variability, meaning dilutions must be determined for each batch used. Ng et al. (2005) also 





issues with DNA as a measure of cell proliferation. For example, DNA concentration varies 
with the cell development cycle, meaning it doesn’t give a constant expression level and 
therefore is only an approximation of cell proliferation; though arguably this is a problem 
with most assays.  
PicoGreen samples also require numerous processing steps, including a 2x PBS/buffer wash, 
addition of lysis solution, mixing prior to freezing, at least one freeze thaw cycle, mixing post 
freezing and finally plating out of test solution, which often includes a dilution step. This is 
time consuming and increases the risk of variation in test volumes between wells, both 
through pipetting error and evaporation. Including duplicate samples also means multiple 
plates must be used, making plate to plate variability a factor (though standard curve 
solutions are included on each plate to limit this). In addition to these practical concerns, 
PicoGreen is also a relatively expensive technique, due mainly to reagent cost. These 
reagents also degrade over time and in exposure to light, necessitating comparisons between 
different reagents and their eventual replacement. Table 2.2 highlights this reagent 
variability, with a difference of 779 relative fluorescence units between reagent 2 and 3 at 









One useful example of PicoGreen reliability is a study which measured the proliferation of 
meniscal fibrochondrocytes on different microcarriers, as it compared DNA quantification to 
MTT and MTS colorimetric assays (Pabbruwe et al. 2005). DNA level did not allow for 
differentiation between the two lowest cell seeding densities, a trend also seen to some 
degree in this work (figure 2.2), whilst in comparison MTS and MTT were much more 
sensitive. Both colorimetric techniques also detected differences in proliferation between 
microcarriers, whilst PicoGreen showed no variation at any cell density. Again, a similar trend 
λ DNA standard concentration (ng/ml) Reagent 1 Reagent 2 Reagent 3
1000 4772 5139 4360
100 757 748 675
10 164 174 152
1 105 98 100
0 86 97 86
R-squared value from standard curve: 0.9983 0.9992 0.9987
Relative Fluorescence Units (Ex: 
480nm, Em: 520nm)
Table 2.2: relative fluorescence units detected by three different PicoGreen reagents over the 
suggested standard curve range. Each reagent was exposed to the same solutions containing λ DNA 
standard at the specified concentrations. Values were detected at excitation wavelength 480 and 





was seen in this work, whereby only small differences in proliferation were seen between 
the DMSO based treatments of chapter 3. This could be a real reflection of extract effects, 
but may also be influenced by PicoGreen as an assay choice.  
Overall, it seems PicoGreen is capable of measuring of cell proliferation, but has several 
hindrances which make it an impractical assay for large scale screening. An ideal proliferation 
measure would be simple, quick, inexpensive, involve limited processing and pipetting steps 
and be capable of detecting clear differences between treatments, with good inter and intra 
variability. MTT and MTS may seem obvious alternatives and are popular choices within the 
literature, though are not actually measures of cell proliferation. Instead they measure cell 
viability, via metabolic activity, and should not be reported as proliferation measures.  
 
2.5.2 Crystal violet 
CV assay was selected as a potential replacement for PicoGreen as it is a true proliferation 
measure which appears to address many of the latter’s shortcomings. CV utilizes the 
triphenymethane dye (4-[(4-dimethylaminophenyl)-phenyl-methyl]-N,N-dimethyl-aniline), 
which has a wide variety of different applications (Vega-Avila & Pugsley 2011). Amongst 
these is determining cell proliferation, as the dye stains DNA present in cell monolayers. After 
solubilisation, the colour intensity is quantifiable through an absorbance reading which is 
proportional to cell number. This assay has obvious benefits; it is simple to undertake, 
cheaper and faster than other absorbance viability measures such as MTT, which requires a 
4-hour incubation period. Furthermore, initial preparation of test plates, including washing, 
fixing and staining, are all completed to saturation by covering the entire monolayer in excess 
solution. Pipetting error is therefore limited to a 100µl addition of solubilisation solution, 
which may in part explain CV’s low intra (figure 2.9) and inter (see later results) variability.  
One of CVs first reported uses was as an approximation of cell death, through measurement 
of residual cell number, a technique which was shown to be more sensitive than others 
available at the time (Flick & Gifford 1984). Subsequently, this method was adapted to stain 
cell monolayers grown on 24 well plates (Gillies et al. 1986), before finally being optimised 
for 96 wells in a method similar to that used in this work (Kueng et al. 1989). It is therefore a 
much older method than PicoGreen, but is well established within the literature and still 
frequently used. For example, CV was used to measure the proliferative effects of fucoidan 
(Kim et al. 2015), as well as cell migration stimulated by nacre (Lee et al. 2012). It is also often 





et al. 2015), such as on glycosaminoglycans (Salbach et al. 2012) and titanium surfaces 
(Bezerra et al. 2017). 
Direct comparisons of CV results with DNA and other cell proliferation measurements are not 
common in the literature, though one study investigating breast cancer cells did briefly 
compare different techniques (Zivadinovic et al. 2005). These results weren’t presented, but 
CV was reported to correlate very well to both DNA content measurements and 
haemocytometer cell counts. Furthermore, MTT assay results were displayed and showed a 
linear correlation with those of CV. Also of note, CV standard error bars were very small in 
this study, supporting the previously stated low variability of this assay. Another study 
investigating breast cancer cell growth also included data from multiple assays; including CV, 
PicoGreen, MTT and Hoescht 33258. All were comparable in their measurement of cell 
response, showing significant increases in proliferation after Interleukin-7 administration (Al-
Rawi et al. 2004). 
However, this technique is not without its own limitations. Firstly, whilst cheap all required 
test solutions are highly toxic. Cell seeding density is again an important factor, though this 
time to ensure monolayer stability rather than detectable fluorescence levels. For example, 
if seeding density is too low, potential differences between treatments are difficult to 
observe. Alternatively, if too high monolayers tend to become unstable, forming a double or 
triple layer of cells which may fold over during culturing (particularly at longer timepoints), 
causing them to be washed away prior to fixing. Pipetting may also scratch monolayers and 
remove cells if not performed carefully (figure 2.8), an early problem which was remedied in 
later assays by rapidly inverting test plates to remove excess solution.  
Figure 2.8: two images of a single well from a 96 well plate, stained with CV. The image on the left 
shows a confluent layer of cells washed by pipette multiple times. The right image shows a confluent 





Finally, it is important to note that CV stain is not specific to cells and will also stain other 
material present within test wells, such as extract residue (as discussed in section 2.4.2). 
However, assuming seeding density is optimised and residue limited, this is a useful cell 
proliferation method; which in this work was consistently more reliable than PicoGreen. 
  
2.5.2.1 Crystal violet – optimisation 
Use of CV necessitated another seeding density optimisation test, to ensure a density was 
chosen that would allow trends to be identified over the full 7-day test period. Figure 2.8 
shows that 1x105 and 5x104 cells/cm2 densities were too high, quickly reaching confluence 
and becoming indistinguishable by day 4. 1x103 cells/cm2 was too low and showed little 
change over time, though 1x104 cells/cm2 was again optimal, showing clear differences 
between time points. Variability was also excellent, with each mean value having tight 














Also of note from figure 2.9, is that increases in optical density values showed a very linear 
relationship with seeding density. This is to be expected, as more cellular material is available 
Figure 2.9: results from CV assays 
conducted on hFOBs at different seeding 
densities including: 1x103, 0.5x104, 1x104, 
5x104 and 1x105 cells/cm2. Cells were 
grown for 1 [A)], 4 [B)] or 7 [C)] days 
before staining. Results are presented as 





to stain, but also suggests that optical density is a good representation of cell number. Figure 
2.10 is a continuation of this, whereby both hFOBs and hBMSCs (from later experiments – 
see section 2.6 for explanation of this term) were seeded in a 2x dilution gradient, with cell 
number per well ranging from 130 to approximately 16,667. As figure 2.10 shows, the 
relationship between optical density and cell number is very linear, with an R2 value of 
0.9993. Not only does this validate CV as a measure of cell proliferation, but it also allows for 













Figure 2.10: results from a CV assay performed on hFOBs [A)] and hBMSCs [B)] (donor 002, passage 
5). hFOBs and hBMSCs were seeded at densities ranging from approximately 130 to 16,667 
cells/well in a 2x dilution gradient. Cells were given a 24-hr attachment period and then 
immediately stained afterwards, limiting proliferation time and therefore variation from the 





2.6 Primary cells (hBMSCs) 
2.6.1 Defining the cellular component of skeletal regeneration 
Stem cells are often defined in terms of two key traits; namely a self-renewing capacity and 
an ability to differentiate into cells from multiple lineages (Morrison et al. 1997; Reya et al. 
2001). It is these characteristics, amongst others, that make stem cells so promising for 
clinical applications, fuelling research in this area (Morrison et al. 1997). Much interest in this 
field was initially focused around pluripotent embryonic stem cells, first cultured by Evans & 
Kaufman (1981), due to their potential for generating all types of human tissue. However, 
these cells were plagued by ethical and immunological concerns (Brooks 2012), whilst even 
immunologically compatible induced pluripotent stem cells present issues for clinical use, 
such as insertional mutagenesis (Teo & Vallier 2010). Consequently, other stem cell sources 
have been intensely researched since this early work. These include, amongst others, 
circulating stem cells associated with mammalian blood (Kuznetsov et al. 2001); umbilical 
cord blood multilineage cells, which show long term viability as a cell reserve (Eom et al. 
2014); placental derived mesenchymal stem cells, which, similar to bone marrow derived 
cells, have a multilineage differentiation potential (Miao et al. 2006); and adipose tissue-
derived stem cells.  The wealth of sources and associated published material can result in 
confusion as to what constitutes a stem cell, facilitating more generalized definitions, whilst 
choosing the appropriate terminology is troublesome for many aspects of stem cell biology 
(Tajbakhsh 2009; Owen 1998).   
A good example of this would be mesenchymal stem cells (MSCs), sometimes referred to as 
mesenchymal stromal cells or multipotent stromal cells, which have a definition that has 
evolved significantly over time (Keating 2012). Originally, MSCs were conceived due to an in 
vivo demonstration of the osteogenic potential of bone marrow cells by Friedenstein et al. 
(1966). Subsequent studies, including in vitro work (Friedenstein et al. 1970; Friedenstein et 
al. 1976), developed this idea and showed bone marrow derived cells to have clonal qualities 
and plastic adherence. Ideas on MSCs have since developed and it is now agreed that they 
have a multi-lineage potential, being able to differentiate into cells of adipogenic, 
chondrogenic and osteogenic lineages (Bronckaers et al. 2014; Hua et al. 2013; Zhu et al. 
2012; Rezwan et al. 2006; Scaglione et al. 2009). However, despite intense research in this 
area there is still no known marker exclusive to MSCs, whilst definitions of the term are 
mostly limited to in vitro, rather than in vivo, demonstrations of stem cell characteristics 





MSCs, preserved through their high proliferative capacity, differentiate through specific 
lineages to produce a wider population of mesenchymal progenitor cells (MPCs). Similarly, 
MSCs and MPCs can be thought of as part of a wider group of bone marrow stromal cells 
(BMSCs); which also contains a variety of other bone marrow support cells (Brooks 2012). 
However, authors may also refer to BMSCs as cells with a multilineage potential, instead of 
saying MSCs; or they may use the terms interchangeably. The latter appears to be most 
common, with the term BMSC being used in place of MSC. Therefore, to avoid confusion the 
term human bone marrow derived mesenchymal stromal cells will be used throughout this 
thesis, abbreviated to hBMSCs. This term will specifically refer to fibroblast-like cells, derived 
from multipotent MSCs in bone marrow, that undergo differentiation to produce bone 
forming osteoblasts. When MSCs are originally cultured, clonal colonies of cells with 
fibroblast-like morphologies are formed, referred to as colony forming unit-fibroblasts (CFU-
fs; where each colony is derived from a single MSC). Such CFU-fs have a high proliferative 
potential and are able to differentiate down chrondrogenic, adipogenic and osteogenic 
lineages, depending on culture conditions (Brooks 2012; Scaglione et al. 2009; Owen 1998).   
 
2.6.2 Rationale of use 
Primary cells were chosen to be used in conjunction with the hFOB cell line during this study, 
to give a better indication of how any treatment would affect cells in vivo. Whilst useful for 
identifying potential osteogenic activity in a quick and cost-effective manner, hFOBs are an 
immortalised cell line and therefore not fully representative of the “normal” osteoblast 
condition. One useful example of this is a study which compared the proliferation, 
differentiation and mineralization activities of primary cells with SaOs2, MG-63 and MC3T3-
E1 lines (Czekanska et al. 2014). Each cell line showed significantly greater proliferative 
activity than human osteoblasts during at least 1 time point, whilst differentiation and 
mineralisation were also highly variable. Expression of key osteoblast genes, such as Runx2 
and osteocalcin, were maintained for all cell lines, but again were often at increased or 
decreased levels compared to primary cells. Similar discrepancies were seen between cell 
line proliferation and alkaline phosphatase expression in comparison to human osteoblasts 
(Clover & Gowen 1994). These concerns do not mean cell lines cannot be used, however, 
they should not be used as a complete replacement for primary cells, and any treatment 





Primary hBMSCs used in this work were acquired from human bone marrow samples, 
collected during vertebral screw placement at the Royal Victoria Hospital in Belfast. Whilst 
commercial sources of these cells are available they were not used for several reasons: 1. a 
limited supply per vial which means that smaller experiments would need to be devised, 2. 
collecting samples means inclusion and exclusion criteria can be better applied to ensure that 
patients were not taking any drugs that would affect results and 3. samples can be collected 
from many patients, allowing repeat experiments with different donors to investigate inter-
patient variability. 
 
2.6.3 Ethical considerations  
Ethical approval for the collection and use of human derived tissue samples from NHS 
patients was granted by the North East-Tyne and Wear South Research Ethics Committee 
(REC ref 15/NE/0250). Informed written consent was obtained from all donors who provided 
samples for use in this work Inclusion criteria were those aged 18-65, who were able to 
consent for themselves and undergoing elective surgery requiring pedical screws; as this 
allowed easy access to bone marrow in the vertebral body. Exclusion criteria were those with 
a concomitant condition, such as rheumatoid arthritis, osteoporosis and other metabolic 
bone diseases, or those taking medication known to affect bone metabolism such as long 
term steroid use and statins. See appendix 1 for ethical consent form, appendix 2 for patient 
information sheet and appendix 3 for the basic information collected from patients. In total 
8 patients provided bone marrow aspirate samples between March 2016 to March 2017, 
which all yielded viable hBMSC populations. Donor information is provided in appendix 4. 
 
2.6.4 Culturing of hBMSCs 
2.6.4.1 hBMSC extraction from bone marrow sample 
Approximately 6-8 mls of bone marrow aspirate was collected by surgeons at the Royal 
Victoria Hospital, Belfast. Samples were mixed with 100 µl of heparin to prevent clotting and 
stored on ice for 1-2 hours before processing. Aspirate was first agitated using a syringe and 
needle, to ensure a single cell suspension. Subsequently, this solution was washed with PBS 
and centrifuged to remove lipid, before the cellular component was resuspended in PBS and 
gently layered onto 4 mls of Histopaque-1077 (Sigma-Aldrich, UK) solution. This mixture was 
centrifuged for 30 minutes at 500 g, to separate out the ‘buffy layer’ containing any white 





in a small volume of complete hBMSC media [see 2.6.4.2]. An aliquot of this suspension was 
then treated with 2% acetic acid to remove red blood cells, before being counted using a 
Neubauer haemocytometer. Cells were subsequently added to T-75s at a density of 1-3x105 
cells/cm2, left for 7 days undisturbed and subsequently fed twice weekly until confluent. 
 
2.6.4.2 Flask, plate culturing and cryopreservation of hBMSCs 
For normal cell growth, cells were cultured in ‘complete media’ which consisted of α-MEM 
media (22561-021, ThermoFisher Scientific, UK) containing 10% FBS, 2 mM L-glutamine and 
100 U/ml penicillin-streptomycin (pen-strep) (15140, Gibco, UK). Cells were cultured in a 
humidified incubator at 37oC and 5% CO2. In experiments which required cell differentiation 
this media was supplemented with 50µg/ml ascorbate-2-phoshpate (A8960, Sigma-Aldrich, 
UK), 2 M β-glycerophosphate (9422, Sigma-Aldrich, UK) and 0.01 µm dexamethasone (D2915, 
Sigma-Aldrich, UK)- termed ‘osteogenic media’.  
For experiments, hBMSCs were cultured at a seeding density of 2x104 cells/cm2 and at no 
later than passage 6 to help ensure phenotype stability. Cryopreservation follows the method 
of 2.3.2.3, except α-MEM media was used instead of DMEM/HAM F12.   
 
2.6.5 hBMSC proliferation optimisation 
As with hFOBs, establishing an optimal seeding density was key before starting large scale 
experiments with hBMSCs. However, at this stage in lab work difficulties surrounding correct 
solvent choice and concentration had also become apparent. Therefore, an experiment was 
carried out to assess cell growth at three different densities using both DMSO and ethanol. 
0.1, 0.5 and 1% ethanol were used, along with 0.1% DMSO – as DMSO had already proven to 
have cytotoxic effects at higher concentrations. Figure 2.11 shows day 1, 4 and 7 data for 
hBMSCs seeded at a 1x104 cells/cm2 density. Data for control (complete media), DMSO and 
ethanol treatments are displayed at each time point, and for the most part cause only minor 
changes in cell proliferation. Day 1 data is the most variable, though standard deviation 
values are still modest and are likely explained by low cell number (both due to the lower 
seeding density used and early day 1 time point). 1% ethanol is also increased compared to 
other treatments at day 1, but not to a significant degree. At day 4 and 7, all treatments were 






control – though at day 7 0.5 and 1% ethanol control – though treatments were slightly 
reduced in value. 
  
Figure 2.11:  results from a CV assay performed on hBMSCs seeded at 1x104 cells/cm2 at days 1 
[A)], 4 [B)] and 7 [C)]. Cells were treated with either complete media (Control), DMSO (0.1%) or 































Figure 2.12: results from a CV assay performed on hBMSCs seeded at 2x104 cells/cm2 at days 1 
[A)], 4 [B)] and 7 [C)]. Cells were treated with either complete media (Control), DMSO (0.1%), EtOH 
(0.1-1%) or extract derived from powdered algae, denoted 614 (1 or 5%). Results are presented as 
the mean +/- standard deviation (n=6 for control, n=3 for treatments), *p<0.05 for treatment 






As shown in figure 2.12, ethanol and DMSO again have little impact on proliferation when 
compared to the plain medium control, except at day 7. Here, increasing ethanol 
concentration decreases proliferation, leading to a significant reduction at 1%. A higher 
seeding density may explain the differences between figures 2.12 and 2.11 at day 7, as 
treatment effects are easier to discern when cells are more confluent and proliferating faster.    
Finally, the highest density of 3x104 cells/cm2 (figure 2.13) maintained most of the trends 
seen at 2x104 cells/cm2, except at day 1 where 0.5% ethanol treatment was significantly 
increased relative to control. However, this is again likely a factor of the early time point, or 
perhaps slight variation in seeding density between wells. By day 4, treatments generally 
evened out in their proliferative effect, except for the slight significant increase with 1% 
ethanol. Day 7 is again where trends are most evident, with all treatments showing decreased 
proliferation relative to control, with 0.1 and 1% ethanol being significantly reduced. This is 
similar to previous results, except that 0.1% ethanol is significantly reduced. The reason for 
this is unclear, but could be due to general sources of error associated with cell culture.  
Overall, this dataset shows some distinct differences to optimisation work with hFOBs. Most 
evident is that 2x104 - rather than 1x104 cells/cm2 - is optimal for determining differences 
between treatments over a 7-day time course. Furthermore, hBMSCs appear to have a lag 
phase after plate out, as proliferation values for both day 1 and 4 time points are very similar. 
By day 7, cells appear to recover and proliferation increases as expected. This makes sense, 
as cell lines generally proliferate faster (section 2.6.2) and are less susceptible to factors such 
as passage number. In terms of treatment inclusion, 0.1% DMSO does not significantly 
decrease cell proliferation, though ethanol does have a dose dependent effect – eliminating 
1% as a potential vehicle in future tests. Finally, these results also further support CV use over 
























Figure 2.13: results from a CV assay performed on hBMSCs seeded at 3x104 cells/cm2, at days 1 
[A)], 4 [B)] and 7 [C)]. Cells were treated with either complete media (Control), DMSO (0.1%), EtOH 
(0.1-1%). Results are presented as the mean +/- standard deviation (n=6 for control, n=3 for 






2.7 Optimisation of long term cultures 
2.7.1 Alkaline phosphatase 
2.7.1.1 Alkaline phosphatase – buffer and freeze/thaw issues 
ALP is an early stage marker of osteogenic differentiation and was therefore a key assay when 
trying to detect osteogenic bioactives. However, it was also difficult to optimise for several 
different reasons. Firstly, any differentiation marker requires longer culturing to be 
expressed, as cells need to mature first. This is challenging, as healthy culture conditions need 
to be maintained over time for confluent test wells, which quickly produce large amounts of 
waste products. Changing media remedies this, though can affect monolayer stability. Even 
with careful feeding, cells tend to clump up over time, despite changes in FBS concentration 
to reduce growth rate. Once folded/clumped, cells are likely to be stressed, show greater 
death and produce variable quantities of ALP (or other markers).  
Culturing concerns aside, a working ALP assay took a long time to establish, with early 
experiments detecting only very small ALP levels. One likely reason for this was that the 
original protocol (which is different to that of 2.2.5) was based on a pre-existing method 
(Palmer et al. 2015), which made use of a PBS buffer. However, other studies in this area 
used a variety of buffers other than PBS, including bicarbonate buffers (Almeida et al. 2001) 
and various tris buffers (Pathomwichaiwat et al. 2015; Bensimon-Brito et al. 2012). Another 
potential issue was that 3 separate freeze thaw cycles were used to ensure membrane lysis, 
and it was thought this could have reduced ALP activity. Therefore, an optimisation study 
was performed to investigate both buffer choice and freeze thaw cycle. For this, a day 7 ALP 
assay was conducted on hFOBs using both an alkaline (5M NaCl, 1M Tris-Cl pH 9.5, 1M MgCl2) 
and PBS buffer, with plates exposed to room temperature or 2, 3 and 4 freeze thaw cycles. 
Both normal and osteogenic media were used during culturing, whilst final lysis solutions 
included either 0.1 or 0.2% Triton X-100.  
Figure 8.1 (see appendix 5) showed clear differences in ALP expression between PBS and Tris 
buffers. Room temperature lysate had reduced ALP activity in PBS compared to Tris, though 
expression was similar between normal and osteogenic media. However, inclusion of 2, 3 or 
4 freeze/thaw cycles drastically reduced ALP expression in PBS, often eliminating it. 
Alternatively, expression was maintained in Tris after freeze/thaw and appeared to increase 
with cycle number, perhaps indicating better or more complete cell lysis. Finally, 0.1 or 0.2% 





This dataset answered the original questions regarding the assay, showing that both PBS 
buffer use and freeze/thaw cycling was reducing ALP activity. The original study which used 
this method, Palmer et al. (2015), tested samples at room temperature, and therefore would 
not have experienced a complete reduction in ALP expression. The reason behind these 
results is unclear, though it is likely that PBS, as a phosphate buffer, provides enough 
phosphate to saturate the binding site of alkaline phosphatase in cell lysate. This would then 
cause a significant reduction in the conversion of p-nitrophenyl phosphate to p-nitrophenyl. 
As testing at room temperature occurs almost immediately, ALP may not have time to be 
inactivated by PBS – whereas multiple freeze/thaw cycling would allow much more time for 
deactivation.  
 
2.7.1.2) Alkaline phosphatase optimisation 
After establishing the working assay protocol a standard optimisation test was conducted on 
hFOBs (figure 2.14) and hBMSCs (figure 2.15), at 7, 14 and 21 days. This aimed to ensure the 
assay was working on long term cultures and to establish any differences in ALP expression 
due to osteogenic supplementation or solvent addition. 
ALP activity in figure 2.14 has been normalised to DNA content (using PicoGreen values) to 
account for variations in cell number between wells and treatments. In general, relative ALP 
activity peaked at day 7 (a), indicating early enzyme expression and cell differentiation. 
Furthermore, there was little variation in activity between treatments, though the highest 
solvent levels did cause slight decreases in activity levels, particularly for DMSO. This was 
likely a result of a slight cytotoxic effect from solvent addition, or suppression of cell activity. 
Day 14 trends (b) were slightly different, with osteogenic medium activity reduced compared 
to that of complete media, whilst 1% ethanol caused a slight increase in relative ALP 
expression. These discrepancies most likely resulted from the large associated error at this 
time point, which was probably PicoGreen related – as DNA values were particularly 
heterogenous. Of note, error is generally greater for ALP measurements than for single 
measures like CV due to normalisation, meaning variability in DNA readings are also a factor. 
However, normalisation is crucial to ensure higher ALP activity is not just a consequence of 



























Figure 2.14: results from an alkaline phosphatase assay performed on hFOBs, at day 7 [a)], 14 [b)] and 
21 [c)]. Cells were plated at a 1x104 cells/cm2 density, given 24 hours to attach and then cultured in 
either complete or osteogenic media. Osteogenic media also had ethanol, DMSO and saline solvents 
added at various percentages. Subsequently, cells were lysed via addition of a Tris buffer containing 
0.2% Triton X-100 and subjected to 2 cycles of freeze thaw.  Results are presented as the mean +/- 






it is interesting to note that complete media showed comparable ALP activity to osteogenic 
supplemented media. This indicates that cell differentiation was not enhanced by 
supplementation. Whilst numerous supplementation recipes exist for hFOBs, there are also 
studies which only use complete media, finding it effective (de Souza Malaspina et al. 2009) 
and supplier (ATCC) guidelines do not recommend supplementation. The results presented 
in figure 2.14 confirm that supplementation with this cell line is not necessary to promote 
osteogenic differentiation.  
hBMSCs (figure 2.15) were much more repeatable, showing lower associated error and 
clearer trends. Firstly, complete media still resulted in a detectable level of ALP activity, but 
it was the lowest of all treatments. Osteogenic supplementation greatly increased activity 
levels as expected, though the inclusion of 10% saline solution in media negated this slightly. 
Apart from the 0.5% ethanol treatment at day 21, solvent inclusion reduced ALP activity 
compared to control in a dose dependent manner – though levels were still greater than 
those of complete media. By day 21, error increased relative to day 7 and 14, but trends were 
still apparent. Compared to hFOBs, primary cells displayed much greater relative ALP activity 
(greater than 1000 for treatments at day 21), whilst differentiation was extensively increased 
by supplementation. Proliferation was also lower for hBMSCs, as evidenced by PicoGreen 
readings and the healthy, 75% confluent monolayer evident during cultures. This is not 
surprising given the higher proliferative capacity of cell lines and their other limitations 

































Figure 2.15: results from an alkaline phosphatase assay performed on hBMSCs, at day 7 [a)], 14 
[b)] and 21 [c)]. Cells were plated at a 2x104 cells/cm2 density, given 24 hours to attach and then 
cultured in either complete or osteogenic media. Osteogenic media also had ethanol, DMSO and 
saline solvents added at various percentages. Subsequently, cells were lysed via addition of a Tris 
buffer containing 0.2% Triton X-100 and subjected to 2 cycles of freeze thaw.  Results are presented 





2.7.2 Mineralisation optimisation 
To ensure best results from alizarin red-S (see 2.2.6) staining a number of different media 
recipes were tested, to determine which would lead to greatest mineralisation levels of 
hFOBs and hBMSCs. Overall, hFOB mineralisation was more variable that that of hBMSCs 
(figure 2.16). For example, day 7 and 14 time points show consistently higher mineralisation 
levels with osteogenic media, compared to complete media control. However, day 21 
osteogenic media showed reduced mineralisation, whereas at day 28 no clear trend was 
apparent. This variation in mineralisation may again be a result of using cell lines opposed to 
primary cells, which show more consistent patterns of mineralisation (Czekanska et al. 2014) 
(figure 2.17). Despite this variability, treatment 4 (50 µg/ml A-2-P, 10 Mm β-
Figure 2.16: results from an alizarin red-S assay performed on hFOBs at day 7 [a)], 14 [b)], 21 [c)] and 
28 [d)]. Cells were plated at a 2x104 cells/cm2 density, allowed to reach 75% confluency and then 
cultured in media with different concentrations of supplements, including: ascorbate-2-phosphate 
(A-2-P), β-glycerophosphate and dexamethasone. A complete media treatment and 4 supplemented 
media types were tested – see figure legend.  Results are presented as the mean +/- standard 





glycerophosphate and 0.01 µM dexamethasone) produced the most frequent promotion of 
mineralisation (treatment 5 cells became over confluent and dis-attached at day 21 time 
point, explaining their absence) across all time points and was therefore chosen for future 
work.  
 
Comparatively, hBMSCs (figure 2.17) showed a much clearer trend than hFOBs. For example, 
use of osteogenic supplements promoted mineralisation level for all media recipes compared 
to complete media control. With the exception of variability at day 14, media recipe 3 – 50 
µg/ml A-2-P, 10 mM β-glycerophosphate and 0.01 µM dexamethasone – performed best at 
Figure 2.17: results from an alizarin red-S assay performed on hBMSCs at day 7 [a)], 14 [b)], 21 [c)] 
and 28 [d)] timepoints. Cells were plated at a 2x104 cells/cm2 density, allowed to reach 75% 
confluency and then cultured in media with difference concentrations of supplements, including: 
ascorbate-2-phosphate (A-2-P), β-glycerophosphate and dexamethasone. A complete media 
treatment and 3 supplemented media types were tested – see figure legend.  Results are presented 





all time points, resulting in a large promotion of hBMSC mineralisation and was thus chosen 
for future work.  
 
2.8 Summary 
Overall, this chapter detailed many in vitro methods utilised within this thesis, why they were 
used and how they were tested and optimised. Throughout lab work it became apparent that 
assays should not be trusted solely because of their reported benefits, or wide literature use. 
Instead, it is important to determine how they perform between cell types/batches, 
experiments, time points and in relation to other similar techniques. PicoGreen was a good 
example of this, as whilst more modern it was not as reliable a proliferation measure as CV. 
Ways of improving other techniques, such as membrane preservation for CV and long-term 
differentiation tests, were also detailed and incorporated into assay methods. Additionally, 
cell culture basics were established, such as why hFOBs and hBMSCs were used and how each 
was cultured. It was important to test both cell types with each assay method, as well as a 
range of solvents. Solvents proved particularly challenging, though eventually 0.1 or 0.5% 
ethanol was shown to be preferable to 0.1% DMSO, whilst higher concentrations of either 
caused increased cell death. Furthermore, the use of alkaline extraction for powder extracts 
was also briefly described, including optimisation to reduce non-specific residue staining. In 
conclusion, method development is arguably the most important stage of any lab work, as it 
determines the quality of all future results. In this thesis, a limited number of in vitro 
techniques were purposefully chosen, to give specific, repeatable and reliable results on 
either cell death, proliferation or differentiation. This approach facilitates comparisons 
between the many different extracts screened, making it easier to highlight those which 


























As of December 2017 there were approximately 242,823 accepted marine species, according 
to the world register of marine species (WoRMS), though this number is constantly being 
updated. An accurate description of marine diversity is extremely challenging and depends 
in part on sampling and classification effort. However, estimations indicate there may be a 
total of 2.2 million marine species, of which only 9% have been identified (Mora et al. 2011). 
This life encompasses fish; mammals; coastal, deep water and littoral invertebrates; plankton 
and bacteria, as well as many more taxa that do not fit within these broad groups. These 
organisms have adapted to survive in challenging environmental conditions, often being 
subjected to extremes of temperature, oxygen depletion, salinity variation and nutrient level 
fluctuation (Jha & Zi-rong 2004). Deep ocean hydrothermal vents are an excellent example 
of this, and before 1977 we were unaware of their existence. Now we understand that entire 
diverse ecosystems exist around these vents which are completely self-sufficient in surviving 
their extreme environment, requiring no external nutrient supply (Fisher et al. 2007).  
In terms of the search for bioactives, high biodiversity and adaptation increase the 
likelihood of detecting novel molecules. Such molecules could be completely unique in 
structure or have functional analogues within the human body. In terms of discovering 
osteogenic bioactives another reason why marine organisms may be of interest is that they 
include many mineralising species (David W. Green et al. 2013). Depending upon the degree 
of conservation of molecules and mechanisms involved in mineralisation, these species may 
be a source of analogues that can promote activity of the BMU for bone maintenance in 
humans. Whilst this project focuses only on marine invertebrates, there are still a huge 
number of taxonomical groups to test extracts from. Positively, this increases discovery 
potential, but it also presents a challenge in terms of where to focus efforts. If a limited 
number of extracts are used tests can be more detailed, but the chances of an activity ‘hit’ 
are reduced. A trade-off is therefore necessary between the number of tests performed and 
extracts screened.  
In relation to this project there are a wide variety of papers that make use of in vitro 
cell based assays. They can be employed to determine osteogenic activity in relatively raw, 
unmodified and novel substances, such as the abalone gastro-intestinal extracts mentioned 
in chapter 1 (Nguyen et al. 2014). Though cell viability (as determined by MTT assay) did not 
vary with abalone extract treatment, ALP activity showed a dose dependent increase. As ALP 





mineralisation, mineralisation level was also quantified and showed another dose dependent 
increase with treatment. This demonstrates how basic assays can help to determine what 
aspect of cell behaviour an extract effects, in this case differentiation, justifying further tests 
on the mechanism of that effect. Alternatively, cell-based assays are just as useful for 
confirming the activity of specific molecules, such as the nacreous protein p10, that was also 
demonstrated to increase preosteoblast differentiation (Zhang et al. 2006). For most work in 
this field these basic cell activity assays are necessary for establishing an effect, and are 
subsequently followed by more detailed tests. Taking fucoidan as an example, there is a 
catalogue of work detailing the osteogenic and anti-osteoclastic activity of this sulphated 
polysaccharide, whilst more recent studies are now working to deduce the mechanism of 
these effects (Kim et al. 2014). Unlike studies on fucoidan or nacre, the extracts tested in this 
thesis have not been screened previously for osteogenic potential, meaning experimental 
work will revolve around searching for extracts which show activity ‘hits’. This approach 
means that detail concerning bioactive structure, or the mechanism of any effects, will not 
be determined, yet it benefits from having a good chance of detecting extracts with novel 
osteogenic activity – which may show even better pre-clinical potential than that of other 
known marine-organism derived compounds.   
This chapter will detail the first set of experiments conducted on marine extracts as 
part of this project. Several cell-based assays were used during the first screen, though those 






3.2.1 Extraction procedure (for processing material, undertaken by the Marine Institute, 
Galway) 
As previously stated, extracts used in this study came from a range of marine invertebrate 
taxa, collected both from shallow and deep water at numerous sites along the west coast of 
Ireland (see appendix 6 for list of taxa tested). Sampling work was undertaken as part of the 
Beaufort Marine Biodiscovery research programme, which aimed to build marine 
biotechnology capacity within Ireland. After collection, specimens were frozen and stored at 
the Marine Institute (NUI Galway) before further processing. Extraction from a specimen 
began with the material being freeze dried, washed with dH2O, freeze dried again and 
subsequently milled into a fine powder (figure 3.1). Five grams of this powdered material was  
Figure 3.1: showing the steps involved in extract production, as taken by Isa Wolfe and 





then mixed with 500 ml dichloromethane (DCM, CH2Cl2) and stirred for 24 h at room 
temperature. The solution was filtered using a vacuum pump, yielding a DCM-soluble extract 
solution and an undissolved dried powder. A rotary evaporator was used (pressure: 685 
mbar, rotation: 140 rpm [revolutions per minute], water bath temperature: ice/40°C, anti-
bumping granules included) to reduce the volume of DCM to a manageable level. Any 
remaining solution was then placed in an open container and left for at least 24 h, producing 
a dried residue. The undissolved powder was then subjected to a second extraction, this time 
using 500 ml of methanol (MeOH, CH3OH), using the protocol as described above (same 
settings as for DCM, except pressure which was set at 236 mbar). The two dried residues 
were finally combined, and it was this material which was shipped to QUB for use in 
experiments. Remaining powder (after the MeOH extraction) was collected in foil, vacuum 
packed and frozen for potential future use.   
 
3.2.2 Processing material at QUB 
All extracts were stored in -20°C freezers upon arrival at QUB (Queen’s University Belfast) 
and covered in foil to prevent UV/light degradation.  
 
3.2.2.1 Extracts MR01-MR43 
Weights for this set of extracts ranged from 4 to 27.7 mg. Dimethylsulfoxide (DMSO) was 
used as a solvent, and in an effort to keep the concentration of extracts high a minimal 
amount of DMSO was added to each vial, in 100 µl increments. However, it quickly became 
apparent that 30 mg of material would likely dissolve in 1 ml of solvent. 100% anhydrous 
DMSO was also used after the first 200 µl additions, to counter the hygroscopic nature of the 
solvent which otherwise decreases its purity. To aid dissolution each extract vial was placed 
on a rotary mixer and heated repeatedly to 37°C, before finally being diluted in culture 
medium. When test wells were treated with 200 µl of test solution this gave an eventual 
concentration of extracts ranging between 4 and 6.34 µg per well, based on a maximum 
addition of 0.1% DMSO.   
 
3.2.2.2 Batch of 25 dissolved in ethanol 
After screening extracts dissolved in DMSO fresh material was received from the marine 





extracts, ethanol was added in varying volumes depending on extract weight, to give an 
approximate concentration of 30 mg of material per ml of solvent. For extracts 294 and 621 
the material received was minimal (0.5 mg and 1.9 mg respectively) and therefore extra 
solvent had to be added to ensure a manageable amount of solution to work with. Each vial 
was then vortexed, heated to 37°C on a rotary shaker and placed in a low-frequency sonicator 
(Branson 3510, USA). For proliferation studies using hFOBs a maximum ethanol 
concentration of 0.5 or 1% was used, which resulted in 30 or 60 µg (respectively) of extract 
material per 200 µl test solution (except for 294: 8.32 or 4.16 µg per 200 µl, and 621: 34.4 or 
17.2 µg/200 µl).   
 
3.2.2.3 Powder residues 
Powder residues are the material which did not dissolve in either DCM or methanol during 
the original extraction process. For each powder extract 60 mg of powdered material was 
added to a 20 ml universal. A minimum addition of 2 ml of solvent was required to 
reconstitute the powders. For most powders 2 ml of 0.1 M NaOH was added to each 
universal, which was subsequently subjected to cycles of vortexing, placement on a rotary 
shaker, heating to 37°C and placement in a low-frequency sonicator. To exclude undissolved 
material from treatments each solution was either centrifuged and the supernatant 
collected, or filter sterilised using a 0.22 µm filter. A small volume of 2 M HCl was then added 
to neutralise the solution (monitored via pH meter), giving a 100 mM solution of NaCl, 
containing dissolved extract material. To make final treatment solutions these solvent 
extracts were mixed with culture medium at either 0.1, 0.5, 1, 5 or 10% concentrations. 
For the powder residue 621, three other solvents were also tested, to determine the effect 
of solvent choice on treatment solution bioactivity: 70% ethanol, 0.1 M HCl (then neutralised 
with NaOH) and pure distilled water. Other than the solvent choice these solutions were then 
treated in the same method as described for the NaOH extraction. 621 was chosen at 
random, as use of three solvents on all powders would have resulted in an unmanageable 
number of treatments.  
 
3.2.3 Cell culture and activity assays 
hFOBs were cultured as detailed in chapter 2 (section 2.2). 





• XTT cell viability – see section 2.2.1. 
• Lactate dehydrogenase cytotoxicity – see section 2.2.2. 
• PicoGreen cell proliferation – see section 2.2.3. 
• Crystal violet cell proliferation – see section 2.2.4. 
• Alkaline phosphatase cell differentiation – see section 2.2.5.  
 
3.2.4 Experimental design 
The seeding density used, unless otherwise stated, was 1x104 cells/cm2 for the experiments 
detailed in this section. Cells were also given a 24 hour ‘attachment’ period, after which point 
the culture medium was removed and replaced with that containing treatments. All medium 
additions, normal or treatment, were 200 µl in volume. During culturing, observations were 
noted on set days.  
3.2.4.1 Extracts dissolved in DMSO MR01-43 
• For proliferation/LDH testing extracts were seeded into 96 well plates, with 4 repeat 
wells per treatment. Cells were fed on day 4 with treatment medium. 
• During culturing two controls were included: 1. complete medium only and 2. 
complete medium+0.1% DMSO.  
• XTT was conducted after 1 day of treatment. 
• Cytotoxicity at day 1 was measured using LDH assay  
• PicoGreen assays were performed at day 4 and 7 on cell lysates (after lysis using 0.1% 
Triton X-100 and four cycles of freeze and thaw) with a set of standards on each plate 
for standard curve calculations (accounting for plate to plate variability). For both 
LDH and PicoGreen tests, supernatant was tested in duplicate—meaning that for 
each well cultured two values were obtained, giving a total of 8 values per treatment. 
• For ALP activity cells were cultured in 96 well plates with four repeat wells per 
treatment. hBMSCs (donor: 008, passage: 4) were used instead of hFOBs and cells 
were fed on day 4. Controls included: 1. complete medium only and 2. osteogenic 
medium+0.1% DMSO. ALP readings were normalised to DNA concentration, using 
PicoGreen assay, and supernatant was tested in duplicate.  
 
3.2.4.2 Batch of 25 extracts dissolved in ethanol 





• During culturing a total of three controls were included: 1. complete medium only, 
2. complete medium+0.5% EtOH and 3. complete medium+1% EtOH.  
• Cytotoxicity at day 1 was measured using LDH assay  
• Proliferation was measured by crystal violet staining at day 4 and 7 (fed day 4). 
Unfortunately, the day 1 cell monolayer detached during washing and this crystal 
violet time point was lost.  
• For differentiation testing, cells were seeded onto 96 well plates for ALP activity 
assay with four repeat wells per treatment. hBMSCs (donor: 008, passage: 4) were 
used and cells were fed on day 4. Controls included: 1. complete medium only and 
2. osteogenic medium+0.5% EtOH. ALP readings were normalised to DNA 
concentration, using PicoGreen assay, and supernatant was tested in duplicate.  
 
3.2.4.3 Powder residues 
• Powder residue extracts were tested on cells seeded onto 96 well plates with three 
repeat wells per treatment. 
• For each powder, five concentrations of 0.1, 0.5, 1, 5 and 10% were included.  
• Two controls included: 1. complete medium and 2. complete medium with either 
0.1, 0.5, 1, 5 or 10% NaCl. 
• For extract 621 different solvents were also investigated [as detailed in section 
3.2.2.3] and appropriate vehicle controls were therefore included.  
• Cytotoxicity was determined by LDH assay at day 4 
• Crystal violet assays were performed for cell proliferation on days 1, 4 and 7.  
 
3.2.5 Statistical analysis 
Results are presented as means +/- standard deviation, based on at least 3 single repeat 
values for each data point. Each dataset was tested for normality using both Kolmogorov-
Smirnov and Shapiro-Wilk tests, as well as equal variance using Brown-Forsythe test. 
Subsequently, sets were tested by One-Way ANOVA, with any significant differences further 
investigated by Dunnetts t-test (two-sided). This compared each treatment to the medium 
and vehicle control group. Only two datasets did not meet the assumptions required for 
parametric testing and for these the Kruskal-Wallis test was used as an alternative. This 
included results shown in figures 3.9 b) and 3.10 b). All statistics were produced using SPSS 






3.3.1 Extracts MR01-MR43 




























Figure 3.2: cell viability (XTT assay) of hFOBs using extracts a) MR01-14, b) MR15-28 and c) MR29-
43. Cells were given a 24 h attachment period, 24 h with treatment and 4 h with treatment and 
the reaction substrate. Results are presented as the mean +/- standard deviation (n=4). *p<0.05 







Within set 1 [figure 3.2 a)] the majority of extracts only show small variations from control 
values. Of these MR07 and 08 are most pronounced, both showing an increase from the 
control. MR08’s increase is statistically significant (p=0.023), though this treatment also 
shows comparatively large standard deviation values. Values for set 2 [figure 3.2 b)] extract 
treatments (MR15-28) vary little from the control. Within these values those for MR21, 22 
and 23 are increased compared to the control, whilst MR25 and 26 are lower. However, of 
these the decrease in absorbance for MR26 is the only significant difference (p=0.048). Set 3 
[figure 3.2 c)] treatment values are all increased relative to the 0.1% DMSO control. Of these 
increases, 6 are statistically significant (p<0.05), including MR32, 35, 36, 37, 39 and 40, 




































Results across the three separate LDH test sets [figure 2a-c)] are comparable in many ways. 
The reliability of each assay was confirmed by a positive kit control. Additionally, 100% cell-
death positive controls (red bar) had similar absorbance values between sets, though were 
slightly higher for set 1 (approximately 0.6, compared to 0.5 for set 2 and 3). All treatment 
data is also within a similar maximum and minimum range, with absorbance values spread 
between 0 and 0.16.  
The main difference is seen for set 1 [figure 3.3 a)], where values for complete media control 
(Comp. media) and control (0.1% DMSO) are closer to those of treatment groups. This is 
different to sets 2 and 3 [figure 3.3 b), 3.3 c)] where cytotoxicity is markedly reduced for all 
treatments (generally below 0.02) compared to controls (at around 0.12). Within set 1, 
extracts MR04, 05, 13 and 14 are significantly lower in value compared to the control 
(p<0.05). Conversely, extracts MR08 and 11 are on a level with controls, whilst all other 
treatments show small cytotoxicity reductions that lack significance.  
Set 2 [figure 3.3 b)] treatment cytotoxicity values (MR15-28) are all significantly lower 
(p<0.05) than those of the control. Of these, MR15, 19, 20 and 24 are the lowest, and are 
very close to absorbance values of zero. Set 3 [figure 3.3 c)] is similar, in that all extracts 
Figure 3.3: cytotoxicity results (LDH assay) for hFOBs challenged with extracts a) MR01-14, b) 
MR15-28, c) MR29-43 and d) 9 extracts, 3 from each identified set of extracts (see text). Cells were 
given a 24 h attachment period, 24 h with treatment and then supernatant was collected for 
testing. Results are presented as the mean +/- standard deviation (n=4). Positive shows the 
absorbance values for 100% cell death. All values are corrected for background absorbance by 
subtracting appropriate negative control values. Kit positive control confirmed the assay worked 







(MR29-43) have significantly reduced (p<0.05) toxicity levels compared to the control. Within 
these, the most pronounced reductions are seen for MR30, 37, 38 and 42.  
To determine repeatability, 3 extracts from each set were retested [figure 3.3 d)]. Within this 
test, set 1 extract values (MR-03, 04 and 05) are closest to those of the control, with extracts 
from set 2 and 3 showing comparatively lower absorbance levels. Comparing between the 
retest and original toxicity assays, set 1 values [d)] are within a similar range to those of 
original results [a)], though MR04 and 05 are no long significantly reduced. Sets 2 and 3 on 
the other hand retain their significant reductions in cell death compared to control [d)], 
though it should be noted that their overall range of values was slightly higher than those 
seen originally [b) c)].  
 
3.3.1.3 PicoGreen assay 
Figures 3.4, 3.5 and 3.6 all present results for double stranded DNA concentration obtained 
from PicoGreen assays, conducted on day 4 and day 7. At day 4 [figure 3.4 a)] MR01, 03, 05, 
07 and 09 have a lower dsDNA concentration, indicating reduced cell number relative to the 
control. Other treatment values are like the control, although MR10 and 11 have a noticeably 
higher concentration. Of these differences, the decrease for MR09 is the only one which is 
statistically significant (p<0.05). At day 7 [b)] concentration values are generally increased, 
approximately clustering around 0.8 µg/ml instead of between 0.5 and 0.7 µg/ml as at day 4, 
demonstrating cell proliferation in all groups. MR05 shows the highest mean dsDNA 
concentration, though at this time point no statistically significant increases relative to the 


































On day 4, except for MR-15, all treatments show lower dsDNA concentrations/cell number 
compared with the control group (figure 3.5). Of these, MR20, 21, 24 and 28 are significantly 
reduced (p<0.05). A similar distribution is seen at day 7 [b)], with MR15 the only treatment 
showing greater cell number than the control. The remaining extracts (excluding MR18) show 
lower cell number relative to the control group. For this time point MR17 and 27 are 
significantly reduced (p<0.05), though MR-20, 21, 24 and 28, as well as 23 and 26, also show 
pronounced decreases.  
Figure 1.4: cell proliferation (PicoGreen assay) of hFOBs when challenged with extract set 1 (MR01-
14). Cells were given a 24 h attachment period and then cultured with treatment for 4 [a)] or 7 [b)] 
days. Results are presented as the mean +/- standard deviation (n=4). *p<0.05 for treatment 





























Set 3 PicoGreen results (figure 3.6) were the most variable of the three, both in terms of 
standard deviation values and results between the two time points. Day 4 [a)] showed 
increases in dsDNA concentration/cell number for all treatments relative to the control 
group. These increases were smallest for extracts MR40 and 43. Statistically significant 
increases were seen for extracts MR29, 30, 32, 36, 37 and 38 (p<0.05).  
 
Figure 3.5: cell proliferation (PicoGreen assay) of hFOBs when challenged with extract set 2 
(MR15-28). Cells were given a 24 h attachment period and then cultured with treatment for 4 
[a)] or 7 [b)] days. Results are presented as the mean +/- standard deviation (n=4). *p<0.05 for 





Comparatively, all the control and test values were higher at day 7 [b)] than at day 4, ranging 
roughly between 0.5 and 0.7 µg/ml (compared to around 0.25 to 0.5 µg/ml). However, day 7 
increases in treatment concentrations (indicating higher cell number) were less pronounced 
relative to the control, when compared to day 4. MR32 actually decreased in value, as did 


























Figure 3.6: cell proliferation (PicoGreen assay) of hFOBs challenged with extract set 3 (MR29-43). Cells 
were given a 24 h attachment period and then cultured with treatment for 4 [a)] or 7 [b)] days. 
Results are presented as the mean +/- standard deviation (n=4). *p<0.05 for treatment compared 






3.3.1.4 Alkaline phosphatase assay 
 
 
ALP activity assay results generally show small deviations in activity values for DMSO 
dissolved extracts compared to control (figure 3.7). Of these, only extracts MR-09, 21 and 24 
are significant, all causing substantial decreases in ALP activity level. MR-21 showed the 
greatest reduction, displaying a relative ALP activity value of only 116 ng/µg DNA, compared 
to a control value of 320 ng/µg DNA. Some of the remaining extract treatments produced 
noticeable reductions (e.g. MR-01, 32) or increases (e.g. MR-20, 27) compared to control, but 
these failed to reach statistical significance.  
  
Figure 3.7: hBMSCs (donor:008, passage:4) differentiation at day 7 using ALP activity assay. Control 
treatment was osteogenic media with 0.1% DMSO, along with a complete media control for 
reference. Cells were challenged with a subset of extracts ranging between MR01-40. Cell 
differentiation is reported as ALP activity normalised to DNA concentration. Relative ALP activity 
is presented as mean +/- SD, (n=4). * indicates a significance difference (p<0.05) between the 





3.3.2 Batch of 25 extracts dissolved in ethanol 
Ethanol was chosen for use as no reliable positive results for DMSO dissolved extracts were 
identified during previous screening. Specifically, ethanol was chosen over other potential 
solvents as it was shown to have a lower toxicity than DMSO during method optimisation 
work (chapter 2). LDH results are included for each of the 25 extracts that were dissolved in 
Figure 3.8: cytotoxicity results (LDH assay) for hFOBs challenged with 25 extracts (split between 
a) and b) for convenience) dissolved in ethanol and diluted in complete medium at a 0.5% 
concentration. Cells were given a 24 h attachment period, 24 h with treatment and then 
supernatant was collected for testing. Results are presented as the mean+/- standard deviation 
(n=4). C+ve (red) shows the absorbance values for 100% cell death. All values are corrected for 
background absorbance by subtracting appropriate negative control values, run on the same 
plate. Kit positive control confirmed the assay worked on each plate as expected. * p<0.05 for 





ethanol (figure 3.8). Kit reliability was again confirmed via inclusion of a positive kit control. 
Furthermore, the 100% cell death positive control was similar in value (0.4861) to those for 
the first 43 extracts tested (figure 3.3).  
The complete media, 0.5% EtOH and 1% EtOH controls were similar in value, with 
approximately a 0.18 absorbance level. Most extracts treatments showed small fluctuations 
around these control values. However, extracts 87, 199, B1295 and 333 showed small but 
evident increases in cytotoxicity, which are all statistically significant (p<0.05). Also significant 
was extract 324, which had the greatest value of 0.467; almost equal to that of the 100% cell 
death positive control.  
Decreases in absorbance value are also seen, including extracts 35, 1083, 12, 294, 625, 621, 
632, B1368 and B787. For the first three extracts mentioned (35, 1083 and 12) these are small 
decreases, though the remainder are larger, particularly those of 625, 621, B1368 and B787. 






Cell proliferation values, as measured by CV assay, are presented as optical density readings, 
taken at the 585 nm wavelength (figures 3.9 and 3.10). Each plate (i.e. a) and b) - separate 
plates for each figure) had its own controls included to account for plate to plate variation in 
cell number. Control values are generally similar between plates, at just below a value of 0.9; 
except for the 0.5% EtOH control of figure 3.9 a), which is lower in value and has a greater 



















Figure 3.9: cell proliferation (crystal violet assay) of hFOBs challenged by 13 extracts (set 1) 
dissolved in ethanol and then diluted in complete media at a 0.5% concentration. Cells were given 
a 24 h attachment period and then cultured with the treatment for 4 [a)] or 7 [b)] days. Results 
are presented as the mean +/- standard deviation (n=4). *p<0.05 for treatment compared with the 





At day 4 [figure 3.9 a)], small cell number decreases for extracts 87, 79 and 199 are seen in 
relation to the 0.5% EtOH control. Extracts 1448 and 1095 show an even greater and 
statistically significant reduction (p<0.05) in cell number. Remaining variation is less 
pronounced, though some small statistically significant increases are seen for extracts 1359, 
1083 and 279. Day 7 [b)] results complement those of day 4, with most trends being 
maintained at the later time point. However, no deviations are statistically significant, as day 
7 data did not have equal variance and was therefore analysed via Kruskal-Wallis test rather 

















Figure 3.10: cell proliferation (crystal violet assay) of hFOBs challenged by 12 extracts (second set) 
dissolved in ethanol and then diluted in complete media at a 0.5% concentration. Cells were given a 
24 h attachment period and then cultured with the treatment for 4 [a)] or 7 [b)] days. Results are 
presented as the mean +/- standard deviation (n=4). *p<0.05 for treatment compared with the 0.5% 





The second set of extracts (figure 3.10) are like the first, in that decreases in absorbance 
values are generally seen relative to the control, indicating reduced cell number. At day 4 
extracts B1693, 324 and 632 show the largest reductions, 333 is slightly higher and B13568 
is roughly two thirds the value of the control. All are statistically significant (p<0.05). Of the 
remaining extracts, 614, 294 and B787 show very small reductions in cell number whilst 
others are similar to the control. Day 4 trends are maintained at day 7, though there is a 
general increase in cell number with time. Previous significant reductions are still reduced, 
though are generally (with the exception of B1693 and 632) no longer significant despite 
being similar in value. This is again because day 7 data did not show equal variance and was 
therefore analysed using the Kruskal-Wallis test. The main change at this later time point is 
that extracts 614 and 294 are now significantly reduced relative to the control (p<0.05).  
 
 
ALP activity assay results of hBMSCs challenged with ethanol dissolved extracts (figure 3.11) 
show a similar trend to those of figure 3.7, with the only significant results being reductions 
(rather than increases) in ALP activity. However, these reductions are more numerous than 
those of figure 3.7, with only extracts 294, 146 and 1359 not significantly decreased relative 
Figure 3.11: hBMSCs (donor:008, passage:4) differentiation at day 7 using alkaline phosphatase 
(ALP) activity assay. Control treatment was osteogenic media with 0.5% EtOH, along with a 
complete media control for reference. Cells were challenged with a subset of ethanol dissolved 
extracts at a 0.5% concentration. Cell differentiation is reported as ALP activity normalised to DNA 
concentration. Relative ALP activity is presented as mean +/- SD, (n=4). * indicates a significance 





to control (0.5% EtOH). All decreases are similar in value between extracts, though extract 
B787 had the greatest effect – reducing ALP activity to value of approximately 35 ng/µg DNA, 
compared to 178 ng/µg DNA for control.   
 
3.3.3 Powder extracts 
Powder extract results are shown in figures 3.12-3.14. As there were so many different 
combinations of solvent type and concentration results have been separated for 
convenience. Figures 3.12 and 3.13 include control values (run on each plate) termed saline 
(0.1-10%), for comparison against extract values. Similarly, figure 3.14 includes saline 
controls relatable to HCl extractions, which were performed for extract 621. 621 was also 
extracted using 70% ethanol and 100% water, values for which - along with controls - are also 
shown in figure 3.14.  
Firstly, 10% treatment with powder 625 reduced absorbance to a value of 0.21 at day 1 
[figure 3.12 a)], relative to a control value of 0.31. This cell number reduction becomes more 
pronounced at days 4 and 7 [figure 3.11 a) and b) respectively]. Conversely, this powder at 
concentrations of 1% and 5% was increased relative to the control at all time points, At the 
lower concentrations of 0.5% and 0.1% there was less activity, though 0.5% was significantly 
increased at day 7. Comparatively, powder extract 294 showed less variation overall, with 
only the 5% treatment being increased from control values at each time point. 0.1% solution 
also showed an increase, but only at day 7. Finally, for 614 no concentration had any effect 
at day 1, but a bell-shaped response was seen at days 4 and 7. Of these 1% was particularly 
significant, having the greatest values at both time points - especially at day 7 where it was 










Figure 3.12: cell proliferation (crystal violet assay) of hFOBs challenged using powders 625, 294 
and 614 dissolved in saline solution. Cells were given a 24 h attachment period and then cultured 
with the treatment for 1 [a)], 4 [b)] or 7 [c)] days. Results are presented as the mean +/- standard 































Figure 3.13: cell proliferation (crystal violet assay) of hFOBs challenged using powders 333, 840, 
621 and 632 dissolved in saline solution. Cells were given a 24 h attachment period and then 
cultured with the treatment for 1 [a)], 4 [b)] or 7 [c)] days. Results are presented as the mean 








No clear trend can be seen at days 1 and 4 for powder 333 [figure 3.13 a) and b)], though by 
day 7 [figure 3.13 c)] there was a negative dose-dependent response. Here the lowest 
concentration powder solutions showed the greatest cell proliferation absorbance values, of 
which 0.5% was significantly increased from the controls. 840 showed a similar negative dose 
dependent response at days 4 and 7, though all treatments were reduced compared to 
controls, indicating low cell number. 621 on the other hand had a reversed bell shape, with 
the lowest absorbance values for mid-range concentrations of 1 and 5%. Conversely, 0.1, 0.5 
and 10% showed small increases, of which 0.5 and 10% were significant (p<0.05), compared 
to the relative saline control at day 7. Finally, except for some variation at the day 1 time 
point, 632 showed a similar negative dose-dependent response to that described for 333 and 
840. By day 7 only the 0.1% 632 powder treatment was similar in value to the control, whilst 
the others were all reduced.  
 
For 621 ‘acid’, where powder was first dissolved in HCl and then neutralised with NaOH, 
there’s no clear relationship between time points [figure 3.14 a), b) and c)]. For days 1 and 4, 
0.1 and 0.5% had the lowest absorbance values, though by day 7 a trend of decreasing 
absorbance with lower powder concentration is seen. For 621 dissolved in ethanol there was 
no significant deviation from controls (0.5% and 1% EtOH) at any time point. Finally, 621 
water extraction values are shown, both for controls and treatments. Apart from day 4, water 
addition to medium decreased cell number in a dose dependent manner. At days 1 and 4, 
W621 showed no concentration response, though at day 7 high values were seen for 5 and 
10% treatments. This was a significant rise from the relative controls (p<0.05), with the 10% 













Figure 3.14: cell proliferation (crystal violet assay) of hFOBs challenged using powder 621 (along 
with relevant controls), dissolved using either an acid first saline extraction, ethanol or water. Cells 
were given a 24 h attachment period and then cultured with the treatment for 1 [a)], 4 [b)] or 7 
[c)] days. Results are presented as the mean +/- standard deviation (n=3). *P<0.05 for treatment 













Outcome Extract Increase Time pts Solvent Conc.
measure Decrease (day) (%)
XTT MR08 1 DMSO 0.1
(Cell MR26 1 DMSO 0.1
viability) MR32, 35, 36, 37, 39, 40 1 DMSO 0.1
LDH MR04, 05, 13, 14 1 DMSO 0.1
(Cell MR15, 16, 17, 18, 19, 20, 21 1 DMSO 0.1
death) 22, 23, 24, 25, 26, 27, 28 1 DMSO 0.1
MR 29, 30, 31, 32, 33, 34 1 DMSO 0.1
35, 36, 37, 38, 39, 40, 41 1 DMSO 0.1
42, 43 1 DMSO 0.1
PicoGreen MR09 4 DMSO 0.1
(Cell MR01, 09 7 DMSO 0.1
proliferation)MR20, 21, 24, 28 4 DMSO 0.1
MR17, 27 7 DMSO 0.1
MR 29, 30, 32, 36, 37, 38 4 DMSO 0.1
MR33 7 DMSO 0.1
LDH 87, 199, B1295, 324, 333 1 EtOH 0.5
(Cell 625, 621, B787 1 EtOH 0.5
death)
Crystal V. 1448, 1095, B1693, 324, 333 4 EtOH 0.5
(Cell 632, B13568 4
proliferation)1359, 1083, 279 4 EtOH 0.5
87, 199, 1448, 1095 7 EtOH 0.5
B1693, 614, 324, 294, 333 7 EtOH 0.5
632, B13568 7 EtOH 0.5
SET 1 EXTRACTS MR01-43
BATCH OF 25 EtOH EXTRACTS
Table 3.1: collation of results showing those treatments with statistically significant (p = <0.05) 
differences compared to the relevant control. This table contains information from set 1 (DMSO) 
and ethanol dissolved extracts. Those extract numbers highlighted in bold showed at least two 
different significant differences, either between time points or different types of assay. Green 











Table 3.2: collation of results showing those treatments with statistically significant (p = <0.05) 
differences compared to the relevant control. This table contains information from powder 
extracts. Those extract numbers highlighted in bold showed at least two different significant 
differences, either between time points or different types of assay. Green arrows represent a 
significant increase, whilst red indicates a significant decrease relative to the control. 
Outcome Extract Increase Time pts Solvent Conc.
measure Decrease (day) (%)
Crystal V. 625 1, 4 ,7 Alkaline 10
(Cell 625 4, 7 Alkaline 5 + 1
proliferation)294 1 Alkaline 10
294 1,7 Alkaline 5
614 4,7 Alkaline 1
614 7 Alkaline 5 + 1 + 0.5
614 7 Alkaline 10
333 1 Alkaline 10 + 1
333 7 Alkaline 0.5
840 4 Alkaline 10
840 7 Alkaline 10 + 5
621 7 Alkaline 10 + 0.5
632 1 Alkaline 10
632 1, 7 Alkaline 0.5
632 4 Alkaline 1
632 7 Alkaline 10 + 5
H621 1, 4, 7 Alkaline 10
H621 1, 7 Alkaline 5
H621 7 Alkaline 1 + 0.5
W621 1, 7 Alkaline 10 + 5







Experimental work detailed within this chapter aimed to assess the impact of crude extracts 
on both cell death and cell proliferation (as well as brief ALP activity [cell differentiation] 
testing). This was achieved for DCM/methanol extracts reconstituted in DMSO or ethanol, as 
well as for powder residue extracts.   
 
3.4.1 DMSO and ethanol extracts  
3.4.1.1 Decreased cell proliferation  
XTT results, whilst not specifically measuring cell proliferation, do give a good indication of 
this variable, as they represent the number of metabolically active cells able to produce the 
formazan product. MR-26 was the only extract which showed a significant reduction in XTT 
value, as ethanol dissolved extracts or powder residues were not tested with this assay. 
Additionally, MR-26 also gave relatively low dsDNA concentration from PicoGreen results. 
PicoGreen gives a quantitative indication of cell number, as with more cells/greater 
proliferation a higher dsDNA concentration would be expected. These results may therefore 
indicate the presence of a specific bioactive, or bioactives, which reduces proliferation. Of 
note, this was the only instance in which an XTT value correlated with dsDNA concentration, 
suggesting that extract-based effects on metabolic activity at this early time point were 
generally not maintained when measuring proliferation at days 4 and 7.   
Many other extracts, both those dissolved in DMSO and ethanol, showed reduced cell 
proliferation values during seven days in culture including: MR01, 09, 20, 21, 24, 26 and 28, 
as well as ethanol-based extracts 1448, 1095, B1693, 324, 333, 632, B13568, 87, 199, 1448, 
1095, B1693, 614 and 294.  
Osteoblasts undergo a sequential development which can be ordered into three main stages: 
a proliferative period, ECM development and finally mineralization of this matrix. Freshly 
seeded osteoblasts tend to be in the proliferative stage, actively undergoing mitosis to 
increase cell number, supported by ample culture space and high nutrient levels. However, 
as osteoblasts develop they begin to differentiate towards the mature phenotype and 
proliferation is reduced (Aubin 2001; Lian & Stein 1995). It may be that the extract mixes 
detailed above suppressed proliferation relative to other treatments and controls. 
Alternatively, they may have supported earlier cell differentiation at the cost of reduced cell 
division. To test this hypothesis a small ALP assay was conducted, focusing on those extracts 





promotion of ALP activity and instead significant reductions were common. This indicates 
that those extracts which suppressed proliferation were not also supporting cell maturation. 
To note, both ALP assays made use of hBMSCs rather than hFOBs, as opposed to other work 
detailed within this chapter. This was a purposeful decision, as hBMSCs previously displayed 
better ALP activity than hFOBs during optimisation testing (chapter 2, section 2.7.1). As only 
a limited number of promising extracts were being tested, and as this was the last measure 
of potential cell activity planned for both extract sets (due to their limited proliferation 
response), hBMSCs gave the best chance of detecting bioactivity.  
Another important factor to consider when discussing proliferation is cytotoxicity, as 
increased cell death levels would naturally also result in a lower cell number. Before 
comparing results, it should be noted that obvious differences in LDH values existed between 
DMSO and ethanol-based experiments, as seen in figures 3.3 and 3.7. Figure 3.3 readings, for 
extracts MR 01-43, were approximately 10 times lower than those for ethanol dissolved 
extracts. However, this was also the case for medium only control treatments, indicating 
higher reading values were not due to extract inclusion, or use of ethanol as a solvent. 
Similarly, this change was unlikely to be due to human error, as cell seeding density was kept 
the same; as confirmed by comparable positive control values between the two experiments. 
Instead these differences were more likely a feature of the FBS used during culturing for each 
test. Originally FBS from PAA was used until it ran out, after which a lot from Sigma-Aldrich 
proved most effective in batch testing. Any use of FBS is known to have a stimulatory effect 
on LDH activity (Baba et al. 2005), and as the new batch was first used just before these 
results were obtained it is likely the cause of variation.  
All treatments dissolved in DMSO which lowered cell proliferation also had low or 
significantly reduced cytotoxicity levels, in comparison with controls. This supports the idea 
that these mixes contain bioactives able to suppress cell proliferation or promote cell 
maturation, rather than toxic compounds. However, there were instances where toxicity 
increased whilst proliferation values decreased, particularly those obtained using the crystal 
violet assay. 324 for example - which was completely toxic - showed very little proliferative 
activity, indicating no cells were present to be stained by the dye. Extract 87 and 199’s lower 
proliferation values (compared to controls) may also be explained through a slight toxic 
effect, as ALP results confirm it isn’t linked to an increase in differentiation. However, there 
are also results which do not follow the ‘expected’ trends based on both LDH readings and 
observations. 632 is a good example of this, as it presented an LDH value lower than that of 





both time points 632 had an optical density almost identical to that of 324, which as 
mentioned was highly toxic. In this instance, it seems evident that 632 was having a toxic 
impact on cells, but perhaps this effect was only seen at the later time points of day 4 and 7; 
for example due to stimulation of apoptotic pathways which had a delayed effect. Extracts 
1448 and 1095 also showed the same trend of a very low O.D. value at day 7, as did B1693; 
which may again indicate a late toxic effect.  
Some extracts had no impact on proliferation but presented reduced cytotoxicity levels, such 
as 625, 621 and B787. This may again suggest the presence of a compound, or compounds, 
able to reduce cell death. Such an effect could be through repression of apoptotic pathways, 
or could have been related to cell differentiation. However, significant reductions in ALP 
activity were seen with all three of these treatments, ruling out this hypothesis. Overall, 
decreases in proliferation are common throughout this work. However, at this stage in 
testing, extracts were being sought which promoted cell proliferation or differentiation, or 
both. In a treatment situation this could potentially yield a larger number of osteoblasts, or 
facilitate precursor development to the mature phenotype, improving bone formation and 
healing rates.  
 
3.4.1.2 Increased cell proliferation 
Treatments which increased hFOB proliferation were less common that those which 
decreased it, though there are still numerous examples to discuss. Extracts 10 and 11 for 
example, increased the proliferative capacity of cells, explaining their noticeably higher 
dsDNA concentration values at day 4. Increased dsDNA concentration was likewise present 
at days 4 and 7 for MR15, which also shows a very low LDH absorbance value. This might 
therefore indicate the presence of a bioactive able to stimulate cell proliferation whilst 
reducing cell death, or at least having limited cytotoxicity. Similarly, extracts MR29-43, 625, 
621 and B787 all coupled their significant reductions in cell death with average to high 
proliferation values, which was as expected if cells are healthy.  
Small LDH test values are not uncommon, especially when low concentrations of natural 
compounds are applied to cells. For example, no LDH release could be observed in 
osteoblasts treated with lactic and glycolic acid until concentrations of approximately 100 
mM were reached (Meyer et al. 2012). Taking MR-29-43 as an example, even the highest LDH 
absorbance levels in this group, those of MR31 and 32, do not appear to have impacted early 





(XTT) and MR31 was still higher in value than the control. Also significant in terms of 
increasing cell viability were MR35, 36, 37, 39 and 40, all of which also showed average to 
low absorbance values in the LDH assay. These day 1 tests therefore support the presence of 
non-toxic compounds able to increase cell metabolic activity in those extracts mentioned. 
Furthermore, PicoGreen results indicate this stimulative effect was maintained at later time 
points, particularly at day 4 where most treatment values were noticeably higher compared 
to the control. 
 
3.4.1.3 Effects between time points  
Treatment effects determined by an assay are often maintained between time points, which 
is as expected if an active compound retains its bioactivity over time. Extracts 32, 36, 37 and 
38 for example showed sustained increases in cell activity over days 1, 4 and 7. Furthermore, 
extracts 625, 621 and B787 all coupled their significant reductions in cell death with 
sustained, but fairly average, proliferation values. Significant inhibitions of cell proliferation 
were also sustained over time in this work, such as for extracts 20, 21, 24, 28, 1448, 1095, 
B1693, 324, 333, 632 and B13568. 
There are however instances where effects were not maintained and instead changed 
between time points. For example, MR10 and 11 appear to have increased the proliferative 
capacity of cells, explaining their noticeably higher dsDNA concentration values at day 4. 
However, this increase in concentration was not mirrored with the same extract treatments 
at day 7. This could mean that a potential stimulatory effect of the extract was limited to 
early time points, or it may have been a feature of contact inhibition. Contact inhibition, 
where a cell stops division when touching another cell or object, is a feature of normal, 
healthy eukaryotic cells (Abercrombie 1979). Furthermore, it is a likely limit to cell growth 
and development within the small well area of assay plates, which would explain why DNA 
concentration values rarely exceeded 0.8 µg/ml for any time point/treatment.  
Alternatively, increases in proliferation can lose their significance at day 7, such as with 
extracts 1359, 1083 and 279. However, for these treatments it is likely that original significant 
results may have been influenced by the relatively low value for the ethanol and medium 
control at day 4, rather than extract activity. Finally, inhibition of proliferation also showed 
changes between time points, such as for MR17, 27, 87, 199, 614 and 294. These extracts 
had average-low cell proliferation values at day 4, which only became significantly reduced 





One particularly interesting example of time point variation is that of MR32, which showed 
the lowest dsDNA concentration value (0.46 µg/ml) at day 7, a trait at odds with the 
significant increase at day 4. As previously discussed this may indicate the extract effect was 
limited to earlier time points, though it may also be a function of the crude nature of extracts 
used in these experiments. For example, processing steps were limited during extract 
preparation, both in production of the dried material and its reconstitution in a solvent. As a 
result, each extract likely contained a mix of different proteins, nutrients and other 
molecules, which may have had a range of effects on cell cultures. Competing extract effects 
could therefore explain the results of MR32, with a bioactive stimulating proliferation at day 
4 outcompeted by one facilitating cell differentiation at day 7. Without knowing more about 
the composition of each extract it is difficult to confirm this, though competition between 
different bioactives is commonly reported in other work. For example, out of four proteins 
isolated from the water soluble matrix (nacre) of Pinctada maxima, three were shown to 
increase ALP activity - whilst one decreased it (Almeida et al. 2000). In this instance, a net 
positive effect on mineralisation was observed, coupled with a decrease in cell number 
characteristic of greater cell differentiation (Almeida et al. 2000). Presumably, if a greater 
proportion of proteins were present which reduced ALP activity then mineralisation would 
not have been enhanced. However, based on the difficulty of separating and characterising 
active molecules many extracts tested within this field are crude, with studies reporting 
overall effects rather than those specific to one molecule.  
 
3.4.2 Issues surrounding solvent choice 
Processing/production of DMSO and ethanol dissolved extracts was very similar. The main 
difference (chapter 2) is that ethanol is tolerated by cells at higher concentrations than 
DMSO. Though some small variation in efficiency is likely, ethanol appears to dissolve 
extracts as effectively as DMSO. It was therefore chosen as a replacement solvent as it allows 
a higher treatment concentration to be achieved, generally increasing the likelihood of seeing 
an extract effect.    
Whilst some interesting trends were found using DMSO and ethanol extractions, no large-
scale increases in proliferation were observed. Therefore, it was decided that powder 
residues - left over from the original DCM/methanol extraction - would also be investigated 
for potential activity. Previous oily residues from combined DCM and methanol extractions 





have the benefit of a much greater surface area, and thus a weaker solvent starting point 
was chosen: 0.1M NaOH. This basic solution has a high polarity - similar to water - and would 
therefore be expected to dissolve other polar or ionic molecules. Its most important benefit 
is that, once properly neutralised, treatments are dissolved in saline solution and should have 
a very limited toxic effect; allowing high concentrations to be used (up to 10%), even greater 
than those used with ethanol.  
Dissolution was achieved, using the method described in 3.2.2.3, and was evidenced by 
colour change in test solutions over time. However, varying degrees of powdered material 
did remain undissolved and therefore solutions were centrifuged before use, to limit addition 
of this to the test plates. Unfortunately, centrifugation alone was not sufficient to remove all 
this residue and, as mentioned in section 2.4.2, leftover material can interfere with results of 
both LDH and crystal violet assays. As such, powder residue results cannot be trusted 
completely, though in many instances residue was minimal and experimental work still gave 
a useful indication of extract bioactivity.  
 
3.4.3 Powder extracts 
Grouping the extracts together, there seems to be three sets: those that caused no increase 
in cell activity; those that had a linear dose response in either direction; and finally those 
which had a bell-shaped response curve.  
Powder residues 840, 632 and E621 (dissolved in 70% ethanol) made up the first group. 840 
and 632 reduced proliferation in a dose dependent manner. LDH results for this experiment 
were limited due to the residue issue, meaning only supernatant from a reduced number of 
low concentration treatments was included for testing. As such, toxicity was hard to confirm 
and these results have not been included, though a slight increase in cell death level was 
observed at 0.1% for treatment 840. It may therefore be the case that proliferation was 
limited through cell death, or a bioactive induced repression of cell division.  
Lack of activity for ethanol 621 extract is particularly interesting, as there did appear to be a 
stimulatory effect of high concentrations of 621 dissolved in other solvents. Water 621 
extract was a good example of this, as cell activity at 10% (day 7) was increased from controls, 
whilst observations confirmed residue was limited in this treatment. As water is a more polar 
solvent than ethanol this suggests the active component(s) of 621 is also polar, such as a 
protein with exposed groups and a high dipole moment. Acid (0.1M HCL neutralised with 





is known to have a positive effect, with greater cell response at higher doses. However, 
observations showed that residue was significant for the acid extraction and therefore this 
will not be considered as an indication of bioactivity. Powder extract 333 was also part of the 
second group, showing activity at lower concentrations of 0.1 and 0.5%, indicating it contains 
a compound able to stimulate cell activity at a low level. It also likely contains another 
compound, or compounds, which repress proliferation at higher concentrations. The same 
may also be true for 294, which, apart from an increase at 5% (likely caused by residue), 
showed similar small-scale increases at 0.1/0.5%.  
625 and 614’s bell shaped proliferation response to treatment is particularly interesting. For 
powder 625 there was obvious residue present which could have led to false positive 
proliferation values. Nonetheless, observations on all days indicated that cells were present 
and healthy, even at the maximum 5% concentration, making this a good candidate for 
further investigation. Finally, 614 was the most promising and interesting powder tested. Its 
peak activity at 1% indicates it may contain multiple bioactives. Lower than this, not enough 
compound may have been present to stimulate cells, whilst above this level another 
repressive molecule could have been obscuring its positive influence.  
 
3.5 Conclusion 
A succinct summary of testing on so many extracts is difficult, as each presents different 
trends, promises and challenges. The first set of tests, conducted on extracts 1-43, was 
limited by the toxicity of DMSO and very low levels of material available for testing. Some 
interesting trends were apparent, including wide spread low toxicity and sustained changes 
in cell proliferation; however, these changes were often small, repeatability was a challenge 
due to issues with PicoGreen reliability and, as stated, amounts of test material were low. 
The latter is most concerning, as it is unlikely that further detailed tests could be conducted. 
Raw extracts dissolved in EtOH were more repeatable, showing sustained decreases in cell 
proliferation, both over time and between assays. However, these too were limited by 
extract availability. On the other hand, much more material was available for powder 
residues left over from the original extraction process, making these more suitable for long 
term testing. Despite being the ‘most’ processed, in terms of components removed by DCM 
and methanol, these extracts resulted in relatively large and significant changes to cell 
proliferation. As such, powder extracts showed the most promising activity of extracts 
detailed within this chapter, indicating good osteogenic potential. Future work needs to test 





a confounding variable. Furthermore, activity should be confirmed using primary hBMSCs - 
which are more representative of cells within the human body and therefore give a better 



























Milling, lyophilization or mechanical degradation of extracts to create powdered material is 
common in natural product testing. These processes serve to break up large material and 
increase the overall surface area of an extract, aiding solvent dissolution. One simple example 
is a method used to create a seed powder extract (Jagtap & Bapat 2013), where seeds were 
simply dried, ground and extracted in water. Likewise, extracts supplied for use in this study 
(by the Marine Institute, Galway) were all treated with a similar initial method (see chapter 
3), being freeze dried and milled to generate a fine powder - before organic solvent extraction 
(Rae et al. 2013). Most studies take this approach and focus on testing fractions which 
dissolve in an organic solvent(s), as (depending on solvent choice) these fractions tend to 
contain the most organic material and therefore give the best chance of detecting bioactivity. 
This was the rationale behind sequential testing used in this study, which focused first on 
material which dissolved in original DCM/methanol extractions. However, residue left over 
from these extractions still presents a viable source of natural products/compounds and 
therefore should also be tested for bioactivity. Therefore, this chapter - and much of the work 
within this thesis - focuses on describing the bioactive potential of ‘powder extracts’. These 
are (as described in chapter 3) the material retained after solvent extraction, which to date 
have seen relatively little focus in natural product research – often being discarded rather 
than tested (Jagtap & Bapat 2013).  
Many published studies which use the terms ‘powders’ or ‘residues’ refer to efforts to 
produce value-added products. For example, in one study residues left over after the juicing 
of star fruit were then extracted with acetone, ethanol and water. These extractions were 
shown to have greater antioxidant potential than the juice fraction which is traditionally 
consumed (Guanghou & Lai 2006). Similar work tested milled powder which was left over 
during the processing of Mate (a species of the holly family), which is commonly consumed 
as a beverage in South America. Again, residue material showed excellent properties – having 
a high polyphenol content and good antioxidant potential (Vieira et al. 2010). In addition to 
these value-added approaches there are also studies which include residue testing during 
their evaluation of natural products, with varying degrees of success. For example, extraction 
residues made during the production of lipids from the mussel Perna canaliculus showed no 
activity as a potential osteoarthritis treatment (Gibson & Gibson 1998). Similarly, aqueous 
residues with low activity levels were produced after extractions using n-hexane, ethyl 
acetate and 1-butanol - on the red alga Polysiphonia urceolata (Duan et al. 2006) and the 





moderate antioxidant capacity which generally did not exceed that seen with the organic 
solvent fractions. However, there are examples where residue material extractions show 
good bioactive properties. For example, ether extraction of a residue produced from an 
alcohol extract of Mormodica charantia (commonly known as bitter lemon) shows 
hypoglycaemic activity (Srivastava et al. 1993), as do extracts from seeds of the plant 
Fenugreek. Here all components had a positive effect on diabetic model rates, including the 
original powder from milling, a methanol extraction and residue from this extraction.    
Despite the variability of residue activity reported in different studies, they were still deemed 
to be important for investigation in this work for multiple reasons. Firstly, aforementioned 
studies showed that residue extractions often contain significant organic material, which may 
have activity potential. Interestingly, reports of osteogenic potential for these extracts was 
also very limited, increasing the novelty of this work. Furthermore, in the present study there 
was a large reserve of powder extracts available for testing, meaning most experiments 
wouldn’t be limited by available material. Finally, upon initial screening (see chapter 3) 
powder extracts showed the best activity potential – highlighting the need for more detailed 
testing. This chapter will determine powder extract activity using hBMSCs, specifically 
focusing on their cell proliferation, differentiation and mineralisation potential. As described 
in chapter 2, primary cells like hBMSCs are more representative of the cells within the human 
body and therefore give a better indication of future treatment potential. These cells also 
displayed more repeatable patterns of cell growth and better differentiation potential when 
compared to hFOBs (chapter 2), as shown by their high ALP expression and superior 







4.2.1 Samples used in powder extract preparation 
 Throughout this chapter extracts from a total of 14 different species were tested, the 
identification information for which is shown in table 4.1.  
 
4.2.2 Powder extract preparation 
4.2.2.1 Powder production at the MI 
Powder residues were originally produced during extraction at the Marine Institute in Galway 
(for details see chapter 3, section 3.2.1). However, fresh algal material was also collected and 
extracted solely for use in this study, using an adapted version of the original extraction 
method.  
 





614* Ceramium secundatum Red alga 05-Jun-12 Finavarra; Co. Clare 
333 Plocamium lyngbyanum Red alga 27-Aug-11 Carraroe; Co. Galway 
334 Plocamium cartilagineum Red alga 05-Sep-16 Donegal and Dorset 
625 Osmundea sp. Red alga 21-May-12 Finavarra; Co. Clare 
294 Boergeseniella fruticulosa Red alga 07-Mar-11 Spiddal ; Co. Galway 
615 Ceramium pallidum Red alga 05-Jun-12 Finavarra; Co. Clare 
621 Punctaria sp. (order: 
Ectocarpales) 
Brown alga 21-May-12 Finavarra; Co. Clare 
840 Sargassum muticum Brown alga 02-Mar-14 Doaghbeg, Fanad, 
Donegal 
632 Cladostephus spongiosus Brown alga 20-Aug-12 Finavarra; Co. Clare 
1358 Psolus squamatus Deep sea 
sponge 
07-Jun-13 Cruise 13008 
137 Genus: Lophelia  Coral N/A N/A 





793 Porphyra linearis As above N/A N/A 




Table 4.1: identification information for all the samples used to produce powder extracts. Included 
are the original identification (ID) numbers, genus and species, taxa (a general description of the 
sample material), sample/ID dates and sample location. Where species is not known ‘sp.’ is 
written. For sample 614, * denotes that another two samples from the same species were also 
collected for ‘in-house’ extraction. These included intertidal material from Donegal and 







4.2.2.2 Powder production method for ‘in-house’ extractions 
In order to test the reproducibility of results, fresh samples were collected for extraction 
from two species of epiphytic red algae: Ceramium secundatum and Plocamium 
cartilagineum. Samples from both species were collected during September 2016 from two 
intertidal locations – Christchurch Harbour, Dorset (UK) and Donegal, Ulster (Ireland). After 
collection, samples were kept in seawater during transport and immediately frozen upon 
arrival at the laboratory (–20°C). As stated, the method used followed that of the Marine 
Institute, to limit variation as much as possible between extractions.  Briefly, 2 – 3.60 g of 
each algae (from either UK or Irish sample locations) was cleaned of epiphytes by hand using 
fresh water and placed into a Savant Modulyo freeze dryer (USA) with an Edwards RV8 
vacuum pump (USA).  
Drying took approximately 3 days, after which each sample was extracted with DCM at room 
temperature for 24 h (with stirring) – at an approximate concentration of 100 ml solvent/1 g 
sample. Dissolved material was then removed via filtration (Whatman 150 mm filter paper), 
placed in a flask and left to air dry, whilst un-dissolved residue was collected separately. 
Residue was then treated with methanol for 24 h (room temperature, stirring) and remaining 
undissolved material was again collected. Solvent extraction left behind 65 – 73% of the 
original starting sample weight as a powder residue. Powders were left on a tray to evaporate 
off any residual solvent, before being weighed, foil packed and frozen (–20°C). This entire 
extraction method was also repeated, using ethanol as a solvent – yielding an ethanol 
powder residue and dissolved extract for each sample. This new ethanol extraction was 
included to test if use of only one solvent, as opposed to DCM and MeOH, would impact 
extract activity. 
 
4.2.2.3 Powder dissolution to form extracts 
As represented in figures 4.1 and 4.2, powder residues were added to either 0.1 M NaOH or 
water at a concentration of 30 mg/ml. This mixture was then subjected to 3 cycles of 
vortexing, placement on a rotary shaker (45 min), heating to 37°C (45 min) and sonication 
(25 min) – using a low frequency sonicator (Branson 3510, USA) with the addition of ice to 
stop heating > 37°C. After dissolution, suspensions were then centrifuged (Heraeus Primo R, 
ThermoFisher Scientific, UK) for 15 min at 3000 g. Subsequently, supernatant was transferred 
to a fresh falcon tube and centrifuged again, for a further 15 min (3000 g) – before being 





neutralised (approximately pH 7.5) via the addition of 0.5 M HCl, using a pH meter (meter: 
Jenway 3051, UK; probe: Orion™ PerpHecT™ ROSS™ Combination pH Micro Electrode, 
ThermoFisher Scientific, UK). This was most crucial for solutions containing 0.1 M NaOH, as 
water based extractions rarely varied in pH level. For alkaline extractions this neutralisation 
created a 100 mM NaCl solution, containing dissolved powder extract material. For each 
extraction changes in colouration, smell and degree of dissolution were noted, along with 
approximate pH value (to allow comparisons between different extractions of the same 
extract). Finally, dissolved powder extracts were added to cell culture media, to create 
concentrations ranging between 0.1 and 10%. Each treatment solution was filtered using a 










































4.2.2.4 Converting concentrations from percentages to µg/ml 
Treatments containing powder extracts were originally produced so that culture media 
contained a stated percentage of extract solution. To convert these percentages to a more 
informative µg/ml value a 500 µl aliquot was placed into a pre-weighed 1.5 ml Eppendorf, 
with 5 holes punctured through the cap using a needle. Each Eppendorf was then frozen (-
80°C) and placed in a freeze dryer (Christ Alpha RVC vacuum centrifuge coupled to a Christ 
Alpha 1-4 freeze dryer, Germany) for 24 h (settings: -45°C, 10 mbar pressure, 300 g). After 
drying, each Eppendorf was re-weighed, allowing the amount of extract material contained 
in the 500 µl aliquot to be determined. This procedure was repeated a total of three times 
for each powder extract tested, allowing an average µg/µl concentration value to be 
determined (table 4.2); giving a better indication of the amount of organic material present 
in final treatments. As a known volume of extract solution was used to create each treatment 
Figure 4.2: Extract production from powder residue material (left over from original organic 





solution, this µg/µl average allowed percentage values to be converted into µg/ml. These 




4.2.3 General experimental design 
For each of these experiments multiple controls were included, to test saline or water 
solvents at all concentrations appropriate for the extracts (i.e. ranging between 0.1-10% 
volume). All controls were compared (via one-way ANOVA) to see if there was significant 
difference between them. If comparable, then controls were grouped together and all extract 
treatments were compared to the one average control value. Alternatively, if deviation did 
occur then those values which were significantly different from the rest were separated, and 
used to determine the statistical significance of extract treatments at the same 
concentration.  
See figure 4.3 for an overall summary of experimental design.  
 
   
µg/µl concentration 
 
ID number Genus, species Solution Set 1 Set 2 Set 3 Average 
614 C. secundatum Saline 5.5 6.3 9.0 6.9 
614 UK C. secundatum Saline 6.6 10.5 8.9 8.7 
614 Ire C. secundatum Saline 8.6 7.2 7.7 7.8 
333 P. lyngbyanum Saline 5.1 8.2 6.5 6.6 
334 UK P. cartilagineum Saline 7.4 7.9 10.8 8.7 
334 Ire P. cartilagineum Saline 9.0 11.7 10.5 10.4 
625 Osmundea sp. Saline 13.8 15.9 14.6 14.7 
294 B. fruticulosa Saline 6.7 8.8 12.7 9.4 
615 C. pallidum Saline 15.5 15.2 15.2 15.3 
615 C. pallidum Water 15.7 15.0 15.0 15.2 
621 Punctaria sp.  Water 7.2 7.6 7.1 7.3 
840 S. muticum Saline 11.3 11.1 7.6 10.0 
632 C. spongiosus Saline 6.6 6.3 7.2 6.7 
1358 P. squamatus Saline 5.3 4.9 5.5 5.2 
Table 4.2: calculation of total powder extract weight contained within aliquots of treatment 
solution, after drying. For each extract solution 3 aliquots (from 3 separate extractions) were dried 
and weighed. Weights were converted to µg/µl concentrations, as displayed. The average 






4.2.3.1 Screening for effects on proliferation 
• Cells were seeded onto 96-well plates at a 2x104 density, with 3 or 4 repeat wells per 
treatment. They were given a 24-hour attachment period, after which culture media 
was changed to that containing treatments.  
• hBMSCs were from donors 002 (passage 5) and 005 (passage 4). 
• Day 1, 4 and 7 time points were included on separate plates. Cells were fed with 200 
µl of treatment media on day 4.  
• All proliferation experiments used complete media: α-MEM media (ThermoFisher 
Scientific, 22561-021) containing FBS (5 or 10% FBS, depending upon the growth rate 
observed), 2mM L-glutamine and 100 U/ml pen-strep. 
• Day 1, 4 and 7 crystal violet assays were performed using cell monolayers. 1 M 
acidified methanol (100 µl) was used to resolubilise crystal violet stain solution and 
a blank was included on each test plate, to account for background absorbance.  
 
4.2.3.2 Screening for effects on differentiation 
• Cells were seeded onto 96-well plates at a 1x104 or 2x104 density, with 3 or 4 repeat 
wells per treatment. They were given a 24-hour attachment period, after which 
culture media was changed to that containing treatments.  
• hBMSCs were from donors 008 (passage 4-5) and 004 (passage 5). 004 cells grew 
more rapidly than those of 008 and were therefore included at the lower 1x104 
density.  
• Day 7 and 14 time points were included on separate plates. Cells were fed with 200 
µl of treatment media on day 4, 7 and 10.  
• All differentiation experiments used osteogenic treatment media: complete media 
recipe (5 or 10% FBS, depending on the growth rate observed) supplemented with 
50 µM ascorbate-2-phosphate and 10 µM β-glycerophosphate. 
• In addition to regular vehicle controls in osteogenic media, a complete media only 
control was included. 
• Day 7 and 14 alkaline phosphatase activity assays were performed with ALP readings 






4.2.3.3 Screening for effects on mineralisation 
• Cells were seeded onto 24-well plates at a 2x104 density, with 4 repeat wells per 
treatment. They were allowed to reach 75% confluency, after which culture media 
was changed to that containing treatments.  
• hBMSCs were from donors 003 (passage 3, 5) and 006 (passage 3). 
• Day 14 and 21 time points were included on separate plates. Cells were fed with 200 
µl of treatment media on day 4.  
• All mineralisation experiments used mineralogenic treatment media: complete 
media recipe (10% FBS) supplemented with 50 µg/ml ascorbate-2-phosphate and 2 
M β-glycerophosphate.  
• In addition to regular vehicle controls, a mineralogenic only and complete media only 
control was included in each layout. 
• Alizarin red-S (AR-S) assay was performed, with optical density read at 550 nm and 
converted to a value for AR-S concentration (via standard curve).  
 
4.2.3.4 Effects of ‘in-house’ extracts  
• Cells were seeded onto 96-well plates at a 1x104 density, with 4 repeat wells per 
treatment. They were given a 24-hour attachment period, after which culture media 
was changed to that containing treatments.  
• hBMSCs were from donor 008 (passage 6). 
• Day 4 and 6 time points were included on separate plates. Cells were fed with 200 µl 
of treatment media on day 4. Complete media was used (5% FBS).  
• Treatments were included from various extractions of C. secundatum (614) and P. 
cartilagineum (334) ‘in-house’ material, including: 1. normal powder extract material 
(termed ‘powder extract normal’), 2. powder extract from ethanol extraction 
(termed ‘powder extract ethanol’), 3. DCM/MeOH extraction reconstituted in 
ethanol and 4. Ethanol extraction reconstituted in ethanol.  
• Day 4 and 6 crystal violet assays were performed as previously detailed.   
 
4.2.3.5 Subfraction testing 
• Experimental conditions and assays used were the same as that of 4.2.3.1, using 





• Extract solutions contained material processed first by ultrafiltration, using Amicon 
Ultra-0.5 Centrifugal Filter Devices with a 3000 Nominal Molecular Weight Limit 
(NMWL). 0.5 ml of powder extract solution was centrifuged at 14,000 x g for 5 
minutes, producing both filtered (<3000 NMWL portion) and retained material 
portions (>3000 NMWL portion).  
 
4.2.7 Statistical analysis 
Results are presented as means +/- standard deviation, based on at least 3 single repeat 
values for each data point. Each dataset was then tested for normality, using both 
Kolmogorov-Smirnov and Shapiro-Wilk tests, as well as for equal variance using Brown-
Forsythe test. Subsequently, sets were tested by One-Way ANOVA, with any significant 
differences further investigated by Dunnetts t-test (two-sided). This compared each 
treatment to the medium and vehicle control group. 2 sets of results did not have equal 
variance and were therefore analysed by Kruskal-Wallis test instead. These included results 
shown in figures 4.11 a) and 4.15.   
One change has been made to the statistical analysis method from that of chapter 3. Now, 
when comparing treatments to control, different levels of significance are included for each 
comparison. This is depicted using stars, which have the following meaning: * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Furthermore, a difference between treatment and 
control will only be deemed statistically significant with p values of 0.01 or below (i.e. two or 
more *). This is because, based on the screening nature of this work, many statistical 
comparisons had to be made, increasing the likelihood of a type one error. Use of a lower p 
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Figure 4.3: flow diagram detailing the experimental 
work undertaken in this chapter. Green colouration 
indicates tests focusing on ‘in-house’ extracts, rather 






4.3.1 Screening for effects on proliferation 
Before conducting a full screen for proliferative effects of powder extracts a smaller 
preliminary test was performed (results not shown), to ensure that undissolved material was 
no longer a factor affecting CV assays. Fortunately, use of two centrifugation cycles coupled 
with filtration of treatment media eliminated the non-specific staining issue (as depicted by 
images of monolayers in figure 4.5). After this initial testing, hBMSC proliferation was 
determined for each powder extract. This involved testing a comprehensive range of 5 
concentrations (ranging from very low to very high µg/ml values) for new extracts and a 
smaller subset of promising concentrations for previously tested samples; as determined 
during hFOB preliminary testing (see chapter 3). Due to the number of extracts tested they 
have been presented in three separate sets.  
For the first set at day 1 [figure 4.4 a)] there was generally little deviation in extract treatment 
values from controls. One major exception to this was 621(w), which caused a large and 
highly significant increase in cell number at both concentrations tested. Alternatively, the 
second extraction showed a lower increase, but was still significant at 730(2) µg/ml 
concentration. 333 also caused a small increase in cell number at the 8 µg/ml treatment, 
whilst 632 appeared to dose-dependently decrease proliferation. By day 4, 317 µg/ml 632 
significantly reduced proliferation [4.4 b)], whilst 333’s proliferative effect was more 
pronounced for all treatments, causing an approximate 3000-4000 increase in cell number - 
which peaked at 40 µg/ml. At this time point 614 and both extractions of 621 also caused 
significant proliferation increases, with 614 similar in size to 333 whilst 621(w) again showed 
the greatest effect on proliferation. By day 7 [4.4 c)] 614 and 333’s proliferative effects had 
grown more significant. In particular, 333 caused substantial hBMSC growth promotion, 
resulting in an increase of over 9000 cells compared to the saline control. 621(w) was more 
variable, with the second extraction increasing proliferation less than the first and only 
reaching significance at 730(2) µg/ml. Contrary to these effects, extract 632 still showed 
lower cell number values than control, though these reductions were no longer significant. 
Across all time points both extractions of 625 had no significant effect on cell proliferation, 































Figure 4.4: results from two separate tests of hBMSC (donor:002, passage:5 on the left and 
donor:005, passage:4 on the right) proliferation at day 1 [a)], 4 [b)] and 7 [c)] using crystal violet 
assay. Control treatments included complete media with saline solution between 0.1-10% (Con 
saline). A separate control is shown for each test. Cells were also challenged with extracts 614, 
333, 294, 632, 621(w) or 625 at varying concentrations, dissolved in either saline solution or water 
(w). (2) indicates a separate extraction from the same sample material. Cell number is presented 
as mean +/- SD, (n=3). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 








Cell monolayers were also stained with crystal violet and imaged (figure 4.5) after 7 days of 
extract treatment. These confirm that treatments had no evident toxic effect and that cell 
number and degree of staining are increased with extract treatment – especially 333 and 
621(w).  
For set 2, extract treatments showed larger deviations at day 1 [figure 4.6 a)], with 614 
resulting in significantly increased cell number at both concentrations - but peaking at 350 
µg/ml (average cell number: 7534, control: 5099). Alternatively, 615 caused a significant and 
dose dependent reduction in cell number at all concentrations excluding the 15 µg/ml 
treatment. 615(w) and 840 also followed this trend, though only their highest treatment 
concentrations - 1520 and 500 µg/ml respectively, reached significance. At day 4 [4.6 b)], cell  
Figure 4.5: Day 7 hBMSCs (donor: 002, passage:5) challenged with either a control (saline 1%) or 
extract treatments 333, 614 and 621 at varying concentrations. Images show the whole of one 





























Figure 4.6: hBMSC (donor:005, passage:4) proliferation at day 1 [a)], 4 [b)] and 7 [c)] using crystal 
violet assay. Control treatment was complete media with saline solution 0.1-10% (Con saline). Cells 
were also challenged with extracts 614, 615, 615(w) and 840 at varying concentrations. Cell 
number is presented as mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 







number trends remained similar with some small variation. For example, cell number 
increases with 614 treatment were more pronounced, reductions with 615 were slightly 
reduced and the 38 µg/ml treatment was no longer significant. For 615(w) a dose-dependent 
increase was no longer apparent, though cell number was still very low for the 1520 µg/ml 
treatment (average cell number: 454, control: 5065). 840 retained its dose dependent effect, 
with all treatments now being significantly reduced in cell number compared to control. At 
day 7 [4.6 c)], 614 and 840 retained similar effects, though 614’s stimulative impact was 
slightly decreased. On the other hand, 615 and 615(w) displayed a bell-shaped response, with 
cell number peaking at 38 µg/ml for 615 and 153 µg/ml for 615(w). For both treatment 
groups the highest concentrations still reduced proliferation, though this was only significant 
for 615(w), as was the reduction with 15 µg/ml of this treatment.  
Set 3 of the cell proliferation screen showed much less variation in cell number at day 1 
[figure 4.7 a)]. Most treatments were similar in value to control, and whilst some increases 
and decreases in cell number were apparent none of these were significant. By day 4 [4.7 b)], 
clearer trends were apparent – such as an increase in cell number with 793 treatment. 698 
showed a dose dependent reduction, as did extract 137, whilst all concentrations of extract 
1358 caused cell number reductions – though only the 510 µg/ml treatment was significant. 
Contrary to its previous effect, extract 294 caused a dose dependent decrease in cell number. 
Day 7 [4.7 c)] results were like those of day 4, with 793 promoting cell number to a significant 
degree – excluding the 1% treatment. Similarly, 1358 still significantly reduced proliferation 
at 510 µg/ml, though 50 and 255 µg/ml treatments no longer caused reductions. Extract 294 
also maintained its dose dependent reduction of cell number, showing a significantly 
increased cell number at 10 µg/ml (average cell number: 9433, control: 8064) and 
significantly reduced at 470 µg/ml (average cell number: 4995). However, extracts 698 and 
137 varied slightly from their day 4 trend, showing smaller deviations from the control value 












Figure 4.7: hBMSC (donor:005, passage:4) proliferation at day 1 [a)], 4 [b)] and 7 [c)] using crystal 
violet assay. Control treatment was complete media with saline solution at 1, 5 or 10% (Con saline). 
Cells were also challenged with extracts 793, 698, 137, 1358 or 294 at varying concentrations. Cell 
number is presented as mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 






































Figure 4.8: set 1, layout 1; hBMSC (donor:008, passage:4/5) differentiation at day 7 [a)] and 14 [b)] 
using ALP activity assay. Control treatment was osteogenic media with saline solution 0.1-10% 
(Control saline), along with a complete media treatment for reference. Cells were also challenged 
with extracts 614, 333, 621, 840, 625, 632 and 615 at varying concentrations. Cell differentiation 
is reported as ALP activity normalised to DNA concentration. Relative ALP activity is presented as 
mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 







In addition to screening for proliferative effects, extracts were also tested for their 
differentiation potential – via alkaline phosphatase (ALP) activity assay. Promising 
concentrations of each extract were split between two separate experimental sets for clarity. 
Day 7 results for set 1 [figure 4.8 a)] showed that complete media promoted differentiation 
to a lesser degree than control saline, which consisted of media with saline solution and 
osteogenic supplements. However, by day 14 there was no evident difference between ALP 
activity levels of either control. Extract 614 at 70 µg/ml concentration was one of two 
treatments, the other being 615 – 153 µg/ml, which resulted in increases to hBMSC ALP 
activity at day 7. Other treatments also appeared to promote activity but not to a significant 
degree, such as 73 µg/ml 621(w), 10 µg/ml 840 and 6 µg/ml 632. Remaining day 7 treatments 
– mostly higher concentrations of those extracts previously stated – tended to decrease ALP 
activity. By day 14 [figure 4.8 b)] most extract activity trends remained similar. Overall, almost 
all extracts significantly stimulated ALP activity at their lowest concentrations, whilst higher 
concentrations tended to decrease activity. For example, 70 µg/ml 614 still significantly 
promoted relative ALP activity (755, control: 408), whilst 73 µg/ml 621(w), 10 µg/ml 840 and 
6 µg/ml 632 had now reached statistical significance. The main difference from the day 7 
dataset was for extracts 615 and 615(w); as 153 µg/ml 615 no longer significantly promoted 
ALP expression, whilst cells exposed to 765 µg/ml 615 dis-attached during culturing/assay 
preparation (explaining their absence in the figure).  
Set 1 results are continued (layout 2) in figure 4.9, where control solutions had very similar 
effects to those of layout 1, with control saline promoting ALP activity compared to plain 
media at day 7, but not at day 14.  For day 7, 294 significantly promoted cell differentiation 
at 10 and 95 µg/ml concentrations, though 470 µg/ml treatment slightly reduced activity. 
This trend was broadly maintained at day 14, though increases were lower – with the 95 
µg/ml treatment losing significance. For 1358, 50 and 255 µg/ml treatments significantly 
increased cell differentiation at day 7, whilst the 5 µg/ml concentration was no different than 
control. By day 14 255 µg/ml treatment had lost its activity, though 50 µg/ml still substantially 
promoted ALP expression (997, control: 353). Extracts 137 and 792 had similar activity 
profiles as each other, causing slight reductions in ALP expression that were significant for 
the 5% concentration of 792 at day 7. Finally, extract 698 showed most activity at the 1% 
concentration, resulting in significant increases at both time points. Conversely, 698 5% 
treatment was more variable, changing from significantly increasing ALP activity at day 7 to 


































Figure 4.9: set 1, layout 2; hBMSC (donor:008, passage:4/5) differentiation at day 7 [a)] and 14 [b)] 
using ALP activity assay. Control treatment was osteogenic media with saline solution 0.1-10% 
(Control saline), along with a complete media treatment for reference. Cells were also challenged 
with extracts 294, 1358, 137, 698 and 792 at varying concentrations. Cell differentiation is 
reported as ALP activity normalised to DNA concentration. Relative ALP activity is presented as 
mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 





































Figure 4.10: set 2, layout 1; hBMSC (donor:004, passage:5) differentiation at day 7 (a) and 14 (b) 
using ALP activity assay. Control treatment was osteogenic media with saline solution 0.1-10% 
(Control saline), along with a complete media treatment for reference. Cells were also challenged 
with extracts 621(w), 840, 625, 632, 615, 615(w), 294 and 1358 at varying concentrations. Cell 
differentiation is reported as ALP activity normalised to DNA concentration. Relative ALP activity 
is presented as mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 







For set 2 at day 7 [figure 4.10 a)], complete media and 0.1 - 5% control saline (CS) treatments 
were very similar in value. Alternatively, 10% control saline treatment was much lower in 
value (CS 10%: 397, CS 0.1-5%: 698), being statistically different from treatments between 
0.1 – 5% concentration, and was thus included separately. At days 7 and 14, extract 621(w) 
increased ALP activity the most at its lowest concentration – 73 µg/ml, which caused a 
significant promotion of activity at day 14. Higher concentrations of 365 and 730 µg/ml 
treatments reduced activity in a dose-dependent manner, though these reductions did not 
reach significance. 840 showed a similar trend, with 10 µg/ml treatment causing a significant 
increase at day 7 – whilst both 10 and 100 µg/ml were significant at day 14. Extracts 625, 632 
and 615 also showed greatest ALP activity at their lowest test concentrations (two 
concentrations tested for each – low and high). On the other hand, 761 µg/ml 615(w) 
significantly promoted ALP activity at both time points, whilst 153 µg/ml was similar or 
slightly reduced in value compared to control saline treatments. At day 7, extract 294 caused 
a dose dependent increase in ALP activity, which was significantly increased compared to 
control at the two highest concentrations. However, by day 14 the 470 µg/ml treatment was 
reduced and had lost significance, whilst ALP activity was significantly increased compared 
to control for 10 µg/ml treatment. Finally, extract 1358 gave a large and significant promotion 
of ALP activity at 50 and 255 µg/ml concentrations, whereas 5 µg/ml was much lower in value 




Figure 4.11: set 2, layout 2; hBMSC (donor:004, passage:5) differentiation at day 7 (a) and 14 (b) 
using ALP activity assay. Control treatment was osteogenic media with saline solution 0.1-5% 
(Control saline). Cells were also challenged with extract 614 at 70 and 350 µg/ml concentrations, 
or 333 at 8, 40 and 80 µg/ml concentrations. Cell differentiation is reported as ALP activity 
normalised to DNA concentration. Relative ALP activity is presented as mean +/- SD, (n=4). 
Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated 







70 µg/ml of extract 614 significantly promoted hBMSC differentiation at both time points 
(figure 4.11), though the largest effect was seen at day 14. Conversely, 350 µg/ml of 614 
showed no difference in ALP activity compared to control. Extract 333 also significantly 
promoted ALP activity levels at its lowest concentration of 8 µg/ml. This effect was of a similar 
size at both time points and exceeded the activity of 70 µg/ml 614 at day 7 – though the 
associated standard deviation was large. 40 and 80 µg/ml concentrations of 333 caused no 
significant change in ALP activity).  
 
4.3.3 Screening for effects on mineralisation 
For each extract tested via mineralisation assay, 4 concentrations were included. At day 14 
(figure 4.12), 3 out of 6 tested extracts had little effect on hBMSC mineralisation levels, 
including 614, 615(w) and 632. For 614 and 615(w) treatment values were very similar to 
control, though 38 µg/ml 615(w) did produce a small increase in mineralisation level. 632 had 
no significant effect on mineralisation, but values were more variable overall – peaking at 16 
µg/ml with an AR-S concentration similar to control and then decreasing at higher 
concentrations. Such limited mineralisation is confirmed by imaging (figure 4.13), whereby 
little to no AR-S staining is evident in 614 treated cells. Alternatively, extracts 333, 294 and 
621(w) had obvious positive effects on hBMSC mineralisation levels, as shown qualitatively 
and in images of 333 and 294 treatments (figure 4.13) – where obvious AR-S staining is 
evident. 333 significantly increased AR-S level at all tested concentrations, though 8, 40 and 


































Figure 4.12: hBMSC (donor:006, passage:3) mineralisation at day 14 using alizarin red-S assay. 
Control treatment was mineralogenic media with 1-5% saline solution (Control Saline), though 
mineralogenic (Min. media) and complete media (Comp. media) only controls were also included 
for reference. Cells were challenged with extracts 614, 615(w), 333, 294, 632 and 621(w), with 4 
concentrations tested for each. Mineralisation is presented as mean alizarin red-S (AR-S) 
concentration (mM), +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 







Extract 294 had a similar activity profile, with only small increases at 10 and 95 µg/ml 
concentrations – whilst the highest treatment concentration of 470 µg/ml had an obvious 
significant effect (AR-S concentration of 1.06, control: 0.24). Finally, 621 (w) caused a dose-






Each extract tested in the first day 14 mineralisation assay was also retested, this time using 
a day 21 time point (figure 4.15). 614 maintained a similar activity trend, causing small non-
significant increases in mineralisation. Extract 632 also showed comparable activity to day 
14, with all treatments similar in value to control – though 63 µg/ml again had the lowest 
reported AR-S concentration of the assay (0.40, control: 0.48). As before, images of control 
and 614 extract treatment wells (figure 4.14) confirm this limited activity, with little AR-S 
staining visible. Conversely, 615(w) had much greater effect on mineralisation at day 21. 
Extract 333 stimulated a dose-dependent increase in hBMSC mineralisation, causing an 
approximate 15-fold increase in AR-S concentration at 165 µg/ml (7.57, control: 0.48). 621(w) 
again had a dose-dependent effect which was very similar to that seen with extract 333, 
Figure 4.13: images of hBMSC (donor:006, passage:3) mineralisation at day 14, challenged with 
control saline solution and extracts 614, 333 and 294 at varying concentrations. Images show 







causing a pronounced mineralisation increase with 365 µg/ml treatment. Finally, extract 294 
increased hBMSC mineralisation at all treatment concentrations, see figure 4.14 for image). 
Despite many treatments having much larger mineralisation levels compared to control, no 
increases were statistically significant. This is likely due to the statistical analysis used, as this 
dataset did not have equal variances and therefore had to be analysed using the Kruskal-






Figure 4.14: images of hBMSC (donor:006, passage:3) mineralisation at day 21, challenged with 
control saline solution and extracts 614, 333 and 294 at varying concentrations. Images show 



































A smaller mineralisation assay testing extracts 840 and 1358 was conducted at day 21 [figure 
4.16]. Extract 840 decreased cell mineralisation at all tested concentrations, though none of 
these were statistically significant. On the other hand, 1358 caused small mineralisation 
Figure 4.15: hBMSC (donor:003, passage:5) mineralisation at day 21 using alizarin red-S assay. 
Results are split for convenience between a) and b). Control treatment was mineralogenic media 
with 0.1 - 5% saline solution or 1/5% water, though mineralogenic (Min. media) and complete 
media (Comp. media) only controls were also included for reference. Cells were also challenged 
with extracts 614, 615(w), 333, 294, 632 and 621(w), with 4 concentrations tested for each. 
Mineralisation is presented as mean alizarin red-S (AR-S) concentration (mM), +/- SD, (n=4). 
Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated 







increases at 50 and 128 µg/ml concentrations. However, it was 255 µg/ml that was most 

















Figure 4.16: a) hBMSC (donor:003, passage:5) mineralisation at day 21 using alizarin red-S assay. 
Control treatment was mineralogenic media with 0.1 - 5% saline solution, though mineralogenic (Min. 
media) and complete media (Comp. media) only controls were also included for reference. Cells were 
also challenged with extracts 840 and 1358 [b)]. 4 concentrations tested for each extract. 
Mineralisation is presented as mean alizarin red-S (AR-S) concentration (mM), +/- SD, (n=4). Statistical 
significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated treatment and 
control. b) images of hBMSC (donor:005, passage:5) mineralisation at day 21, challenged with control 
saline solution or extract 1358 at 128 µg/ml concentration. Images show portions of treatment wells 













Figure 4.17: hBMSC (donor:008, passage:6) proliferation at day 4 [a)] and 7 [b)] using crystal 
violet assay. Control treatment was complete media with saline solution 0.1-5% (Control saline). 
Cells were also challenged with powder extracts C. secundatum (614) or P. cartilagineum (334) 
(using both UK and Irish sample site material) at varying concentrations. Powders were 
produced via normal (DCM/methanol) or ethanol extraction, giving two groups of treatments – 
‘powder extract normal’ and ‘powder extract ethanol’. Cell number is presented as mean +/- 
SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between 







Powder extractions performed ‘in-house’, using either DCM/methanol or ethanol solvents, 
were also tested for their proliferative effects (figure 4.17). These extractions included 
material from Ceramium secundatum (614) and Plocamium cartilagineum (334), collected at 
either a UK or Irish sample site. ‘Normal’ DCM/methanol extracted powders only caused a 
reduction in cell number at day 4 with one treatment [figure 4.17 a)] - UK 614 extract at a 
525 µg/ml concentration (average cell number: 2514, control: 5203). Remaining 614 
treatments from both sample locations resulted in small deviations from control values, at 
days 4 and 7. ‘Normal’ extractions of 334 on the other hand caused large sustained increases 
in cell number at various treatment concentrations. Irish-derived material at concentrations 
of 12 and 58 µg/ml are the only exceptions to this, as they did not reach significance at either 
time point (though at day 7 both were increased from control). Powder extractions using 
ethanol, ‘EtOH’, showed different proliferation trends than those previously described. For 
example, Irish-derived 334 samples promoted cell number – showing a dose-dependent 
effect which reached significance at day 4 for 1% treatment (average cell number: 7379, 
control: 5203) and at day 7 for both 0.5 and 1% treatments. Alternatively, UK-derived 
material had little effect on cell number, other than a significant reduction with 1% treatment 
at day 7 [figure 4.17 b)]. Finally, 614 treatments from both sample locations reduced cell 
number to varying degrees, particularly at day 4. 
Overall, solvent dissolved extracts (figure 4.18) resulted in less deviation from control values 
than powder extracts. For example, DMSO dissolved Ceramium secundatum (614) and 
Plocamium cartilagineum (334) extracts had little effect on cell number at day 4, compared 
to control. This was also true at day 7, excluding the 0.5% concentration of 614 (Ireland) 
which caused a significant promotion of cell number – though it also had the largest 
associated standard deviation value (6229 +/- 2832 cells, control: 3978 +/- 433 cells). Ethanol 
dissolved extracts were very similar in their limited proliferative effect to those dissolved in 
DMSO, except for 0.5% 614 (Ireland). Rather than promoting cell number, as with the DMSO 



































Figure 4.18: hBMSC (donor:008, passage:6) proliferation at day 4 [a)] and 7 [b)] using crystal violet 
assay. Control treatments included 0.1 or 0.5% ethanol. Cells were also challenged with ethanol 
dissolved extracts (originally extracted with either DCM/methanol or ethanol  – dried extracts then 
re-solubilised in ethanol) C. secundatum (614) or P. cartilagineum (334) (using both UK and Irish 
sample site material) at either 0.1 or 0.5% concentration. Cell number is presented as mean +/- SD, 
(n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the 





































Figure 4.19: a) hBMSC (donor:003, passage:5) mineralisation at day 21 using alizarin red-S assay. 
Control treatment was mineralogenic media with 0.1 - 5% saline solution, though mineralogenic 
(Min. media) and complete media (Comp. media) only controls were also included for reference. 
Cells were also challenged with extracts 334 and 614, using sample material from both UK and 
Irish sample sites. 4 concentrations tested for each extract. Mineralisation is presented as mean 
alizarin red-S (AR-S) concentration (mM), +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated treatment and control. b) images of 
hBMSC (donor:005, passage:5) mineralisation at day 21, challenged with control saline solution, 
extract 614 Irish at 72 µg/ml concentration or extract 334 Irish at 117 µg/ml concentration. Images 







In addition to CV assay, ‘in-house’ 614 and 334 extracts were also tested for their effects on 
hBMSC mineralisation. Specifically, ‘powder extract normal’ was tested for each species (i.e 
the material left over from original DCM/MeOH extraction which was then dissolved via 
alkaline extraction and neutralised to produce the final extract in saline solution).  As in 
previous assays, two separate samples of Plocamium cartilagineum (334) and Ceramium 
secundatum (614) were included, derived from either a UK or Irish sample site [see section 
4.2.2.2]. All treatments greatly promoted mineralisation at day 14, particularly sample 334 
(figure 4.19 a) and confirmed by images b)] - of which most concentrations resulted in an 
approximate ten-fold increase in mineralisation level compared to control. Of those 
concentrations tested, 117 µg/ml promoted mineralisation level most, reaching an AR-S 
concentration of 11.81 mM – compared to a control value of 0.73. Comparatively, 614 
treatments had less of an effect, though still resulted in substantial hBMSC mineralisation at 
all tested concentrations. Between Irish and UK samples no sustained pattern to this activity 
was evident, though UK material at a 525 µg/ml concentration promoted mineralisation most 
(5.82 mM, 8-fold increase from control). 
 
4.3.5 Subfraction testing 
Filtered (<3000 NMWL) solutions of extractions 333, 614 and 621(w) had no significant 
impact on hBMSC proliferation, except for the lowest concentration of 614 (350 µg/ml) which 
reduced cell number at days 1 and 4 (figure 4.20). However, retained material (>3000 NMWL) 
had a much greater impact, particularly for 333 which caused a large sustained increase in 
proliferation at all time points (e.g. 10252 cells at day 4, control: 4351). Retained material 






































Figure 4.20: hBMSC (donor:005, passage:4) proliferation at day 1 [a)], 4 [b)] and 7 [c)] using crystal 
violet assay. Control treatment was complete media with saline solution 0.1-10% (Con saline). Cells 
were also challenged with extracts processed first by ultrafiltration, for extracts 333, 614 and 621. 
Cell number is presented as mean +/- SD, (n=4). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** 








This chapter’s purpose was to give a better indication of the osteogenic potential of powder 
extracts, using hBMSCs. Specifically, this focused on measures of cell proliferation, 
differentiation and mineralisation. It was hoped that this would give a better description of 
extract activity, allowing those with the best osteogenic and preclinical potential to be 
selected for in vivo testing.  
 
4.4.1 Extraction method 
As mentioned in the results section, optimisation of the powder extraction method meant 
that undissolved extract material was no longer stained by crystal violet in this chapter – 
eliminating false positive results as an issue. The current works use of an alkaline extraction 
was briefly justified in the chapter 2 (section 2.4.2). To give more detail, alkaline extractions 
are not common in similar bioactive research, whilst using it on material which has already 
been exposed to organic solvents (i.e. original DCM/methanol extraction) makes this studies 
method even more unique. However, use of conventional solvents such as DMSO and 
ethanol had already shown limited success in detecting bioactivity (as did use of ethanol to 
dissolve powders during ‘in-house’ extractions of extracts 614 and 334). Therefore, trying a 
new extraction method was a logical progression of the search for osteogenic activity. 
Furthermore, despite their limited use within the literature, alkaline solutions are generally 
accepted as a feasible method for extractions from plant sources. Extraction conditions 
employed in this thesis are based on those used to yield proteins from green tea (Shen et al. 
2008). This research found alkaline solutions to be more effective than enzyme based 
methods, whilst also examining the impact of other variables, including: molarity, 
temperature, extraction time and weight to volume ratio. 0.1M NaOH solutions at 
temperatures of roughly 40°C over a period of 2-4 hours were most effective (Shen et al. 
2008), all of which were adopted in the current experiment. Such conditions yielded extracts 
containing 56.4% of green tea proteins, whilst studies on seaweeds also found similar 
conditions to be optimal for alkaline extractions of intact proteins (P. A. Harnedy & FitzGerald 
2013a). In addition to proteins, polysaccharides can also be obtained from alkaline 







4.4.2 Screening for effects on proliferation 
Plocamium lyngbyanum (333), a species of epiphytic red algae, is a good example of an 
extract treatment which promotes cell proliferation, whilst having no apparent toxic effect. 
Only three low concentrations of P. lyngbyanum were tested for their proliferative effect, 
including 8, 40 and 80 µg/ml. This decision was due in part to the large number of extracts 
being tested, necessitating a reduced number of concentrations per extract to ensure 
experimental design was feasible. Furthermore, initial screening work was conducted 
partially for this reason – to identify concentrations that had the most effect on cell activity, 
allowing for focused experimental design. Overall, P. lyngbyanum extracts promotion of 
hBMSC proliferation was notable for its size and repeatability between time points. 
Concentrations as low as 8 µg/ml were enough to cause a two-fold (or greater) increase in 
cell number, whilst increasing extract concentration only had a limited further impact on 
growth. This suggests the presence of a potent bioactive(s), able to stimulate (and potentially 
saturate) cell proliferation over a period of 7 days. Similar crystal violet results were 
presented by Kim et al. (2015), whereby 0.1-10 µg/ml fucoidan significantly increased hBMSC 
proliferation over a 3-day time-course. Although Rhodophyta do not contain fucoidan, P. 
lyngbyanum appears to contain a bioactive which produces similar effects. Similarly, Park et 
al. (2016) found that a total algal extract of Scytosiphon lomentaria (Lyngbye) Link stimulated 
proliferation, but to a much lesser extent than that of P. lyngbyanum. Furthermore, the 
concentration required to promote cell growth was much greater than that used in the 
present study, again supporting the potency of P. lyngbyanum treatment.  
Ceramium secundatum (614) is another species of epiphytic red algae able to increase cell 
growth, though its proliferative effect was weaker than that of P. lyngbyanum, requiring a 
10x greater concentration of 70 µg/ml to promote an increase in cell number. Additionally, a 
large increase in concentration, to 350 µg/ml, was required to further promote growth. One 
potential explanation is that C. secundatum contains a different active component(s) than 
that of P. lyngbyanum, one which stimulates cell proliferation to a lesser degree. 
Alternatively, the same active may be present at a lower concentration, or other anti-
proliferative molecules could be having an effect. No direct comparisons between this study’s 
treatments and those of other work are possible, as there have been no previous reports 
about the osteogenic capacity of extracts from either P. lyngbyanum or C. secundatum. 
Despite this, the characteristic of increasing proliferation for either extract would be 
beneficial for an osteoporosis or fracture treatment, as increased osteoblast cell number 





Extracts from Boergeseniella fruticulosa (294), C. spongiosus (632), Punctaria sp. [621(w)] and 
Osmundea sp. (625) were also included in the initial proliferative testing of powder extracts. 
621(w), also caused pronounced increases in cell number, at 365 and 730 µg/ml 
concentrations. Extract solution was available from two water extractions of the powder 
residue and therefore both were included (two saline extractions were also included for 625), 
to investigate variability in activity between separate extractions. As shown, treatments from 
both caused an increase in cell number, though extraction (2) had a greater effect. Variability 
between extractions was limited as much as possible, however, some degree was still likely, 
perhaps through slight differences in the timings of particular steps - such as vortexing. 
Furthermore, whilst the powder to solvent ratio was always 30 mg/ml, the overall amount of 
powder extract used changed, based on the amount of solution required for each 
experiment. Within the small area of a 15 ml falcon tube this could have potentially altered 
powder solubility. Such variability is often reflected in the µg/ml values of table 4.2, which 
show some substantial differences in the amount of dissolved material between separate 
extractions [though 621(w) extracts repeatability is relatively good]. Use of large stock 
solutions was considered to eliminate separate extractions as a source of error, but at this 
stage of work more experiments (especially in vivo work) were still being planned, which may 
have required use of another solvent. Furthermore, using small extract amounts each time 
meant that any potential mistakes (such as issues neutralising alkaline solutions or accidental 
heating above 37°C, which occurred once due to the constant vibration of a low frequency 
sonicator) would only impact a small portion of available powder residue material.  
Another source of potential variability for all hBMSC activity measured within this chapter is 
interpatient variability. Human-derived derived stem cells are known to show differences in 
activity between patients, including significant variation in proliferative capacity (Alraies et 
al. 2017), alkaline phosphatase activity (Chavassieux et al. 1990) and expression of many 
other markers of differentiation (Verrier et al. 2010). This is likely the cause of variation for 
day 1 activity of extracts from C. secundatum (614) in the first two experiments; as no 
increase in proliferation was seen in experiment 1, whilst both concentrations caused 
significant increases in experiment 2. Whilst interpatient variability cannot be eliminated as 
a variable, ideal experimental design would have accounted for it, through repeat 
experiments using 3-6 different sets of donor cells. However, this was unfeasible in this study 
for a multitude of reasons: 1. large repeat experiments (due to extract number) would have 
been very time consuming, 2. growth of hBMSCs is slower than hFOBs, further 





allowed a full range of repeat experiments for all extracts (especially mineralisation testing 
which required much more material).  
B. fruticulosa extract (294), had opposing effects at low and high concentrations, significantly 
stimulating growth at 10 µg/ml and decreasing it at 470 µg/ml. This may indicate the 
presence of competing bioactives, such as previously suggested for MR-32 (chapter 3). For 
example, this extract may contain a bioactive which stimulates proliferation, but which is 
suppressed or outcompeted by another component when at a higher concentration. 
Osmundea sp. extract (625) had no effect on cell proliferation at any concentration. 
Processing 625 with 0.1M NaOH (and to a lesser extent water) produced an extract that was 
highly viscous and frothy, especially during mixing. Red algae are known to contain high levels 
of polysaccharides (Cian et al. 2015), whilst their presence would also explain the viscosity of 
test solutions. However, as supported by the current study these polysaccharides are unlikely 
to be bioactive, as Rhodophyta such as Osmundea sp. tend to contain cell wall sulphated 
polysaccharides – such as carrageeenan’s and agar – which have shown no previous reports 
of osteogenic potential (Wijesekara et al. 2011). Finally, C. spongiosus (632) extracts 
sustained decrease in cell number may indicate that it is having a toxic effect. Unfortunately, 
LDH cytotoxicity assay could not be used to test powder extract toxicity, as solutions 
contained very fine dissolved material (making them appear slightly cloudy). Whilst this 
material didn’t interfere with CV assay, it did cause false positive LDH readings for some 
extracts and thus these results have only been included in the appendix (appendix 7). 
Therefore, there is no way to determine for certain the toxicity of extracts, though CV 
determined reductions in proliferation give some indication of toxicity; including C. 
spongiosus extract (632), Ceramium pallidum [615(w)] at 1520 µg/ml concentration, the ‘in-
house’ extraction of UK 614 extract at 1% and Sargassum muticum (840) extract. 
Other extracts tested either had a limited effect on proliferation, like 625, or caused 
decreases in cell number – often at higher tested concentrations. For example, extract 1358, 
from the deep-sea sponge Psolus squamatus, had no proliferative effect at lower 
concentrations and decreased cell number at 510 µg/ml. Similarly, extract 615, processed 
from the species Ceramium pallidum, was specifically requested after initial powder testing, 
as red algae – including the related species Ceramium secundatum – had stimulated hBMSC 
proliferation. Unlike C. secundatum or P. lyngbyanum, this extract did not promote 
proliferation, though it did have interesting differentiation and mineralisation effects. 
Likewise, other requested powders, including extracts from the seaweeds Porphyra linearis 





sustained effect on hBMSC cell number. This indicates several possibilities: 1. no bioactives 
able to impact cell proliferation were present, 2. bioactives were present but not at a 
biologically relevant concentration or 3. multiple bioactives had competing effects which 
negated each other. Regardless, these extracts were screened for differentiation effects 
before a final subset was chosen for in vivo work.  
 
4.4.3 Screening for effects on differentiation 
As discussed in chapter 3, osteoblasts undergo a sequential development passing through an 
early proliferative stage before starting to differentiate to the mature phenotype (Aubin 
2001). As ALP is a marker of early differentiation (Miron & Zhang 2012), extract treatments 
which promote cell maturation would be expected to cause increased ALP activity. Across 
sets 1 and 2 hBMSCs displayed ALP expression in all treatments tested, including plain media 
without osteogenic supplementation. For extract set 1 supplementation increased ALP 
expression at day 7, but not at day 14; whereas during optimisation (chapter 2) addition of 
supplements to 10% saline solution markedly increased hBMSC ALP activity at days 7, 14 and 
21. Similarly, extract set 2 showed no stimulation of activity after supplementation. These 
differences are most likely due to the aforementioned issue of interpatient variability 
between the different donor cells. Despite this variation, both hBMSC screens were able to 
detect extract dependent stimulation or repression of ALP activity. Two screens were 
performed to give an indication of repeatability, and overall results between the two are very 
similar.  
A good example of an extract which shows a clear differentiation effect is that from C. 
secundatum (614), which was effective at promoting ALP activity at 70 µg/ml, but reduced 
activity at 350 µg/ml; a reversal of the proliferative trends described. This can be attributed 
to sequential osteoblast development; whereby proliferative capacity is reduced during 
differentiation towards the mature phenotype (Aubin 2001). This would explain why 70 
µg/ml C. secundatum has a limited proliferative effect, but causes the greatest promotion of 
differentiation. Sequential osteoblast development would also explain why 333, P. 
lyngbyanum, had a limited differentiation effect, as cells were being maintained in a 
proliferative phase for at least 7 days. This idea is also supported by similar work, such as one 
study which investigated the osteogenic effect of floridoside [α-D-galactopyranosyl-(1-2)-L-
glycerol], derived from the red algae Laurencia undulata Yamada (Ryu et al. 2015). This 





differentiation and eventual mineralisation. A range of other extracts have similar effects, 
such as myricetin (a flavonoid present in fruits and vegetables) (Hsu et al. 2007) and abalone 
gastro-intestinal extracts (Nguyen et al. 2014). Both extracts had no impact on cell 
proliferation or viability, but caused dose dependent increases in ALP activity. Taking 
myricetin as an example, this compound elicited its effect through increased activation of 
SMAD 1/5/8 and p38 MAPK signalling pathways. However, it should be noted that extracts 
which promote cell growth can still enhance differentiation, as with fucoidan treatment (Kim 
et al. 2015). Additionally, nacre WSM is known to cause dose dependent increases in both 
proliferation (interpreted from protein concentration) and ALP expression of rat bone 
marrow stromal cells (Pereira Mouriès et al. 2002). 
Punctaria sp. water extract [621(w)], which was also previously identified as having a strong 
proliferative effect, had a similar activity trend to C. secundatum extract. For example, low 
concentration treatment of 73 µg/ml increased differentiation – whereas 365 µg/ml resulted 
in small decreases of ALP activity but large cell number increases. 73 µg/ml treatment was 
included in differentiation screening but not proliferation assays (which tested 365 and 730 
µg/ml concentrations). This was because 621(w) appeared to have a dose-dependent effect 
on proliferation, and therefore a lower treatment concentration was predicted to have better 
differentiation potential (based on the idea of sequential development).   
Higher concentrations of extracts from S. muticum (840) and C. spongiosus (632) inhibit 
growth and differentiation, perhaps due to toxicity, whilst 6 and 10 µg/ml treatments reduce 
proliferation but promote cell differentiation. 615 (C. pallidum) in saline solution also shows 
higher ALP activity at 153 µg/ml compared to 765 µg/ml. This could indicate a slight toxic 
effect at higher concentration, but is hard to determine as cells for the 765 µg/ml treatment 
detached and were washed away before day 14. This could have been due to toxicity, though 
seems unlikely as 840 and 632 still displayed ALP activity despite their probable toxic effect. 
Alternatively, 615 in water was more variable, increasing ALP activity most at 153 µg/ml in 
extract set 1, layout 1, whilst 761 µg/ml was most active in extract set 2. These differences 
are most likely caused by variation in levels of active components between the separate 
extractions of 615(w) used for each experiment (variation between extracts was limited as 
much as possible, but impossible to completely control for).  
The most interesting results of this differentiation screen were for extracts 294, from the red 
algae B. fruticulosa, and 1358 – derived from P. squamatus, a deep-sea sponge. Treatments 





coupled this with very little proliferative effect. This indicates the presence of a bioactive 
which stimulates cell maturation, whilst also maintaining growth - or potentially two separate 
actives. It also reinforces the importance of using multiple measures of activity when 
determining an extracts bioactive potential.   
Extracts from Porphyra umbilicalis (792) and Porphyra linearis (793) were used 
interchangeably. This was necessary, as 792 extract solution was too viscous for inclusion 
during proliferation testing  – requiring a lower extract to solvent ratio (10 mg/ml opposed 
to 30 mg/ml) to mitigate this issue. 793 would have been included in differentiation testing 
along with 792, but not enough material remained for testing. This, along with both extracts 
limited effects, meant they were not chosen for further investigation. It was also decided 
that Lophelia sp. (137) extract would not be tested further, due to its lack of effect on hBMSC 
growth and differentiation. Alternatively, Percursaria percursa (698) extract was promising, 
stimulating cell differentiation in a similar way to B. fruticulosa (294) and P. squamatus (1358) 
extracts. However, not enough extract material remained for further testing, with very 
limited extract stocks at QUB and no remaining material at the Marine Institute. As such, 
despite its promise, this extract could not be tested in mineralisation or in vivo assays.  
 
4.4.4 Screening for effects on mineralisation 
Mature osteoblasts are best characterized by their ability to mineralise an extracellular 
collagen matrix, through production of hydroxyapatite, leading to the formation of new bone 
(Hadjidakis & Androulakis 2006). As this project focused on identifying a novel osteogenic 
treatment option it was important to establish the mineralisation potential of each extract, 
through AR-S staining. Mineralisation work necessitates the use of longer time points and 24 
well (rather than 96 well) plates, which require a larger number of cells and a greater volume 
of extracts to produce treatment solutions. As such, it was necessary focus experimental 
design (due to limited hBMSC stocks), through use of either day 14 or 21 time points and 
exclusion of extracts 625, 615 (saline solution excluded, water tested), 137, 792/793 and 698. 
Excluded extracts were chosen based on those that had shown least potential in 
proliferation/differentiation screening or those with limited stocks, as previously discussed. 
Therefore, extracts tested in for mineralogenic effects were: red algae extracts 333, 614, 294, 
615(w), ‘in-house’ extracts of 614 and 334; brown algae extracts 840, 632, 621(w); and an 





C. secundatum (614) caused a small non-significant increase in the degree of hBMSC 
mineralisation, whilst P. lyngbyanum (333) caused a significant promotion shown by both 
visualisation of the dark red staining and subsequent quantification. Considering mature 
osteoblasts produce factors which control mineral production (Matsuo & Irie 2008), 
treatments which had the greatest differentiation effect would also be expected to promote 
mineralisation level the most. Despite this, C. secundatum extract coupled its strong 
promotion of differentiation with a limited mineralisation effect, whilst the opposite was true 
of P. lyngbyanum extract. This could again be due to differences in extraction solution used 
between experiments, though even with this variability a greater mineralisation level would 
be expected for C. secundatum extract. Another potential explanation is that P. lyngbyanum 
extract treatments mineralisation potential is due to promotion of cell number. This growth 
promotion would allow 100% confluency to be reached quickly (as cells were first treated 
with extract solutions when they reached 75% confluency), limiting further growth. Cell-cell 
contact in confluent monolayers creates contact inhibition, stabilising monolayers (Pautke et 
al. 2004), and is known to aid cell maturation, due to the effect of osteogenic factors which 
require contact between cells (Yamada et al. 2016).  This is similar to the idea of 
macromolecular crowding, whereby macromolecules mimicking crowded in vivo conditions 
are known to cause increased ECM deposition by human corneal (Kumar et al. 2018) and 
dermal (Satyam et al. 2016) fibroblasts. 
Another inconsistency is that for both C. secundatum and P. lyngbyanum extracts the highest 
treatment concentration gave the greatest mineralisation level increase, whereas cell 
differentiation peaked for both extracts at lower concentrations. Relevant studies show 
examples where increases in ALP and mineralisation level are tightly correlated, as with 
fucoidan (Y.-S. Cho et al. 2009; Hwang et al. 2016). However, as previously mentioned, there 
are also examples of other trends, such as with floridoside (Ryu et al. 2015). This extract 
displayed a similar trend to that of the present study, whereby the highest floridoside 
concentrations promoted the greatest degree of mineralisation in murine bone marrow 
mesenchymal cells, but not always greatest ALP activity. It therefore appears that, like with 
floridoside, both extracts have their greatest effects on mineralisation and differentiation at 
different concentrations, perhaps reflecting extract composition. For example, as extracts 
are a crude mixture, mineralisation may be promoted by a different bioactive to that which 
supports hBMSC differentiation – which is more active at a higher concentration.   
Remaining extracts tested for their mineralisation potential can be split into two groups; 





first group is the largest and comprises extracts the red algae extracts C. pallidum [615(w)] 
and B. fruticulosa (294), brown algae extract Punctaria sp. [621(w)], and the deep-sea sponge 
P. squamatus (1358) extract. These extracts are similar in that their maximum concentrations 
caused the greatest increase in mineralisation level, though variations in activity do exist 
between them. For example, 615(w) had no effect at the day 14 time point, whilst some 
extracts also increased mineralisation at concentrations other than the maximum tested. 
Furthermore, this group of extracts had similar effects on other measures of cell activity – 
promoting differentiation but having little effect on proliferation. Punctaria sp. is the only 
exception to this, as it also significantly promoted cell growth. Overall, these extracts join 
those already described in the literature which are able to promote in vitro mineralisation; 
such as molluscan extracts like nacre (Brion et al. 2015) and other shell derived proteins 
(Hyung et al. 2016), previously discussed algal bioactives (Kim et al. 2015; Ryu et al. 2015) 
and other marine derivatives like Aquamin (Gorman et al. 2012) and abalone gastro-intestinal 
extracts (Nguyen et al. 2014). Such effects are particularly promising whilst searching for a 
bioactive to aid bone healing, as they may provide a treatment option to stimulate bone 
formation in osteoporotic patients or those suffering from complex fractures or 
delayed/non-union.  
The second group, those treatments which did not stimulate in vitro mineralisation, include 
extracts from the brown algae S. muticum (840) and C. spongiosus (632). Both extracts also 
failed to stimulate proliferation and only promoted differentiation at their lowest 
concentrations. This is most likely caused by a suppressive effect, which appears to limit cell 
development. Toxicity is also a possibility, but is unlikely considering that a limited number 
of non-mineralising cells survived 21 days of exposure to both extracts. Despite their limited 
in vitro effects, these extracts [along with Osmundea sp. (625)] will also be taken forward to 
in vivo testing as “negative controls” - in order to test the ability of in vitro tests to predict in 
vivo activity.  
 
4.4.5 Effects of ‘in-house’ extracts 
To test reproducibility, fresh sample material was also sourced for the active extracts C. 
secundatum (614) and Plocamium cartilagineum (334). In-house extractions were 
undertaken specifically to show that bioactivity could be maintained between separate 
extractions of sample material. Material was collected from two sample locations, Donegal 





500 miles apart). This allowed determination of potential differences in activity based on 
sample location, whilst both were collected within 3 days of each other to eliminate 
seasonality as a variable.  Unfortunately, no species information was available for extract 
621, despite its promising activity, and therefore fresh material could not be sourced. Extra 
powder material, solvent dissolved material, original samples and voucher specimens were 
all requested from the Marine Institute with the hope of determining 621 species 
information, but no material remained in any form. Existing powder extract material for 621 
was sent for DNA identification, though amplification of the COX1 gene was unsuccessful and 
results for more specific brown algae primers are still pending. Furthermore, Plocamium 
cartilagineum (334) was collected rather than the originally used Plocamium lyngbyanum 
(333), as no P. lyngbyanum was available at either sample site. Though not ideal, both species 
are very similar, with P. lyngbyanum a recently described species which was previously 
accepted as being a molecular entity equivalent to P. cartilagineum (Cremades et al. 2011). 
Differences between the two are based mainly on morphological aspects such as thallus 
colour and ramuli per series, as well as some habitat variation, and therefore molecular 
composition between them is likely very similar.  
UK-derived material of extract 334, from P. cartilagineum, had a similar activity profile to 
original 333 extract (P. lyngbyanum), with all concentrations increasing hBMSC cell number; 
whilst only the highest concentration of Irish-derived material had a stimulative effect. 
Overall, this shows that both extracts 333 and 334 contain compounds/molecules which have 
a similar proliferative effect. Irish derived powder extract showed more variation compared 
to UK and original extract material, particularly at lower concentrations which were less 
active. These differences are unlikely to be due to species variation of active components, as 
UK derived P. cartilagineum (334) extract performed similarly to P. lyngbyanum (333). 
Likewise, seasonality is not likely to be an issue, as UK and Irish-derived samples were 
collected between 10-13th September 2016 – whilst original 333 sample material was 
collected on August 27th 2011. More likely, was that less of the active component(s) was 
present, potentially due to differences in extraction efficiency or habitat based variation in 
algal compound/molecule composition. This would explain why a higher concentration of 
117 µg/ml (compared to 9 µg/ml for UK sample) was required to significantly promote cell 
number.  
Ethanol was also used to create both solvent dissolved and powder extracts for 334 and 614. 
This was performed to test if one extraction solvent, as opposed to two (DCM and methanol), 





residue. Ethanol was chosen as it had been used previously (chapter 3), showing low toxicity 
with hBMSCs. Compared to ‘powder extract normal’ – extracted with DCM/methanol – the 
activity trend was reversed, with no UK effect but a dose-dependent increase in activity for 
Irish-derived powder extract. As such, this extract appears to contain a bioactive which 
stimulates proliferation, which is likely different from that present in ‘powder extract normal’ 
- as this material promoted cell number with both UK and Irish-derived extracts.  
As with the two species of Plocamium, ‘in-house’ C. secundatum (614) extract was tested at 
an equivalent concentration range to that used with original 614. However, cell proliferation 
with ‘in-house’ 614 was much different to that previously described, with no sustained 
increases in cell number at either tested concentration for both UK and Irish-derived 
material. Furthermore, the obvious reduction with 525 µg/ml (UK) treatment at day 4 
indicates the presence of a compound/molecule able to suppress growth at a high 
concentration. Overall, proliferative bioactives present in the original extracts may not have 
been extracted, could be present at a much lower concentration or their activity may be 
being masked by another suppressive molecule. Whilst disappointing, this loss of activity is 
less surprising than it would have been for 334, as original 614 extract had less of a 
proliferative effect; which would have been more easily lost/masked with subsequent 
extractions. Reasons for this loss of activity are numerous, though are most likely due to 
variation in algal extract composition – caused by different conditions between sample 
locations (i.e. temperature and intertidal position) – or seasonality, as original 614 samples 
were collected on June 5th; compared to September 10-13th for ‘in-house’ extracts. An 
excellent example of this variability is a study by Rødde et al. (2004), which investigated 
effects of both seasonality and geographical location on chemical composition of the red alga 
Palmaria palmata (L.) Kuntze. It was shown that composition of major constituents like 
proteins and low molecular weight carbohydrate varied with season, including between early 
and late summer. Furthermore, all major constituents had variation based on geographical 
location, which (amongst others) included sample sites in Northern Ireland (Portaferry) and 
Ireland (Galway). In addition to this study, seasonal and geographic variation in the 
composition and activity of algal extracts is well documented. For example, macroalgae 
extracts from a variety of species are known to show variation in antifouling (Hellio et al. 
2004; Maréchal et al. 2004), antibacterial and antifungal activity (Stirk et al. 2007), based on 
the season they were collected in. Similarly, geographic variation, both small and large scale, 
is known to affect the levels of secondary metabolites like phenolic compounds (Van Alstyne 





nutrient and light levels. Returning to results of the present study, 614 ‘powder extract 
ethanol’ was also disappointing, reducing cell number to varying degrees at all tested 
concentrations – indicating a suppressive effect of extracted compounds/molecules. Overall, 
despite 334 (Irish) showing good activity in ethanol, this solvent was not effective enough to 
justify its use with all extracts.  
For ‘in-house’ extractions both DCM/methanol and ethanol dissolved fractions were also 
tested for proliferative activity, after reconstitution in ethanol. Compared to powder extracts 
these treatments had very little effect on cell number. 0.5% DCM/methanol extract of 614 
(Irish) significantly increased cell number, though this is almost certainly an anomaly caused 
by the large variability across repeats. Alternatively, 0.5% ethanol extract of 614 (Irish) 
contained components able to significantly reduce hBMSC cell number. Other than these 
exceptions solvent dissolved material caused little variation in activity, supporting the results 
of chapter 3 and the decision to focus on powder extracts instead.   
Finally, ‘In-house’ extracts of C. secundatum (614) and P. cartilagineum (334) were 
particularly notable in their mineralisation effects, causing very large promotions in 
mineralisation level at all tested concentrations.  For P. cartilagineum (Irish, 117 µg/ml) this 
resulted in a complete covering of the cell monolayer with stained calcium deposits, making 
individual nodules hard to distinguish. This effect correlates with that of P. lyngbyanum (333), 
though the higher overall mineralisation level may indicate that more bioactive material is 
present – or potentially the presence of a more potent molecule/compound. C. secundatum 
‘in-house’ extract greatly exceeds the mineralisation effect seen with original extract 
material, indicating more of the original active, or a completely new one, was extracted from 
these samples. This is not unexpected, considering the aforementioned differences in 
proliferation effects between original and ‘in-house’ extract material, as well as sampling and 
extraction method variables. However, it is important to note that Irish and UK-derived ‘in-
house’ extracts had very similar effects, indicating a similar composition despite their vastly 
different sample sites. It may be that use of fresh extract material, as opposed to that stored 
since June 2012 and exposed to repeat freeze/thaw cycles, may have better preserved 
bioactive structure, explaining the activity seen with ‘in-house’ compared to original extract 
material. Unfortunately, ALP activity assay results are not available for comparison to both 
sets of ‘in-house’ extracts. However, it can be hypothesised that extracts from both species 
would likely have caused large increases in ALP activity levels, as such pronounced effects on 





4.4.6 Subfraction testing 
Of those extracts tested, those from C. secundatum (614), P. lyngbyanum (333) and Puncatria 
sp. [621(w)] were most promising, solely in terms of their stimulative effect on cell number. 
As such, these extracts were also processed via ultrafiltration, to give an indication of the size 
of their bioactive components. This produced two separate solutions – one containing 
material which passed through the filter (<3000 NMWL portion) and one comprised of 
retained material (>3000 NMWL portion). More extract material passed through the filter 
than was retained and thus only one retained concentration was able to be tested, compared 
to two for filtered material. Overall, filtered extract treatments had no effect on cell number, 
whereas retained treatments performed better - particularly at day 4 whereby all three 
extracts significantly increased growth. This was especially true for 333, indicating that its 
bioactive component(s) is greater than 3000 NMWL in size – such as DNA > 25 base pairs (BP) 
in length or proteins > 15k molecular weight (MW). However, though increased at day 4, 
extracts 614 and 621(w) showed much less activity than in previous tests. One potential 
reason for this is damage to compound structure due to shear during ultrafiltration, which 
may have altered compound activity. Nevertheless, this is more often reported in large scale 
industrial processing or with long centrifugation times (Thomas & Geer 2010), and therefore 
seems an unlikely issue in this work (0.5 ml solution centrifuged for 5 minutes). Another 
technical limitation may have been the unfolding of structures (i.e. proteins) and their 
aggregation at the membrane interface (Cromwell et al. 2006). More likely is that the 
concentration of retained test solutions were too low to reach previous activity levels, or had 
only displayed significant activity as a mixture. Of all potential explanations a mixture seems 
most likely, as both 614 and 621(w) had displayed significant activity before processing. 
 
4.5 Summary 
A succinct summary of testing on so many extracts is difficult, as each presented different 
trends for each measure of in vitro activity. This chapter detailed powder extract potential in 
terms of hBMSC proliferation, differentiation and mineralisation. For the most part these 
extracts had first shown potential during testing with hFOBs, and therefore a small range of 
promising concentrations was selected for use with hBMSCs. Most of those extracts tested 
displayed significant positive effects on at least one or more measures of cell activity. For 
example, P. lyngbyanum caused significant and notable promotions of proliferation, 
differentiation and mineralisation at different tested concentrations, indicating its excellent 





proliferative or mineralogenic effects, still significantly promoted cell differentiation at their 
lowest concentrations. As such, the majority of extracts tested within this work will be 
included within future testing. Exceptions to this include seaweed extracts P. umbilicalis (792) 
and P. linearis (793), as well as the coral Lophelia sp. (137), which were excluded from future 
testing due to their limited effects on hBMSC activity. Furthermore, despite its ability to 
promote ALP activity levels, limited material was available for P. percursa (698) extract and 
therefore it will not be included in future work. Those extracts which showed potential and 
will be tested further include: the red algae C. secundatum (614), C. pallidum (615) P. 
lyngbyanum (333), P. cartilagineum (334) and B. fruticulosa (294); the brown algae Punctaria 
sp.; and the deep-sea sponge P. squamatus (1358). Those extracts which didn’t show great 
potential, but will be included as negative controls, include: the brown algae C. spongiosus 
(632) and S. muticum (840) and the red algae Osmundea sp. (625).  
Overall, powder extracts tested within this chapter show highly promising in vitro potential, 
despite being the material left over from original organic solvent extractions. Experimental 
work within the remainder of this thesis will now describe the in vivo potential of each 
extract, specifically their ability to promote the growth bone and regeneration of zebrafish 
bone. This will indicate if extract effects are maintained within a whole organism and will also 





























In vitro methods are generally used to screen for bioactive potential, before deciding on 
further testing – of which in vivo studies are a key component. Such testing allows 
confirmation that activity – like osteogenic potential – is maintained within a whole 
organism. Furthermore, it allows the effect of physiological conditions on an 
extract/compound to be determined and gives an indication of tissue response to a particular 
bioactive (Pearce et al. 2007).  
Traditionally, in vivo models within this field focus on mammals, such as ovariectomised mice, 
rabbits and sheep - which are commonly used for assessing the osseointegration of implants 
(Alghamdi, van den Beucken & J. a. Jansen 2014), though they are also used in studies testing 
extracts. It should be noted though that mammalian models are generally very different to 
each other and therefore difficult to compare (Clarke & Jordan 2008). One extract based 
study tested mycoepoxydiene, a compound isolated from a marine fungus (Diaporthe sp. 
HLY-1), showing it to reduce ovariectomy-induced bone loss (Zhu et al. 2013); a model which 
is useful for determining the activity of potential systemic treatments for osteoporosis. 
Furthermore, after well characterised in vitro testing, water soluble nacerous factors (from 
Pteria martensii) were shown to help prevent osteoporotic bone loss through osteoclast 
inactivation in mice (Kim et al. 2012). Of particular relevance to this work, algal extracts have 
also been tested in vivo – such as that of Sargassum horneri. This was shown to cause a 
significant increase in bone components of femoral diaphyseal and metaphyseal tissues in 
both young and aged rats (Uchiyama & Yamaguchi 2002). Similar work demonstrated the 
potential of other marine algae to increase bone calcium content of mice, including Undaria 
pinnatifida, Eisenia bicyclis and Cryptonemia scmitziana, though S. horneri had the best 
overall effect (Yamaguchi et al. 2001). Of note, whilst ovariectomy is common it is not the 
only type of in vivo model used. For example, fracture models can be used, to test bone 
healing or the performance of synthetic bone substitutes (Pearce et al. 2007), and diet can 
also be manipulated – such as in one study testing Aquamin. In this work, mineral rich extract 
of Lithothamnion calcareum (Aquamin) was shown to reduce bone defects in mice fed a high 
fat western diet (Aslam et al. 2010). 
Overall, use of mammals such as mice and rabbits give a good indication of in vivo skeletal 
response to a material or extract, as evidenced by their common usage and similarities to 
human bone (Pearce et al. 2007). However, no model organism, no matter how closely 





mammalian models suffer from practical concerns, such as long generation times and low 
fecundity, strict ethical regulations and high running costs, which can act as a barrier to 
experimentation. One increasingly popular alternative is zebrafish, Danio rerio (Hamilton, 
1822), a small freshwater fish which lives in tropical regions of South and Southeast Asia. At 
first comparison, mammals - being higher vertebrates and more closely related to humans – 
are obviously preferable in vivo models. Despite this, zebrafish have many characteristics that 
make them suitable for use, particularly for testing multiple different extracts (as in this 
study). Firstly, despite the last common ancestor between zebrafish and humans existing 
approximately 420 million years ago, there are many similarities between teleost and 
mammalian skeletons (Laizé et al. 2014). For example, both skeletons are comprised of many 
identical bones, formed via a cartilaginous anlage being replaced by bone - through both 
endochondral and dermal ossification. Furthermore, there is also a good conservation of 
developmental events and key bone formation regulators between the two (Laizé et al. 
2014). Additionally, there are practical benefits to using zebrafish, including: 1. high fecundity 
and short generation times (meaning many juvenile and adult individuals can be quickly 
sourced for testing), 2. they are low cost, 3. in vivo assays using zebrafish tend to be quick 
and high throughput, and 4. robustness – individuals are easy to manipulate and quick to 
adapt to different conditions (Laizé et al. 2014). Based on these characteristics it was feasible 
to test multiple extracts identified as having osteogenic potential within this work (chapter 
4), despite the relatively early stage of their development. Within similar studies there is a 
general tendency to test 1 active/compound at a time, after detailed chemical and in vitro 
characterisation – most likely due to costs associated with mammalian models. However, this 
risks activity being lost within an organism and necessitates use of a smaller number of 
compounds, and was therefore not the approach used in this work.  
Overall, zebrafish have been used as a model organism for over 100 years, with early work 
focusing on embryogenesis (Sullivan & Kim 2008). In the 1970’s genetic research began, but 
it was not until the last 20 years that zebrafish use drastically increased, as its application in 
testing for different activities became apparent (Langheinrich 2003). This increase in research 
intensity is partly due to the aforementioned benefits of zebrafish, such as their high 
fecundity, low cost and ability to be used for rapid screening (Parng et al. 2002). However, 
they also benefit from having a fully sequenced genome, and are particularly useful for drug 
discovery and testing due to their permeable and transparent embryos (Kari et al. 2007). 
Cardiovascular, anti-angiogenic and anti-cancer drugs have all shown comparable responses 





toxicity and tetragenic effects (Parng et al. 2002). Of particular relevance to this work, 
zebrafish, and to a lesser extent medaka, are also used to test osteogenic and osteotoxic 
molecules through several separate systems; of which two were used in this phase of work 
to screen for in vivo osteogenicity. Firstly, operculum (gill bone) area changes were assessed 
in larval zebrafish, to quantify an extracts effect on bone formation (Tarasco et al. 2017). 
Secondly, regeneration of adult caudal fins was used to determine effects on bone 
regeneration (Cardeira et al. 2016). Both systems, especially the operculum, are robust, 
reliable and novel measures of in vivo skeletal response to extract treatment, which will be 
discussed in further detail throughout this chapter.  
This chapter describes the in vivo osteogenic potential of promising powder extracts, as 
identified in chapter 4. Specifically, extract effects on bone formation, as assessed through 
the operculum area changes of larval zebrafish, are determined in detail for a large number 
of extracts. A smaller subset was also tested for in vivo potential using a system of adult 







5.2.1 Extracts tested 
5.2.1.1 Extracts tested - operculum area in juveniles 
Table 5.1 details extracts that were tested using the operculum area system in juvenile 
zebrafish. Results from each experiment are presented in the order extracts are listed in this 
table. Sample sizes are reported as those planned at the start of experiments and therefore 
















5.2.1.2 Extracts tested – caudal fin regeneration in adults 
Table 5.2 details extracts that were tested using the caudal fin regeneration system in adult 
zebrafish.  
  
   
Sample size 











Saline   15 
615 Ceramium pallidum Both 15 15 
333 Plocamium 
lyngbyanum 






Saline   15 
294 Boergeseniella 
fruticulosa 
Both 10 15 
625 Osmundea sp. Both 15 15 
621 Punctaria sp. Water 15   
840 Sargassum muticum Both 10 10 
632 Cladostephus 
spongiosus 
Both 15 10 
1358 Psolus squamatus Both 15 10 
Table 5.1: list of all extracts tested using the operculum area system in juvenile zebrafish, including 
the genus and species for each. Also included is information on whether a water or saline extract 















5.2.2 Extract preparation 
Water or saline dissolved extracts tested during this chapter were produced using the 
method detailed in chapter 4. Briefly, powder extracts were dissolved in either water or 0.1 
M NaOH at a concentration of 30 mg/ml, before being dissolved (including vortexing, heating, 
sonication and rotation). Solutions were then centrifuged twice to remove undissolved 
material and the resulting supernatant was pH tested and neutralised, via addition of weak 
(0.1-0.5 M) HCl or NaOH. Final extract concentrations were determined using the method 
detailed in chapter 4 (section 4.2.2.4) and are stated in all figures.   
For operculum area studies, larvae were constantly exposed to treatments during the test 
period; through submersion in 10 ml of water containing dissolved extracts. For each 
experiment this treatment water was prepared by first adding extract solution at the 
maximum test concentration, followed by a dilution series to achieve the lower 
concentrations. Concentrations were chosen based on a small pilot study using P. squamatus 
and C. spongiosus extracts (results not shown) and generally mimic those used in vitro, 
though maximum test concentrations were higher than those of cell work.  
For caudal regeneration tests, adults were injected with extract solutions rather than being 
submerged in them. These intraperitoneal injections were limited to a 3 µl volume per 100 
mg fish weight, to prevent undue swelling and damage to test individuals. Therefore, extract 
solutions had to first be concentrated, to ensure that individuals would be treated with a 
Extract Genus/species Extraction Concentration 
(µg/mg fish weight) 
Sample size 
1358 P. squamatus Water 0.025 5 
632 C. spongiosus Water 0.13 7 
632 C. spongiosus Water 0.25 5 
614 C. secundatum Water 0.51 6 
621 Punctaria sp. Water 0.93 6 
632 C. spongiosus Water 0.25 5 
632 C. spongiosus Saline 1.3 5 
614 C. secundatum Saline 1.12 5 
333 P. lyngbyanum Saline 0.82 5 
632 C. spongiosus Saline 0.65 5 
615 C. pallidum Saline 1.56 5 
294 B. fruticulosa Saline 0.68 5 
Table 5.2: list of all extracts tested using the caudal fin regeneration system in adult zebrafish, 
including the genus and species for each. Also included is information on whether a water or saline 












relevant amount of extract material. To accomplish this, a known volume of each extract 
solution was transferred to a pre-weighed Eppendorf tube, with 5 holes added to the lid to 
allow sublimation to occur in a freeze dryer Christ Alpha RVC vacuum centrifuge coupled to 
a Christ Alpha 1-4 freeze dryer, Germany) for 24 h (settings: -45°C, 10 mbar pressure, 300 g). 
Drying time was > 4 hours. Afterwards, each Eppendorf was re-weighed to determine dried 
extract weight. Saline or water solvent was then added to each tube, at volumes calculated 
so that the maximum injection volume (3 µl/100 mg fish weight) would give an extract 
concentration which approximated to that used in vitro, or during operculum testing.   
 
5.2.3 Husbandry 
Water conditions for all test individuals were as follows: pH 7.5 ± 0.1, conductivity 700 ± 50 
µS, NH3 and NO2 lower than 0.1 mg/L, NO3 at 5 mg/L. This water was produced by adding 
sodium bicarbonate and salt mixture (Instant Ocean, Blacksburg, VA) to reverse osmosis 
treated water. Fish were fed twice daily, once with Artemia nauplii (EG strain from INVE 
Aquaculture, Dendermonde, Belgium) and once with commercial dry food (Zebrafeed from 
Sparos LDA, Portugal). Photoperiod was set to 14 h light and 10 h dark. 
Individuals used in the caudal fin regeneration system were adult AB wild-type strain 
zebrafish, aged between 3 and 5 months. For operculum testing, sexually mature AB wild-
type strain zebrafish were mated, and fertilised eggs were collected. Larvae hatched from 
these eggs were used in testing.  
 
5.2.4 In vivo operculum area system 
Operculum area was determined in zebrafish larvae (figure 5.1) by measuring operculum 
area after a three-day exposure period to extract treatments, following a method described 
by Tarasco et al. (2017).  
Fertilised eggs were collected and transferred to a 1-L container, to which methylene blue 
(0.0002% w/v) was added to prevent fungal growth. Eggs were then placed in an incubator 











At three days post-fertilisation (dpf), viable larvae were transferred into 6-well plates. During 
experimentation each well housed 15 larvae in 10 ml of system water. Upon initial exposure, 
larvae were placed in wells with 3 ml of system water, to which a further 7 ml - containing 
dissolved extracts - was added. Each experiment had a vehicle control group, which exposed 
larvae to the maximum concentration of solvent used with extract treatments - either 10% 
Figure 5.1: illustration depicting the method used to assess the in vivo osteogenic potential of 
extracts in larval zebrafish. Key steps from the whole process are included, from collection of 













water or saline solution dissolved in system water. Furthermore, a positive control group was 
also included in each experiment, consisting of either 10, 15 or 20 pg/ml calcitriol (Tocris, 
Bioscience) dissolved in ethanol, as well as a negative control for this group – containing only 
0.1, 0.15 or 0.2% ethanol. Differing positive control concentrations were necessary as 
calcitriol degrades in light, meaning its activity decreased after repeated use during the 4-
month study period; thereby necessitating higher concentrations. 70% of treatment water 
was replaced daily with that containing fresh extract treatments, during the three-day 
exposure period. Subsequently, larvae were stained in excess AR-S solution (0.01%, pH 7.4) 
for 15 min, washed twice in system water (5 min) and then sacrificed (1:1000 dose of 2-
phenoxyethanol dissolved in system water; Sigma-Aldrich, UK).  
Larvae were sacrificed in batches of 15 individuals and imaged (via lateral placement on a 2% 
agarose gel) directly after euthanasia, to limit tissue degradation. An MZ 7.5 
stereomicroscope (Leica, Wetzlar, Germany) was used, equipped with a green light filter 
(λex = 530–560 nm and λem = 580 nm) and a black-and-white F-View II camera (Olympus, 
Hamburg, Germany). Image parameters were as follows: exposure time 2 s, gamma 1.00, 
image format 1376 x 1032 pixels, binning 1x1. Images were subsequently analysed using 
image J 1.49v software. Firstly, the red channel images were isolated before measurements 
of the head and operculum were taken using built-in tools on image J (see example in figure 
5.2). Ratios comparing the head and operculum area were then calculated and given as a 
percentage of the control.  The following two equations were used to calculate the change 





          
 (2)   𝑜𝑝𝑒𝑟𝑐𝑢𝑙𝑢𝑚 𝑠𝑖𝑧𝑒 (% 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) =
𝑟𝑎𝑡𝑖𝑜
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑟𝑎𝑡𝑖𝑜











5.2.5 In vivo caudal fin regeneration system 
Caudal fin regeneration experiments used a method modified from Cardeira et al. (2016).  
Adult individuals were anesthetised via submersion in a water bath containing MS222 
(Sigma-Aldrich, St. Louis, MO) and subsequently quickly dried and weighed. Injection 
volumes were calculated for individual weight, based on a target addition of 3 µl solution per 
100 mg fish weight. For each experiment treatment solutions included concentrated 
dissolved extracts and a vehicle control – either saline solution or water. After weighing, 
caudal fin was amputated 1-2 segments anterior to the bifurcation of the most peripheral 
branching lepidotrichia. After amputation, individuals were inverted (ventral side up) and 
placed within a foam holder so that treatments could be administered via intraperitoneal 
injection. Individuals were then placed into plastic containers holding 900 ml of water, at a 
density of 5-7 fish per container. 50% of container water was renewed daily and heated to 
33°C to accelerate the regenerative process (Boominathan & Ferreira 2012). Fish were fed 
twice daily, once with Artemia nauplii (EG strain from INVE Aquaculture, Dendermonde, 
Belgium) and once with commercial dry food (Zebrafeed from Sparos LDA, Portugal). 
Photoperiod was set to 14 h light and 10 h dark.  
After a five-day period, fish were live-stained by submersion in 200 ml of 0.01% AR-S solution 
for 15 min, then washed for 5 min before being anesthetized in a solution of MS222 
(Bensimon-Brito et al. 2016). Caudal fin areas were then immediately imaged, using the same 
camera system and settings as described for the larvae (except for exposure time which was 
Figure 5.2: example image of a larvae stained with AR-S, for which the red channel image has been 
isolated. Dotted white lines indicate the head area (as measured in image J), whilst green is the 
operculum. One vertebral segment has also been highlighted (red dotted line), as whilst not 












set to 500 ms). Fluorescence and bright field images were collected for each individual.  
Images were then analysed using Image J 1.49 software, allowing several measurements to 
be taken. Total regenerated area (REG) was measured from the amputation plane to distal 
end of the fin and was corrected with the stump width (STU). Mean ray width (RAY) was 
determined as the mean width of rays at the first intersegment joint below the amputation 
plane. Real mineral area (RMA) was measured after applying a colour threshold which 
selected only the mineralised red areas. Finally, the intensity of calcium staining was assessed 
using the intensity of pixels within mineralised regions (using the YUV colour model and 















Previously detailed measurements were then used to calculate the degree of osteogenesis 
and regeneration associated with each treatment and control, using two equations: 
(1) 𝑅𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 =
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑎𝑟𝑒𝑎 (𝑅𝐸𝐺)
𝑆𝑡𝑢𝑚𝑝 𝑤𝑖𝑑𝑡ℎ (𝑆𝑇𝑈)
           
 
(2) 𝑂𝑠𝑡𝑒𝑜𝑔𝑒𝑛𝑒𝑠𝑖𝑠 =
𝑅𝑒𝑎𝑙 𝑚𝑖𝑛𝑒𝑟𝑎𝑙 𝑎𝑟𝑒𝑎 (𝑅𝑀𝐴)
𝑀𝑒𝑎𝑛 𝑟𝑎𝑦 𝑤𝑖𝑑𝑡ℎ (𝑅𝐴𝑌)
/ 
𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑒𝑑 𝑎𝑟𝑒𝑎 (𝑅𝐸𝐺)
𝑆𝑡𝑢𝑚𝑝 𝑤𝑖𝑑𝑡ℎ (𝑆𝑇𝑈)
           
           
Figure 5.3: from Cardeira et al. (2016). (A) 
Inter-specimen variability of the 
regenerated area (REG; outlined by the 
black dashed line) is corrected with the 
stump width (STU). Numbers (1–4) show 
the designation of the lepidotrichia from 
each of the two fin lobes (L1 and L2). (B) 
Estimated mineralized area (EMA; outlined 
by the yellow dashed line) corresponds to 
the area comprising the mineralized 
lepidotrichia and the inter-ray space. (C) 
Real mineralized area (RMA; outlined by 
the yellow dashed lines) corresponds to 
the area stained with alizarin red S, 
excluding the inter-ray space. The 
measurements necessary to calculate the 
mean ray width below the amputation 












In addition to these equations, pixel intensity data was collected for arbitrary unit values 
between 5 -254, though generally only a limited number of pixels were present above a value 
of 50. Subsequently, an overall range was chosen for analysis, based on the spread of values 
seen, which was generally between arbitrary unit values of 7 - 30. Within this range pixel 
intensity values were converted to percentage values. Subsequently, histograms of average 
percentage values were then plotted for each treatment group. Finally, two pixel intensity 
classes were chosen from this range (one low and one high). Intensity classes were again 
chosen based on the spread of values seen within an experiment, though were generally 
comparable between experiments. For an individual within a treatment group the mean pixel 
intensity for each class was then calculated. Values for each test subject within a treatment 
group were then averaged and presented as ‘average percentage frequency’ for each class; 
allowing for comparisons of changes in pixel intensity (as a measure of bone density) 
between control and extract treatments.  
Of note, caudal fin regeneration experiments had to be smaller in scope compared to those 
using the operculum system, as adult individuals needed more space and were more difficult 
to initially treat with extracts (fish can become overly stressed if this process takes too long). 
As such, fewer extracts were tested using this system, whilst lower sample sizes were also 










Figure 5.4: illustration depicting the caudal fin regeneration system used in adult zebrafish, to 
determine the in vivo osteogenic potential of extracts. Three key steps of the process are 












5.2.6 Ethics statement 
Experiments involving zebrafish were completed in Portugal. All experiments followed the 
EU Directive 2010/63/EU and related guidelines (European Commission, 2014), as well as 
Portuguese legislation (Decreto-Lei 113/2013) for animal experimentation and welfare. Only 
trained operators handled the animals and all fish facilities were accredited by the 
Portuguese National Authority for Animal Health (DGAV).  
 
5.2.7 Statistical analysis 
Prism version 6.00 (GraphPad Software, Inc. La Jolla, CA) software was used for statistical 
analysis. Datasets were tested for normality using D’Agostino-Pearson and Shapiro-Wilk test, 
as well as for equal variance using Brown-Forsythe test. Statistical comparisons were 
analysed with one-way ANOVA and post-hoc with Dunnett’s multiple comparison test. 
Comparisons between positive controls and their relevant negative controls (operculum 
data) were made using unpaired t-tests with Welch’s correction. For all tests, a p-value < 0.05 
was considered statistically significant. One set of results, those of figure 5.20, did not have 
equal variance and were thus analysed via Kruskal-Wallis test. Sample sizes can be found in 
each figure legend. Statistical analysis was performed using Prism version 6.00 (GraphPad 
Software, Inc. La Jolla, CA). 
As with chapter 4, when comparing treatments to control a difference will only be deemed 
statistically significant with p values of 0.01 or below. On figures, stars have the following 







5.3.1 Operculum area system 
In the main, fish tolerated the treatments well and there were only small losses in each 
experiment. Sample sizes could be lower than planned for one of three reasons: 1. mortality 
during the three-day growth period, 2. loss of fish during placement for pictures (larvae are 
both small and delicate, meaning this was sometimes unavoidable) and 3. excluded outliers. 
For mortality losses, if significant a survival plot has been included to illustrate losses. If 1-2 
individuals died during testing, which was not uncommon, then a mortality plot was not 
included. This occurred in both control and treatment solutions – suggesting toxicity of 
treatments was not the sole cause of death. Fish lost during placement was a rare occurrence 
and was almost always limited to 1 fish/treatment group. Finally, exclusions were also rare, 
with only obvious outliers (confirmed by Grubbs’ test) removed. Full details of all losses in 




The safety of the vehicle controls was first tested by comparing larvae growth exposed to 
saline to those reared in water containing 10% distilled water (figure 5.5). Only two 
mortalities occurred in the 0.1% saline treatment group (14.4% of total population). 
Figure 5.5: Operculum area for 10% distilled water and 0.1, 0.5, 1, 2.5, 5 or 10% saline solution 
treatments. Corrected operculum area is presented as mean +/- SD (n=15, 0.1% treatment n=13 – 
mortality). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between 







Operculum area was similar for all saline solution treatments (0.1-10%) with the exception 
of 1% saline treatment, which showed a small but statistically significant increase in corrected 



























C. secundatum water extract caused a significant increase in corrected operculum area at 
170 and 340 µg/ml concentrations, of approximately 44% [figure 5.6 a)]. 34 µg/ml treatment 
Figure 5.6: a) Operculum area for C. secundatum treatments dissolved in water. Control was 
system water with 10% distilled water along with a calcitriol positive control (10 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=13-15). b) Operculum area for C. secundatum 
treatments dissolved in saline solution. Control was system water with 10% saline solution. 
Corrected operculum area is presented as mean +/- SD (n=14-15). For each, EtOH treatment 
provided the vehicle control for calcitriol. Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 











increased operculum area (16.2 ± 22.2%), but not to a significant degree; whilst the two 
lowest treatment concentrations (1.4 and 6.8 µg/ml) were comparable in value to control. 
Similarly, saline treatment caused a dose-dependent increase in operculum area over the 
treatment period [figure 5.6 b)]. This ranged from an average increase (from control) of 24.9 
± 20.3% at the lowest concentration of 24 µg/ml, to 66.3 ± 23.8% at 1120 µg/ml. Comparing 
between water and saline extracts, both caused significant operculum area at their two 
highest tested concentrations (though overall saline extract concentrations were higher than 
those dissolved in water), which exceeded that seen with calcitriol treatment; though saline 
dissolved extract had a greater effect (maximum area increase of approximately 66% 
compared to 44% with water). Furthermore, saline based extract was more active than water 





Ceramium secundatum Irish extract (‘in-house’) caused a significant increase in corrected 
operculum area at all tested concentrations (figure 5.7). Increases were similar in size 
between all treatments, with no obvious dose response. UK extract treatments had less of 
Figure 5.7: Operculum area for C. secundatum treatments dissolved in saline solution, from either 
Irish or UK-derived original sample material which was extracted ‘in-house’. Control was system 
water with 10% saline solution. Positive control was calcitriol (15 pg/ml), with EtOH treatment as 
the vehicle control. Corrected operculum area is presented as mean +/- SD (n=14-15). Statistical 













an effect overall, causing small increases at 14 and 72 µg/ml concentrations, but, 360 µg/ml 
caused a large significant increase in operculum area of 45.8 ± 23.6%, equal to that of the 
calcitriol control. Both extracts from UK and Ireland produced results similar to the original 
extract.   
A significant mortality event occurred in response to both water and saline extracts of C. 
pallidum [figures 5.8 b) and d)], see discussion for explanation of this. For water extract 11/15 
individuals died (73%) at 150 µg/ml concentration 72 hours post exposure, yet higher 
Figure 5.8: a) Operculum area for C. pallidum treatments dissolved in water. Control was system 
water with 10% distilled water. Positive control was calcitriol (20 pg/ml). Corrected operculum area 
is presented as mean +/- SD (n=4-15). b) Percentage survival associated with each water based 
treatment at either 24, 48 or 72-hour timepoints, which was notably lower at 72 hours for the 150 
µg/ml treatment. c) Operculum area for C. pallidum treatments dissolved in saline solution. Control 
was system water with 10% saline solution. Positive control was calcitriol (15 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=14-15, n=0 for 1600 µg/ml). d) Percentage survival 
associated with each saline based treatment at either 24, 48 or 72-hour timepoints, which was 
notably lower at 48 hours for the 1600 µg/ml treatment. For each, EtOH treatment provided the 
vehicle control for calcitriol. Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 












concentrations caused no significant mortality. Conversely, saline extract caused complete 
mortality at the highest treatment concentration of 1600 µg/ml, 48 hours post exposure. In 
terms of effect on operculum area, water extract [5.8 a)] was most effective, causing 
significant increases at all concentrations tested. Treatment had a dose dependent effect, up 
to 750 µg/ml with a maximum increase of 86.1 ± 33.3% and subsequently decreasing to 78.5 
± 24.3% at 1500 µg/ml concentration. These increases were much greater than those seen 
with 20 pg/ml calcitriol (29.6 ± 31.6%). Comparatively, saline extract had less of an effect [5.8 
c)], only causing a significant increase in operculum area at 800 µg/ml – though this was still 























Figure 5.9: a) Operculum area for P. lyngbyanum treatments dissolved in water. Control was 
system water with 10% distilled water. Positive control was calcitriol (10 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=13-15). b) Operculum area for P. lyngbyanum 
treatments dissolved in saline solution. Control was system water with 10% saline solution. Positive 
control was calcitriol (15 pg/ml). Corrected operculum area is presented as mean +/- SD (n=13-15). 
For each, EtOH treatment provided the vehicle control for calcitriol. Statistical significance: * p ≤ 









Plocamium lyngbyanum water extract produced less extract solution than anticipated and 
thus not enough was available to use for conversion of percentage values to µg/ml. P. 
lyngbyanum extract had no effect on corrected operculum area at 0.04 or 0.2% 
concentrations, with both being comparable to control [figure 5.9 a)]. However, 1, 5 and 10% 
treatments caused a dose-dependent increase in operculum area, which reached significance 
at 5 and 10% - with 10% treatment causing an increase of 51.7 ± 27.7%. Saline extract [5.9 
b)] also had a dose dependent effect, with all treatments (excluding 16 µg/ml) significantly 
increased from control. These increases peaked at 410 µg/ml with a value of 64.6 ± 14.7%, 
decreasing slightly to 58.1 ± 21.6% at 820 µg/ml. Comparing between extracts these trends 






Figure 5.10: Operculum area for P. cartilagineum treatments dissolved in saline solution, from 
either Irish or UK sourced original sample material which was extracted ‘in-house’. Control was 
system water with 10% saline solution. Positive control was calcitriol (15 pg/ml), EtOH treatment 
was the vehicle control. Corrected operculum area is presented as mean +/- SD (n=14-15). 
Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated 











P. cartilagineum (‘in-house’) saline extract (figure 5.10) also showed a similar trend to that 
of C. secundatum ‘in-house’ saline extract (figure 5.7). For example, Irish-derived extract 
promoted corrected operculum area at all tested concentrations, in a dose-dependent 
manner. These increases were greater than those of C. secundatum, peaking at a maximum 
value of 45.1 ± 13.4% with 585 µg/ml treatment. UK extract of P. lyngbyanum was again very 
similar to the UK extract of C. secundatum, causing significant promotion of operculum area 
at 540 µg/ml concentration – though not at 22 or 108 µg/ml (9.0 ± 18.7%). Increases for 
maximum concentrations of both UK and Irish-derived extracts were similar in value to those 
seen with calcitriol (41.7 ± 29.5%). It should be noted when making comparisons between 
extracts that different concentration ranges were included, partly due to the amount of 
material which dissolved during extraction and partly based on previous in vitro indications 
of an effective concentration range. Taking UK derived ‘in-house’ extracts as an example, P. 
cartilagineum was tested between 22-540 µg/ml, whilst C. secundatum was tested between 











Boergeseniella fruticulosa caused a dose-dependent increase in operculum area at 0.2, 1 and 
5% concentrations, which reached significance (43.6 ± 7.7%) at 5% [figure 5.11 a)]. Contrary 
to this trend, the lowest concentration of 0.04% also increased operculum area, reaching a 
value of 28.8 ± 21.7%. Saline extract of B. fruticulosa also had a dose-dependent effect [5.11 
b)], causing significant increases in operculum area of 17.6 ± 15.7% at 140 µg/ml and 48.8 ± 
17.6% at 700 µg/ml. However, saline extract also had notable associated mortality, with 6 
Figure 5.11: a) Operculum area for B. fruticulosa treatments dissolved in water. Control was system 
water with 10% distilled water. Positive control was calcitriol (10 pg/ml). Corrected operculum 
area is presented as mean +/- SD (n=8-10). b) Operculum area for B. fruticulosa treatments 
dissolved in saline solution. Control was system water with 10% saline solution. Positive control 
was calcitriol (15 pg/ml). Corrected operculum area is presented as mean +/- SD (n=9-15, n=0 for 
1400 µg/ml). c) Percentage survival associated with each saline based treatment at either 24, 48 
or 72-hour timepoints, which was notably decreased with 700 and 1400 µg/ml treatment. For 
each, EtOH treatment provided the vehicle control for calcitriol. Statistical significance: * p ≤ 0.05, 












individuals (40%) dying in the 700 µg/ml treatment 24 hours after exposure. Furthermore, 







Osmundea sp. treatments had very little effect on corrected operculum area, either with 
water or saline extracts (figure 5.12). A slight increase was seen with 600 and 1200 µg/ml 
water based treatments, though these were not significant. One small increase in operculum 
area was seen with 800 µg/ml saline extract (29.5 ± 9.7%), though this increase was lower 
Figure 5.12: a) Operculum area for Osmundea sp. treatments dissolved in water. Control was 
system water with 10% distilled water. Positive control was calcitriol (15 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=8-15). b) Percentage survival associated with each 
water based treatment at either 24, 48 or 72-hour timepoints, which was notably reduced with 
1200 µg/ml treatment. c) Operculum area for Osmundea sp. treatments dissolved in saline 
solution. Control was system water with 10% saline solution. A Positive control was calcitriol (15 
pg/ml). Corrected operculum area is presented as mean +/- SD (n=4-15). d) Percentage survival 
associated with each saline based treatment at either 24, 48 or 72-hour timepoints, which was 
notably reduced for 800 and 1600 µg/ml treatments. For each, EtOH treatment provided the 
vehicle control for calcitriol. Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 












than that caused by 15 pg/ml calcitriol treatment (34.6 ± 17.1%). Alternatively, mortality was 
notable for both extracts of Osmundea sp. For example, 1200 µg/ml water extract caused an 
approximate 50% reduction in larvae population size 72 hours post exposure. Saline extract 
caused an even greater decrease (74% reduction) at the maximum concentration of 1600 




Operculum area significantly increased at concentrations of 72 µg/ml and above for 
Punctaria sp. extract (water based). 14.4 and 72 µg/ml treatments caused similar increases 
in size, of approximately 30%. This was also true for 360 and 720 µg/ml Punctaria sp. water 
extract, which caused an increase of approximately 55% - exceeding that of 20 pg/ml calcitriol 
treatment (29.6 ± 31.6%). 
Figure 5.13: Operculum area for Punctaria sp. treatments dissolved in water. Control was system 
water with 10% distilled water. Positive control was calcitriol (20 pg/ml), EtOH treatment was the 
vehicle control. Corrected operculum area is presented as mean +/- SD (n=15, control n=11). 
Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the stated 


















Sargassum muticum water extract resulted in a dose-dependent increase in corrected 
operculum area, reaching a peak at 58 µg/ml – with a value of 36.7 ± 11.9% [figure 5.14 a)]. 
However, mortality was also significant for this treatment, with only approximately 50% of 
larvae surviving exposure [5.14 b)]. Furthermore, the two highest treatment concentrations 
– 290 and 580 µg/ml – resulted in complete mortality only 24 hours after initial exposure. 
Saline extract of S. muticum caused a decrease in operculum area of 14.7 ± 28.7% at 3 µg/ml 
[5.14 c)]. 15 and 76 µg/ml treatments were very similar to control and had no associated 
mortality. However, as with water extract treatments, higher concentrations of 380 and 760 
Figure 5.14: a) Operculum area for S. muticum treatments dissolved in water. Control was system 
water with 10% distilled water. Positive control was calcitriol (10 pg/ml). Corrected operculum 
area is presented as mean +/- SD (n=0-10). b) Percentage survival associated with each water based 
treatment at either 24, 48 or 72-hour timepoints. c) Operculum area for S. muticum treatments 
dissolved in saline solution. Control was system water with 10% saline solution. Positive control 
was calcitriol (10 pg/ml). Corrected operculum area is presented as mean +/- SD (n=0-10). d) 
Percentage survival associated with each saline based treatment at either 24, 48 or 72-hour 
timepoints. For each, EtOH treatment provided the vehicle control for calcitriol. Statistical 













µg/ml were highly toxic. 760 µg/ml caused complete mortality 48 hours after exposure [5.14 
d)], whist with 380 µg/ml treatment only 1 larva survived to 72 hours. This larva was excluded 







Cladostephus spongiosus water extract was tested at two concentrations – 200 and 400 
µg/ml [figure 5.15 a)]. Both caused large significant increases in operculum area, though 400 
Figure 5.15: a) Operculum area for C. spongiosus treatments dissolved in water. Control was 
system water with 10% distilled water. Positive control was calcitriol (10 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=0-15). b) Percentage survival associated with each 
water based treatment at either 24, 48 or 72-hour timepoints. c) Operculum area for C. spongiosus 
treatments dissolved in saline solution. Control was system water with 10% saline solution. 
Positive control was calcitriol (10 pg/ml). Corrected operculum area is presented as mean +/- SD 
(n=0-10). For each, EtOH treatment provided the vehicle control for calcitriol. Statistical 












µg/ml treatment was greatest – reaching a value of 62.5 ± 35.4%; exceeding that seen with 
10 pg/ml calcitiriol (26.7 ± 29.1%). Of note, the 400 µg/ml treatment group also suffered 4 
mortalities (26% of total population) 48-72 hours post exposure. Four concentrations of 
saline extract were also tested [5.15 c)], ranging in concentration between 13 and 640 µg/ml. 
Treatment had a dose-dependent effect on operculum area, reaching a maximum increase 
of 43.2 ± 14.8% at 640 µg/ml concentration – which again exceeded that seen with 10 pg/ml 

















Figure 5.16: a) Operculum area for P. squamatus treatments dissolved in water. Control was 
system water with 10% distilled water. Positive control was calcitriol (10 pg/ml). Corrected 
operculum area is presented as mean +/- SD (n=14-15). b) Operculum area for P. squamatus 
treatments dissolved in saline solution. Control was system water with 10% saline solution. 
Positive control was calcitriol (10 pg/ml). Corrected operculum area is presented as mean +/- SD 
(n=8-10). For each, EtOH treatment provided the vehicle control for calcitriol. Statistical 











Psolus squamatus water extract had no effect on operculum growth [figure 5.16 a)] at 
concentrations of 0.65, 1.3 or 160 µg/ml; though 790 µg/ml treatment caused a significant 
28.0 ± 14.1% increase in operculum area, similar to the increase seen with 10 pg/ml calcitriol 
(26.7 ± 29.1%). For saline extracts [5.16 b)], 6.6 µg/ml caused a 19.1 ± 20.1% decrease in 
operculum area. Subsequently, increasing extract concentration caused a dose dependent 
increase in operculum area, though these values were not significantly different from control 
– even at the maximum concentration of 1660 µg/ml. Interestingly, the positive control also 
didn’t show a significant increase in operculum area in this experiment. Rather than being 
related to brood stock this was most likely a result of repeat testing using calcitriol, as it is 
known to degrade upon exposure to light. This means that over time higher concentrations 
are required to sustain effects on bone growth (i.e. 15 or 20 pg/ml concentration).  
 
5.3.2 In vivo regeneration - caudal fin 
Caudal fin experiments were smaller in design than those testing operculum area changes. A 
maximum of 6 treatment groups were included in each experiment, with 5-7 adult individuals 
in each group.  
Both P. squamatus (1358) and C. spongiosus (632) extracts had very little effect on 
osteogenesis or regeneration of fins, [figure 5.17 a) and b)]. However, the higher dose of C. 
spongiosus and the single concentration tested of P. squamatus did cause a change in the 
pixel intensity analysis with a shift to the right in the distribution curve [5.17 c)]. Comparing 
average percentage frequency between low and high classes, both 0.25 µg/mg C. spongiosus 
and P. squamatus treatments had fewer low intensity pixels and more high intensity ones 
compared to control; though neither was significant. Alternatively, 0.13 µg/mg C. spongiosus 








Figure 5.17: for all figures control was IP injection of distilled water 3 µl/100 mg fish weight. 3 
treatments were tested, including 0.025 µg/mg (fish weight) P. squamatus, 0.13 and 0.25 µg/mg 
C. spongiosus, which were all dissolved in water. a) Degree of regeneration at 120 hpa. b) Degree 
of osteogenesis at 120 hpa. c) Histogram showing pixel intensity frequencies in classes 8-13 and 












In the second caudal experiment, mortality was significant for 0.93 µg/mg Punctaria sp. (621) 
and both concentrations of C. spongiosus (632) (see table 5.3). For each of these groups only 
1 individual survived and therefore, these results have been excluded from statistical and 
pixel intensity analysis. Briefly, in terms of regeneration [figure 5.18 a)] Punctaria sp. and 0.25 
µg/mg C. spongiosus treatments (water extracts) caused a slight increase compared to 
control, whilst 1.3 µg/mg C. spongiosus (saline extract) was reduced. Alternatively, all 
treatments reduced the degree of osteogenesis, though this was greatest for 1.3 µg/mg C. 
spongiosus (saline). Notably, 0.51 µg/mg C. secundatum (614) suffered no mortality during 
the 5-day experimental period, though it also showed no discernible effect on caudal fin 
regeneration or degree of osteogenesis. However, pixel intensity analysis was again more 
informative. Here, mean frequency for C. secundatum peaked in low intensity pixel classes 
(10-16) and had a much smaller distribution in higher intensity classes (17-23) [5.18 d)]. 
Conversely, the water control histogram was spread evenly between each class. Average 
percentage frequency for C. secundatum compared to control reflects these trends, as 
extract treatment caused a significant increase in frequency of low intensity pixels and a 
significant reduction in high intensity ones.   
Treatment Concentration Mortality (hours with treatment) Final mortality 
(Water) (µg/mg) 24 48 72 96 120 (%) 
Control water 
 
          0 
614 (water) 0.51           0 
621 (water) 0.93 3 1 1     83.3 
632 (water) 0.25 4         80 
Control saline 
 
          0 
632 (saline) 1.3 4         80 
of 8-13. e) Average percentage frequency for control and treatments within pixel intensity classes 
of 14-19. 1 mortality occurred after 24 hours within the control group. Results for figures a), b), d) 
and e) are presented as the mean +/- SD (n=4-7, 1 mortality in control group). Statistical 









Table 5.3: mortality at 24, 48, 72, 96 and 120 hpa for control and extract treatments of ‘caudal 
experiment 2’. Also included is a final mortality value, representing the percentage of total 
population that died during the 120-hour experimental period. Starting sample size was 6 for 
control water, control saline, C. secundatum (614) and Punctaria sp. (621). Sample size for C. 













In the final caudal experiment, all extracts tested had little effect on regeneration or 




Figure 5.18: for all figures control was either IP injection of distilled water (3 µl/100 mg fish weight) 
(C. Dh2O) or saline solution (C. saline) and 4 treatments were tested. These included 0.51 µg/mg 
(fish weight) C. secundatum, 0.93 Punctaria sp. and 0.25 C. spongiosus dissolved in water, as well 
as 1.3 µg/mg C. spongiosus in saline solution.  a) Degree of regeneration at 120 hpa. b) Degree of 
osteogenesis at 120 hpa. c) Histogram showing pixel intensity frequencies in classes 10-16 and 17-
23. d) Average percentage frequency for control and treatments within pixel intensity classes of 
10-16 and 17-23. Mortality was significant for Punctaria sp. and both C. spongiosus treatments – 
see associated mortality table. Results for figures a), b) and d) are presented as the mean +/- SD 
(n=1-6). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 between the 
























Figure 5.19: for both figures control was IP injection of saline solution (3 µl/100 mg fish weight), 
and 5 treatments were tested. These included 1.12 µg/mg (fish weight) C. secundatum, 0.82 µg/mg 
P. lyngbyanum, 0.65 µg/mg C. spongiosus, 1.56 µg/mg C. pallidum and 0.68 µg/mg B. fruticulosa 
in saline solution. a) Degree of regeneration at 120 hpa. b) Degree of osteogenesis at 120 hpa. 


















Figure 5.20: for all figures control was IP injection of saline solution (3 µl/100 mg fish weight), and 
5 treatments were tested. These included 1.12 µg/mg (fish weight) C. secundatum, 0.82 µg/mg P. 
lyngbyanum, 0.65 µg/mg C. spongiosus, 1.56 µg/mg C. pallidum and 0.68 µg/mg B. fruticulosa in 
saline solution. a) b) Histogram showing pixel intensity frequencies in classes 7-13 and 14-20. c) 
Average percentage frequency for control and treatments within pixel intensity classes of 7-13 and 
d) 14-20. Results for figures c) and d) are presented as the mean +/- SD (n=5, n=4 for C. spongiosus 
due to 1 mortality). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 









Mean frequency of control treatment peaked within the low intensity pixel class (7-13), and 
therefore had a much smaller distribution within the high intensity class. P. lyngbyanum (333) 
shared this trend, though its peak was at an even lower frequency than that of control. 
Contrary to this, C. pallidum (615) had a more even distribution and comparatively a much 
greater mean frequency within high intensity classes. Remaining extracts [B. fruticulosa 
(294), C. secundatum (614) and C. spongiosus (632)] gave pixel distributions similar to each 
other and to control. Average percentage frequency data [figure 5.20 c) and d)] showed some 
differences between treatments and control. For low intensity classes C. secundatum and C. 
pallidum reduced the frequency. C. pallidum also had a greater average percentage 
frequency than control within high intensity classes. Other effects were also evident, such as 
an increase for C. secundatum and two reductions for P. lyngbyanum and C. spongiosus 
treatments – though despite their apparent size these were not statistically significant.  
 
 






















615 (w) Ceramium 
pallidum 
  
615 (s)   
333 (w) Plocamium 
lyngbyanum 
  






294 (w) Boergeseniella 
fruticulosa 
  




625 (s)   
621 (w) Punctaria sp.   
840 (w) Sargassum 
muticum 
  
840 (s)   
632 (w) Cladostephus 
spongiosus 
  
632 (s)   
1358 (w) Psolus 
squamatus 
  
1358 (s)   
Table 5.4: summary of each extracts performance, highlighting whether they had a stimulatory or 














































621 (w) [0.93 
µg/ml] 
Punctaria sp.   






632 (s) [1.3 
µg/ml] 
  

































This chapter’s purpose was to test the in vivo potential of powder extracts using two zebrafish 
systems, one determining operculum bone formation in larval zebrafish and the other 
assessing caudal fin regeneration in adults. It was hoped that these results would 
complement previous in vitro data, whilst giving a better indication of those extracts with the 
best osteogenic and preclinical potential.  
 
5.4.1 Operculum area system 
5.4.1.1 Operculum system design and benefits 
The operculum, or gill bone, is a flat bone that sits near the surface of the skull; making it 
easy to image. Over time, the operculum becomes dermally ossified, covering the gills of 
adult fish and making up (along with 28 other bones) the outer covering of the skull (Nüsslein-
Volhard & Dahm 2002). In larvae, the operculum is one of the earliest cranial bones to ossify, 
being visible via alizarin red-S staining at only 3 dpf (Kimmel et al. 2010). Additionally, 
zebrafish larvae have translucent bodies, further aiding imaging of operculae and other 
bones. As such, operculum staining is a viable option for determining the degree of bone 
growth in larvae, which are relatively inexpensive to work with and (due high fecundity), easy 
to source. This model was first detailed in a study by Tarasco et al. (2017), which showed the 
operculum to be sensitive to both pro and anti-osteogenic effects caused by calcitriol and 
cobalt chloride treatments. Results using this system were highly repeatable and - due to its 
short three-day experimental period – allowed for rapid and high throughput determination 
of in vivo osteogenic potential. Other similar methods used to screen for osteogenicity have 
been described, such as that of Luo et al. (2016) which determined mineralisation in larval 
cranial bones. However, this method and others like it do not account for inter-specimen size 
variability, which is often significant and can impact results – as larger individuals also have 
larger bones, leading to false positives. The present operculum system used in this work 
accounts for this, through normalisation of operculum area to head area measurements, and 
is therefore more robust.  
The most important benefit of using this model for the current project was the low levels of 
extract material required for testing, despite its use of waterborne exposure instead of 
intraperitoneal injection. This was because 6 well plates used to house larvae only required 
10 ml of treatment water, equating to relatively small amounts of extract material even at 





available for use than those dissolved in ethanol and DMSO, but not an exhaustive amount. 
This system therefore allowed experiments to be completed without depleting extract 
stocks.  
 
5.4.1.2 Extract effects on operculum area 
Previous in vitro work, with some exceptions such as Punctaria sp. (621) extract, tested 
extracts dissolved in saline solution – rather than water. Upon starting in vivo testing there 
was a concern that required saline concentrations during treatment (of up to 10% total 
volume) would lead to increased larval mortality, as zebrafish are a freshwater species. As 
such, water extracts of P. squamatus (1358) and C. spongiosus (632) were used for initial 
testing, which also included a preliminary test of saline solutions between 0.1 and 10% 
concentrations. Contrary to initial concerns, zebrafish survived saline concentrations of up to 
10% with no significant change in mortality rates. Of note, 1% saline solution did cause a 
small significant increase in operculum area. However, this effect was isolated and was not 
seen at higher or lower concentrations, suggesting it was an anomaly. Overall, this suggested 
saline extracts should be tested, though water based treatments had also shown potential to 
increase operculum area in preliminary tests. Therefore, it was decided that future work 
would test both saline and water based extracts.   
Overall, powder extracts frequently caused large increases in operculum area over the three-
day experimental period. Red algae are an excellent example of this, as extracts from multiple 
species caused notable increases in operculum area – both when dissolved in water and 
saline solution. For example, high concentrations of water and saline dissolved C. 
secundatum (614) extract caused increases in operculum area that exceeded those seen with 
calcitriol. Calcitriol - the bioactive form of vitamin D - was used as a positive control, as it is 
known to enhance operculum growth (Tarasco et al. 2017) and the development of other 
skeletal structures (Fleming et al. 2005). Both extracts outperformance of calcitriol therefore 
demonstrates their excellent ability to promote bone growth, indicating higher mammals 
may also show an osteogenic response to treatment. Of note, lower concentrations of water 
based C. secundatum extract had less of an effect than comparable concentrations of saline 
extract; indicating a different bioactive may be present in each, or water extract may contain 
a lower bioactive concentration. Comparing to in vitro data (chapter 4), original C. 
secundatum extract caused increased hBMSC proliferation, particularly at 350 µg/ml, whilst 





mineralisation. These results, coupled with the described operculum area increase, indicate 
that in vitro effects are being maintained in vivo. As such, larval bone formation may have 
been stimulated through increased osteoblast number and/or differentiation. One relevant 
study showed a similar effect of tashinol, a polyphenolic compound from the root of Chinese 
sage, Salvia miltiorrhiza Bunge (Luo et al. 2016). Here, water extracts containing tashinol 
were shown to stimulate zebrafish bone formation and bone mass, as determined through 
fluorescence intensity after AR-S staining. This effect was thought to be due to the 
antioxidant capacity of tashinol, as the compound helped protect bone formation whilst 
larvae were exposed to oxidative stress. Similar work also described the ability of 
deferoxamine, an iron chelator, to remove iron and reduce oxidative stress in iron-
overloaded larvae – helping to preserve the degree of bone formation (Chen et al. 2014). 
‘In-house’ C. secundatum (614) was expected to have a comparable effect to original powder 
material, but, although significant increases in operculum area were still seen, the overall 
effect was reduced. This could be due to changes in brood stock, as these extracts were 
tested at the end of the 4-month experimental period; at which point a younger (and more 
fecund) breeding couple were being used for egg production. Eggs from this couple tended 
to hatch larvae that showed smaller changes in operculum area, even upon calcitriol 
treatment. Alternatively, it reflects a difference in extract activity, potentially due to 
differences in bioactive composition or concentration. Furthermore, there are a range of 
other variables to be considered between original and fresh (‘in-house’) extract material (as 
mentioned in chapter 4); including geographical variation, seasonality effects, differences in 
sampling location conditions and small variations in extraction method. Comparing to in vitro 
data, these results are less surprising, as both Irish and UK-derived ‘in-house’ extracts had 
less of an effect on cell proliferation than original C. secundatum material. However, 
mineralisation levels with ‘in-house’ extracts were much greater than those seen with 
original powder extract. This could potentially indicate that an increase in osteoblast 
proliferation is most important to stimulate early bone formation in larvae. Overall, given the 
difference in brood stock used to test original and ‘in-house’ extracts, in vivo activity between 
these extractions appears to be repeatable. In vitro, activity between extractions was not 
repeatable, though both still stimulated separate measures of cell activity (indicating 
bioactive presence).   
Another species of the Ceramium genus, C. pallidum (615), also caused a large increase in 
operculum area. Saline extract likely contained a different bioactive compared to water 





was smaller and limited to one concentration. Furthermore, mortality at 1600 µg/ml 
indicated that saline extract contained different constituents to those of water, that were 
toxic at this concentration. Alternatively, changes in operculum area upon water extract 
treatment were particularly notable, with the maximum increase of 86.1 ± 33.3% the greatest 
pro-osteogenic effect seen using this system to date. As with C. secundatum extracts, this 
indicates a strong promotion of in vivo mineralisation and therefore good pre-clinical 
potential, particularly at high concentrations. Higher concentrations regularly performed 
better in the operculum system, which was not unexpected - given that treatments were 
applied systemically and had to adsorb through the skin or be ingested via swallowing (Zhang 
et al. 2015). Of note, one large mortality event did occur 72 hours post treatment in 150 
µg/ml water extract group. Whilst concerning, this event is unlikely to indicate extract 
toxicity, considering it was limited to one treatment well and not seen when individuals were 
exposed to higher concentrations. Comparing to in vitro data, C. pallidum extracts greatest 
impact was on hBMSC mineralisation, as well as one significant increase in day 7 ALP activity. 
Therefore, operculum activity may be supported by potent bioactives able to stimulate cell 
maturation and eventual mineralisation levels – which would explain the increase in 
operculum area described. Related work, also utilising the zebrafish operculum system, 
showed that crude extracts from the green macroalgae Cladophora rupestris and Codium 
fragile stimulated operculum area increases (Surget et al. 2017). These effects were similar 
but just smaller than those of C. pallidum, with each macroalgae causing an approximate 75% 
increase in operculum area – as opposed to the 86% of the current study.  
P. lyngbyanum’s (333) promotion of operculum area was very similar to that of C. 
secundatum (614), for both water and saline extracts – with saline performing better overall 
but water promoting operculum area at the two highest concentrations. This suggests 
extracts from each species contain bioactives which are similar in their in vivo effect and 
ability to promote bone growth. However, it is unlikely that extracts from both species 
contain identical bioactives, based on differences in their in vitro activity profiles. For 
instance, like C. secundatum, P. lyngbyanum promoted hBMSC activity, though its effect was 
greatest on cell proliferation and mineralisation – rather than differentiation. ‘In-house’ 
extract of P. cartilagineum again had very similar activity to that of C. secundatum (‘in-
house’), causing significant increases in operculum area; though not to the same degree as 
those seen with original extract material. Again, this is could have been impacted by the 
change to a new brood stock or extract based variables such as sampling location, extraction 





previously detailed, P. cartilagineum was the closest match to P. lyngbyanum present at 
sample sites, and thus was used as a replacement).  
B. fruticulosa (extract 294) caused a smaller stimulation of operculum area than C. 
secundatum, C. pallidum and P. lyngbyanum extracts. However, increases at the highest 
concentrations (5% water extract and 700 µg/ml saline) were still significantly increased from 
control and comparable to those of calcitriol. One increase, with 0.04% water treatment, 
appears to be an outlier or anomalous result, as higher concentrations of 0.2 and 1% had a 
smaller effect on operculum area. As with C. pallidum, saline extract of B. fruticulosa likely 
contains a molecule or compound which is toxic at high concentrations, explaining the 
mortality seen within the 1600 µg/ml treatment group. Comparing to in vitro data, B. 
fruticulosa had no toxic effect and instead reduced hBMSC proliferation at its highest test 
concentration (470 µg/ml), but promoted differentiation and mineralisation; particularly at 
high concentrations. This could therefore indicate that increases in operculum area are 
stimulated upon extract treatment due to an increase in cell maturation and degree of 
mineral production. 
Water and saline dissolved extracts of Osmundea sp. (625) were an exception to the 
previously described activity of red algae, having a limited effect on operculum growth. Only 
800 µg/ml saline extract promoted operculum area, whilst higher extract concentrations of 
both extracts had moderate-large toxic effects. This indicates the presence of material which 
is toxic at higher concentrations, which could – particularly for saline extracts – mask 
osteogenic effects of other molecules/compounds. This limited activity is not surprising 
though, as Osmundea sp. extract had very little in vitro effect on either proliferation, 
differentiation or mineralisation and was specifically brought forward for in vivo testing as a 
negative control. Its lack of effect therefore supports previous in vitro results and the 
robustness of the operculum area system for determining osteogenic effects.  
Remaining extracts included those from the brown algae’s Punctaria sp. (621), S. muticum 
(840) and C. spongiosus (632), as well as the deep-sea sponge P. squamatus (1358). Punctaria 
sp. was only tested as a water extract, as saline dissolved material was not included during 
in vitro testing. It had a similar activity profile to red algaes such as C. secundatum and P. 
lyngbyanum indicating it also contains an osteogenic bioactive(s), which is particularly 
effective at higher concentrations. Furthermore, in vitro results again support in vivo findings, 
as Punctaria sp. extract promoted all cell activity measures – proliferation, differentiation 





work also showed another brown algae extract, a hot water extraction by-product from 
Hizikia fusiforme, to stimulate zebrafish bone formation (Jeong et al. 2016). However, it 
should be noted that this study only carried out qualitative analysis of stained bones and 
therefore its results are less robust than those of the current study.  Continuing with the 
current work, S. muticum (another negative control extract) showed much less activity than 
Punctaria sp., being similar to Osmundea sp. extract in its effect and actually decreasing 
operculum area at lower concentrations. Furthermore, increases in operculum area seen 
with water extract were small (lower than those produced by calcitriol), whilst higher 
concentrations of both water and saline extract were toxic. However, unlike Osmundea sp. 
extract, S. muticum produced complete mortality at higher concentrations; indicating the 
presence of more potent toxic constituents or a greater concentration of weaker molecules. 
In vitro, reduced cell growth and differentiation seen with high S. muticum concentrations 
may have also been due to toxicity, which would help to explain the mortality described in 
this chapter. Studies reporting osteogenic effects of extracts in larvae are rare and mostly 
limited to compounds which help to promote or preserve bone formation, such as those 
previously discussed (Chen et al. 2014; Luo et al. 2016). However, there are examples of those 
which hamper bone formation, such as Dorsomorphin – a small-molecular inhibitor of BMP 
which reduces zebrafish bone mineralisation (Yu et al. 2008).  
Interestingly, C. spongiosus (the third and final negative control extract) had very similar in 
vitro activity to S. muticum, including increased ALP activity at lower concentrations and 
concerns over toxicity at higher levels. However, these results do not correlate with the 
increase in operculum area seen upon treatment with high concentrations of water and 
saline dissolved C. spongiosus extract. This is the first time where in vitro data has not 
correlated to some degree with in vivo findings, indicating that hBMSC effects are not always 
predictive of whole organism effects. The permeability of larval zebrafish to small molecules 
makes waterborne exposure an easy and reliable method of extract exposure (Wilkinson & 
Pritchard 2015). However, applying treatments directly to cells, as opposed to systemic 
exposure to the body of the host, are two very different dosing regimens. In vivo,  compounds 
are subject to metabolic processes,  directed by the liver, which can affect both the 
bioavailability of the drug and the structure, leading to the formation of secondary 
metabolites. These secondary metabolites may be bioactive themselves but can also be toxic.  
Furthermore, there is often inter-specimen variability, particularly in humans (due to 
variables such as gender and race), making the pharmakinetics of a compound an important 





Finally, P. squamatus was again similar in activity to Osmundea sp., and only one 
concentration (790 µg/ml water extract) significantly increased operculum area. For saline 
extract treatments, the calcitriol positive control also failed to significantly increase 
operculum area, which may indicate fish used within this experiment were not responsive to 
pro-osteogenic treatments. Alternatively, and more likely, was that calcitriol had become 
degraded upon repeat exposure to light; as after this experiment higher calcitriol 
concentrations were used, which resulted in expected operculum area increases. P. 
squamatus, like C. spongiosus, also had variation between in vivo and in vitro datasets, 
though this time it was cell activity that was greater than that of the operculum system. For 
example, hBMSC differentiation and mineralisation was greatly increased upon exposure to 
saline P. squamatus extract. Other extracts which had similar in vitro effects, such as those 
of B. fruticulosa and C. pallidum, also displayed notable increases in operculum area. P. 
squamatus’s limited operculum system response therefore indicates that bioactivity of this 
extract is lost in vivo, perhaps due to changes in bioactive(s) structure during exposure or 
whilst being metabolised by larvae.  
Whilst high throughput methodologies for detecting osteogenic activity using zebrafish do 
exist – such as the in vivo operculum system (Tarasco et al. 2017) and ex vivo scale assay (de 
Vrieze et al. 2015) – these have not previously been used for large scale screening efforts 
testing novel compounds/extracts. The closest example of a similar screening effort is that 
which discovered dorsomorphin (previously described inhibitor of BMP-2), whereby 7500 
compounds were tested for their ability to dorsalize zebrafish embryos, i.e. to promote 
structures at the dorsal pole to the detriment of ventral structures (Yu et al. 2008). In vitro 
screening methods also give some indication the difficulty of this work and the low 
accompanied success rate in detecting positive activity, i.e. ‘hits’. For example one study 
carried out a high throughput chemical screen of 45,000 small molecules, finding only two 
series of small molecules with potent osteogenic activity (Han et al. 2009). As such, finding 
novel in vivo activity is also likely to be challenging and therefore this projects results are 
promising – showing a large proportion of those tested extracts to increase the degree of 
bone formation in juvenile zebrafish. This is likely to have been influenced by the extraction 
method used to create powder extracts, as other more conventional extracts showed little 







Based on the original description of this system, its ability to detect pro and anti-osteogenic 
effects and the results of this chapter, it is a highly useful method of determining in vivo 
osteogenic activity. However, it – along with the work of this chapter – is not without 
limitations. For example, as mentioned previously, and in the original system description 
(Tarasco et al. 2017), a more detailed screen of at least 100 different molecules (both novel 
and previously tested material) would give a better indication of the systems capabilities. 
Furthermore, as with any biological system, inter-individual variability is a factor and 
changing the brood pair can have significant repercussions; as shown by the smaller 
operculum area changes with the brood pair used for later experiments. Within this project, 
the operculum system – with its shorter running time and excellent repeatability, was used 
more extensively than the caudal fin regeneration model. Despite this, due to time 
limitations three tests were planned but not completed, including: testing of water extracts 
614 ‘in-house’ and 334 (also ‘in-house’) and retesting of 615 water extract, to obtain a 
dataset without the anomalous mortality event described.  
Another limitation concerns the comparison of in vitro and in vivo results, as assays using the 
same species should ideally be used for both in vitro and in vivo screening (Kunz et al. 2006). 
In this study, human derived primary cells were used to identify promising candidates before 
in vivo testing, as opposed to using available fish cell lines such as VSa16 (Tiago et al. 2011). 
Despite this, in vitro data generally predicted and complemented operculum activity very 
well. Furthermore, as this project concerns finding a bioactive to treat human pathologies, 
use of hBMSCs gives the greatest likelihood of identifying active compounds at the cellular 
stage of work. Therefore, mixing results from human derived cells with those of zebrafish is 
justified, but should still be considered as a potential variable – which may help to explain 
previously described differences between the in vitro/in vivo datasets for C. spongiosus and 
P. squamatus extracts. Finally, it is also important to note that this system investigates 
changes in operculum area during its formation, rather than healing in a wound situation. 
Therefore, whilst informative and indicative of osteogenic potential, the operculum system 
was also complemented by caudal fin regeneration results, to give a better indication of an 






5.4.2 Caudal fin regeneration system 
5.4.2.1 Caudal fin regeneration system design and benefits  
As with the operculum method, the caudal fin regeneration model is a recently described 
and valuable in vivo tool, allowing for the testing/development of existing and novel 
bioactives able to stimulate skeletal regeneration. Humans have a limited capability to 
regenerate, whilst other vertebrates have a range of capabilities - such as axolotl (Mexican 
salamander) which takes approximately 30 days to regrow a limb (Yokoyama 2007). Zebrafish 
are particularly fast, with this model utilising increased temperatures of 33°C (up from 28°C) 
to facilitate rapid tissue growth, allowing an entire caudal fin to be re-grown in only 5 days 
(Boominathan & Ferreira 2012). Fins are comprised from two main elements; lepidotrichia 
or segmented bony rays and inter-ray mesenchymal tissue - which is covered externally with 
epidermis. Production of bone matrix and mineralisation of lepidotrichia relies upon 
osteoblasts, or scleroblasts as they are referred to within the caudal fin. After amputation, 
scleroblasts are produced from the blastema, a temporary structure of undifferentiated cells 
with a high proliferative capacity – formed by dedifferentiation of existing cells around the 
amputation site (Knopf et al. 2011; Cardeira et al. 2016). As seen with the operculum system, 
the main benefit of this method (other than its speed, low cost and ease of working with 
zebrafish) compared to those existing within the literature is that it accounts for inter-
specimen size variability. This is accomplished through normalising RMA (real mineralised 
area) measurements by a mean ray width value for each individual, which reduces data 
dispersion (Cardeira et al. 2016).  
Before discussing extract effects, it should be noted that the operculum area and caudal fin 
regeneration systems measure two very different processes, and therefore test for different 
extract effects. The operculum is a dermal bone, formed through intramembranous (rather 
than endochondral) ossification after the development of MSCs into osteoblasts (Hammond 
& Schulte-Merker 2009). As stated, this is the first dermal bone to ossify in the pharyngeal 
arches, becoming visible at 3 dpf when embryos have just hatched to produce larvae (Kimmel 
et al. 2010). Therefore, the operculum system measures de novo bone formation of larvae, 
which would equate most closely to intramembranous bone formation during human foetal 
development. However, this does not mean that an extract which supports operculum area 
increases isn’t also likely to simulate bone growth in adult humans, as there is likely to be 
cross over in the mechanisms between the two. Caudal fin regeneration is supported by the 
dedifferentiation of cells to form a blastema (Knopf et al. 2011), which ultimately produces 





and callus formation at sites of human fracture, which help to support subsequent 
endochondral and intramembranous bone formation (Einhorn 1998). As such, the caudal fin 
regeneration system allows the ability of extracts to promote tissue regeneration to be 
tested, which could help to identify a potential treatment to stimulate bone formation after 
complex fracture or a mobile/soluble additive which could be included during scaffold 
insertion.  
 
5.4.2.2 Extract effects on caudal fin regeneration 
As both water and saline based extracts had shown promise using the operculum system, 
both were also tested in adult individuals. However, unlike in the operculum model, most 
powder extracts tested had a limited effect on caudal fin regeneration. For example, neither 
P. squamatus (1358) or C. spongiosus (632) water extract had any notable effect on 
regeneration or osteogenesis. Of these two measures, osteogenesis is most important for 
this study – as it directly relates to bone formation due to extract treatment. A bioactive able 
to also stimulate the formation of other tissues, i.e. promoting regeneration, would be an 
interesting discovery, but is not the focus of this project. Of note, mineralogenic effects can 
be influenced by changes in regenerative output, leading to false positives; as osteogenesis 
refers solely to bone formation, whilst regeneration includes the formation of all tissue 
comprising the caudal fin. As such, it was important to measure regeneration, so that it could 
be used to normalise bone formation values.  
Interestingly, C. spongiosus water extract increased the number of high intensity pixels in the 
regenerated fin, indicating extract treatment increased bone mineral density despite its lack 
of effect on osteogenesis. One potential explanation for the disparity between these two 
measures is that pixel intensity analysis is a more sensitive technique, which is better able to 
detect mild mineralogenic outcomes. This is also supported by results reported in the original 
study description (Cardeira et al. 2016), which as part of its testing included warfarin 
treatment; an anticoagulant drug which is known to reduce osteoblast differentiation and 
alter larval skeletal development (Fernández et al. 2014). Osteogenesis was unaffected upon 
warfarin treatment (rather than decreasing as expected), though an increase in low intensity 
and decrease in high intensity pixels was seen – representing the expected reduction in bone 
density. This appears to indicate that overall sensitivity within this system is lower than that 
of the operculum method, which may stem from the inherent differences between each 





large space is available for growth and bone formation is not constrained by pre-existing 
structures. Alternatively, whilst adult individuals are completely re-growing fins and 
therefore technically not constrained, regrowth occurs outwards from existing lepidotrichia 
to quickly produce a fully functioning fin to mimic that which was lost. Compared to the head 
area of juveniles, this new fin area is densely packed with tissue, meaning less unoccupied 
space is available for significant bone formation to occur in. This could therefore explain why 
bone density, opposed to osteogenesis (which includes size measurements), is a better 
indicator of pro or anti-osteogenic effects.  
The second caudal fin experiment was marked by significant mortality in all but one 
treatment – that of C. secundatum (614) water extract. This could have been due to toxicity 
of the extracts, though admittedly C. spongiosus (632) water extract showed no toxicity when 
tested previously. One explanation is a difference in extraction efficiency between the two 
treatments, as each was prepared separately and therefore could have contained differing 
toxin concentrations. Furthermore, the majority of deaths took place within 24 hours, when 
a response to the trauma of fin amputation may have contributed to the mortality rate. 
Therefore, it is difficult to make any conclusions about the toxicity of these extracts. Ideally 
this experiment would have been repeated but time did not permit.  
As with C. spongiosus treatment, C. secundatum water extract had no significant effect on 
regeneration or osteogenesis, though did show a different pixel intensity distribution 
compared to control. Contrary to previous results, pixel analysis indicated C. secundatum 
extract caused a decrease in bone density. This effect doesn’t correlate with previous in vitro 
and operculum system results for this extract, as these indicated it was pro-osteogenic and 
capable of increasing cell growth/differentiation and operculum area. The most likely reason 
for this disparity is differences in preparation of extracts between the two studies. For 
example, use of IP injection meant that only 3 µl of extract solution could be injected into an 
individual, necessitating concentration of extract solutions. As discussed in the methods, this 
involved further processing steps, including drying and re-solubilisation of extract solutions, 
which could have impacted bioactive structure and extract composition – particularly for 
volatile constituents (Abascal et al. 2005). Furthermore, it should be noted that injection of 
extracts is a very different dosing regimen compared to continuous exposure in water. For 
example, C. secundatum extract may contain a mixture of different bioactives, including one 
which has a pro-osteogenic effect but is degraded quickly in vivo. As such, a continuous 
exposure, as opposed to a single large dose, may have increased the overall effective 





caudal fins tends to focus on developmental biology and as such studies reporting 
extract/compound effects on regeneration are limited. However, one relevant study did 
undertake a chemical screen for inhibitors of caudal fin regeneration, finding two compounds 
that inhibited adult regeneration (Oppedal & Goldsmith 2010) – though to a much greater 
extent that that of C. secundatum water extract.  
As only one saline dissolved extract was tested in the first two experiments, the final 
experiment focused on these for many promising red algal species; as well as C. spongiosus 
(632). For this extract, the test concentration was halved, which successfully reduced 
mortality. Despite this, no significant effect was seen for any measure tested, though pixel 
intensity analysis did indicate a non-significant reduction in bone density. P. lyngbyanum 
(333) saline extract was almost identical to C. spongiosus in its effect, again indicating (though 
not to a significant degree) a reduction in bone density. As with C. secundatum (614) water 
extract, this result is at odds with previous in vitro and in vivo results, which indicated a pro-
osteogenic extract effect. This disparity could again be feature of extract preparation and 
exposure method used for these experiments. Interestingly, C. secundatum saline extract had 
the opposite pixel intensity effect to that of P. lyngbyanum, C. spongiosus and its own water 
extract, indicating an increase in bone density; though this effect was also not significant. 
Therefore, retesting with a higher extract concentration may better stimulate bone density 
increases within regenerating fins. Furthermore, higher extract concentrations may have 
been beneficial in stimulating an in vivo response for all treatments, as only one extract 
showed significant deviation from control and no mortality was observed. In addition to this, 
results of this experiment support those of the previous two, showing pixel intensity analysis 
to be a more sensitive measure than regeneration and osteogenesis. One anomaly that 
should be discussed is C. spongiosus, as water extract showed a small increase (non-
significant) in bone mineral density but significant mortality upon retesting, whilst as 
discussed saline extract had no evident effect. The precise reason for this lack of repeatability 
is unclear, but the morality may have been due to the separate treatment solutions used 
between tests of water extracts, whilst alkaline extraction (saline extract) may have had a 
different composition to that of water.    
As in the operculum system, C. pallidum (615) extract again caused the most evident 
response in treatment individuals. Admittedly, adult fish did not respond as obviously to C. 
pallidum treatment as larvae, though unlike in larvae no toxic effect was seen (n.b. only one 
concentration in adults, rather than a range, was tested). Furthermore, no effects were 





results did not have equal variance and were thus analysed using the non-parametric Kruskal-
Wallis test. Despite this, measurements of pixel intensity indicated brighter pixels and 
therefore a stronger staining in bony rays regenerated in fish exposed to this red algae 
extract. This indicates that, relative to control, C. pallidum extract treatment was promoting 
the bone density of the regenerated rays, correlating with the previous in vitro and in vivo 
operculum effects seen. The slight increase in osteogenesis and decrease in regeneration 
supports this effect, though these were also not significant in size. The original description of 
the caudal fin regeneration system only tested warfarin and retinoic acid treatments, neither 
of which significantly promoted measures of regeneration or mineralogenic activity (Cardeira 
et al. 2016). As such, comparison of C. pallidum extracts effect is difficult and further work is 
required to better test the ability of this model to detect anti and pro-osteogenic activity.  
 
5.4.2.3 System limitations/future work 
The biggest limitation to using this system was that extracts had to be injected into 
individuals, as too much extract material would have been required for waterborne exposure 
in large (900 ml) containers. This meant extracts had to be concentrated via drying and re-
solubilisation, which as mentioned may have impacted upon bioactive(s) structure. 
Concentrations were chosen to reflect doses used in in vitro and in the operculum testing. 
However, injection would have given a larger immediate dose of extract treatments, which 
could also explain mortality if toxic compounds were present in extract mixtures. Despite this 
large initial dose, overall treatment concentrations were probably lower than that of the 
operculum system, as adults were not constantly exposed to extracts; meaning osteogenic 
effects could have become reduced or lost over time. 
Another issue was that the number of samples per group was smaller in this model which 
meant that statistical power of the experiments to detect an effect was correspondingly 
lower. This smaller number of repeats was due to limitations involved in using adult 
individuals. For example, experiments needed to be feasible, so that amputation and 
treatment of fish could be accomplished within a reasonable time frame, therefore reducing 
fish stress. Furthermore, ideally only 5-7 adults should be housed in one 900 ml container, 
whilst the water bath used only comfortably held 6 containers. As such, experiments were 
limited to testing 6 treatment groups, each containing approximately 5 fish. Future work 
could focus on addressing these methodological concerns. For example, larger buckets could 





thus improve power and repeatability of results. In terms of exposure, waterborne exposure 
could be used for extracts with the greatest available stocks of material. Alternatively, a 
second IP injection could be performed partway through the experimental period, to boost 
circulating extract concentrations; though this could also increase extract and injection 
related mortality. Another potential method to increase sensitivity of the system would be 
to try different time points of sacrifice, rather than the 5 days originally described and used 
so far with this system (Cardeira et al. 2016). In particular, use of a shorter exposure period, 
perhaps of three days, would likely catch fins in the middle of the regeneration process – 
allowing differences between control and treatments to be highlighted more easily. 
Furthermore, this system would also benefit from inclusion of a positive control, such as 
calcitriol used with larval zebrafish, to confirm its ability to detect anabolic effects between 
experiments.   
As operculum testing gave more interesting results and was faster (3 days compared to 5) to 
complete, more extracts were tested in it compared to the caudal fin regeneration system. 
This, coupled with time limitations, meant that testing of some extracts could not be 
completed – such as water extract of C. pallidum and retesting of saline extract at a higher 
concentration. Despite this, considering the 4-month period available for work, in vivo testing 
detailed within this chapter is a useful addition – giving a better indication of extract activity.  
 
5.5 Summary 
This chapter detailed the potential of both water and saline dissolved powder extracts in vivo, 
focusing on their operculum area effects in larvae, but also detailed changes to caudal fin 
regeneration in adults. Numerous extracts, particularly those from red algae, caused large 
increases to operculum area during the experimental period, many of which were dose-
dependent. This indicated the presence of osteogenic molecules/compounds within these 
extracts, which were able to stimulate bone formation. Furthermore, for the most part these 
effects also correlated well with previous measures of in vitro activity, giving an indication of 
how each extract was stimulating osteoblast activity within larvae. Alternatively, with some 
notable exceptions, such as C. pallidum saline extract, most treatments showed a limited 
potential to stimulate mineralogenic activity and regeneration of adult caudal fins. This is 
likely due to differences between extract preparation and exposure method between the 





that some extracts treatments were able to both increase and decrease bone density in 
regenerated lepidotrichia.  
Overall, powder extracts tested within this chapter showed promising in vivo potential, 
indicating that these effects may be maintained upon further testing in higher 
mammals/humans. Future in vivo work should focus on further optimisation of the caudal fin 


























6.1 Further discussion 
6.1.1 Short summary 
The overall aim of this research was to discover a novel marine-organism derived osteogenic 
bioactive(s). It was envisaged that this would be a potential treatment option to stimulate 
new bone formation in those suffering from musculoskeletal conditions, such as osteoporosis 
or healing after complex fracture. The work described in this thesis consisted of three main 
parts; 1. a large screen for osteogenic activity from a total of 101 marine-organism derived 
extracts/fractions, mainly using the hFOB cell line (chapter 3), 2. a more detailed screen of 
powder extracts using hBMSCs (chapter 4) and 3. use of two zebrafish systems to assess 
osteogenic activity of powder extracts in vivo (chapter 5). Screening work was conducted on 
many extracts from a wide range of taxonomic groups, that were available for testing through 
a partnership with the Marine Institute Ireland. Whilst mineralising species were 
hypothesized to contain compounds/molecules that may also promote mineralisation in 
human cells, the potential effect of other taxonomic groups was largely unknown; therefore 
no taxonomic group was excluded.  
Interestingly, mineralising species, as well as extracts produced with the use of conventional 
solvents (i.e. material extracted with DCM/methanol), only had a limited effect on osteoblast 
activity. Instead, powder extracts – the material left over from DCM/methanol extraction 
which was then dissolved using 0.1M NaOH (neutralised to form a saline extract) or water – 
had the greatest osteogenic effect. When tested in detail, using hBMSCs, 13 out of 17 powder 
extracts had a positive effect on either hBMSC proliferation, differentiation or mineralisation. 
hBMSCs were chosen for more detailed testing, as they are more representative of cells 
within the human body and therefore give a better indication of pre-clinical potential. Finally, 
when tested in vivo, all extracts identified during in vitro work also promoted an increase in 
operculum area of juvenile zebrafish. Many of these increases were highly statistically 
significant, further supporting each extracts osteogenic potential and indicating that further 
in vivo testing (for example in mammalian models) may also yield interesting results. 
Combining both in vitro and in vivo results, the following powder extracts showed the most 
osteogenic potential:  
• 4 red algae extracts: Plocamium lyngbyanum (333), Ceramium secundatum (614), 
Ceramium pallidum (615) and Boergeseniella fruticulosa (294). 
• 1 brown algae extract: Punctaria sp. (621).  





Unfortunately, the exact species of the Punctaria sp. extract remains unknown, though 
substantial efforts are continuing to identify it (as detailed in the discussion section of chapter 
4). Therefore, this discussion will concentrate on the remaining species which have been 
identified, the likely composition of these extracts and their future potential.  
 
6.1.2 Taxonomic descriptions and related studies 
Determining accurate species information for each extract is of utmost importance. This 
information means fresh sample material can be sourced, allowing experiments to be 
repeated and further work to be carried out. Furthermore, it also gives an indication of other 
species that may contain bioactives and the likely constituents of each extract (if chemical 
analysis has not been completed). Determining the species used to source extracts was a 
limitation of the present study, as for some extracts these records (from the MI) were not 
available - like the aforementioned Punctaria sp. (621). Fortunately, this was not an issue for 
the majority of powder extracts which showed potential within this project.  
 
6.1.2.1 Plocamium genus 
 
Plocamium is a genus of red algae commonly found in shallow water areas along Northeast 
Atlantic coasts, often growing epiphytically on other larger algae (Cremades et al. 2011). The 
two species sampled in this work, P. lyngbyanum and P. cartilagineum, are morphologically 
similar, though genetically distinct (Cremades et al. 2011). So far very little work has been 
conducted on this algal species, both in terms of chemical composition and bioactivity. It is 
known to contain volatile halogenated metabolites (Kladi et al. 2005), whereby halogens 
present in seawater are incorporated into organic compounds with between 1 and 30 carbon 
atoms. However, these compounds are thought to largely aid defence against 
microorganisms and are unlikely to be osteogenic. In fact, some studies indicate they may be 
cytotoxic and instead show greater antibacterial or antioxidant potential (Smit 2004; Kladi et 
al. 2005).  
One relevant study focused on chemical composition and showed that, in addition to 
halogenates, other volatiles including alcohols, esters and aldehydes, as well as four organic 





polysaccharides are the most common osteogenic organics present in algae, those found in 
this study may also show activity. Also of note, Valentão et al. showed considerable 
antioxidant activity of P. cartilagineum, whereby aqueous extracts were tested for their 
scavenging potential of free radicals and reactive oxygen species. Similar capabilities were 
also observed in extracts from three species of Romanian algae, including the genus 
Ceramium (Horincar et al. 2011). Antioxidants are known to support osteoblast action, as 
even low exposure to molecules such as H2O2 can otherwise reduce mineralisation and gene 
expression of osteogenic markers (Arai et al. 2007). In fact, many osteogenic extracts possess 
antioxidant capabilities, such as nacre water soluble matrix (Chaturvedi et al. 2013) and 
sulphated polysaccharides of algae like Laminaria japonica (Wang et al. 2008), including the 
well characterised fucoidan (Mak et al. 2013). In vivo, this could explain Plocamium sp. 
extracts ability to support larval operculum growth, though it is not the cause of the increased 
in vitro activity described. Also, it seems unlikely that antioxidant capabilities would be solely 
responsible for the positive effects during the short 3-day exposure period used with the 
operculum system.  
 
6.1.2.2 Ceramium genus  
 
 
Ceramium is another genus of Rhodophyta, with a ubiquitous distribution across Northeast 
Atlantic coasts - including multiple species in the British isles (Maggs & Hommersand 1993). 
Of these, C. secundatum and C. pallidum are closely related, belonging to different subclades 
of the Ceramium genus (Maggs et al. 2002).  Morphologically they are readily distinguishable 
because C. pallidum is regularly branched every 4-8 segments, whereas C. secundatum is 
branched at intervals of 9 or more segments.  Ceramium sp. are typically smaller than 30 cm 
in length and are found in both shallow and deep water coastal areas. This genus, like those 
of all the samples discussed in this chapter, has very little published information available 
concerning potential bioactive components. What is apparent is that, like those derived from 
Plocamium sp., extracts may have both antiviral (Serkedjieva 2004) and antibacterial (Dubber 





6.1.2.3 Boergeseniella fruticulosa 
 
B. fruticulosa is a small (up to 15 cm) branched red algae, which lives epiphytically on other 
algae or rocks. This species has a wide distribution, including eastern Atlantic habitats such 
as Morocco, the Mediterranean, Britain and also Ireland (Rindi & Guiry 2004). As with 
Plocamium and Ceramium, most research conducted to date on extracts from B. fruticulosa 
have been focused on antiviral and antibacterial activity, although even these studies are 
limited. For example, one paper investigated whole extracts from 23 red algae species, 
including B. fruticulosa, P. cartilagineum and C. virgatum, for their antiprotozoal, 
antimycobacterial and cytotoxic effects (Allmendinger et al. 2010). All extracts showed 
activity in at least one measure, such as against the parasite T. brucei rhodesiense – though 
C. virgatum was the most potent. As in the current study, no chemical analysis was completed 
as the work focused on screening and identifying activity, though secondary metabolites 
were identified as the likeliest source of activity; such as alkaloids, polyphenols, sulphated 
sugars, sterols and halogenated mono and diterpenes.  
 
6.1.2.4 Rhodophyta 
As most active extracts described in this chapter come from Rhodophyta species it suggests 
the bioactive component might be common to members of this phyla. Overall, red algae are 
known to have a particularly high protein content, of up to 47% of their dry matter, along 
with high levels of polysaccharides and minerals (Cian et al. 2015). For polysaccharides, an 
obvious comparator is fucoidan, which shows similar activity profiles from many different 
species of brown algae. It is particularly relevant to this work, as low treatment 
concentrations (like those used with P. lyngbyanum extract) are able to significantly increase 
MSC proliferation, (Kim et al. 2015). However, red algae do not contain fucoidan, though they 
do contain cell wall associated sulphated polysaccharides such as carrageenans and agar 
(Usov 1998; Wijesekara et al. 2011). Whilst these polysaccharides have been incorporated in 
scaffolds which themselves have osteogenic potential (Li et al. 2015), there are no reports of 
activity when they are included as mobile/soluble additives. In terms of minerals, those 
derived from red algae have well-known and characterised mineralogenic effects, such as the 
marine derived multi-mineral Aquamin. This commercial extract is able to promote in vitro 





vivo human trials (Frestedt et al. 2008; Frestedt et al. 2009). However, the present study used 
only non-mineralising species and these are therefore unlikely to contain biologically relevant 
mineral levels. This leaves proteinaceous material as the most likely active component of 
each extract, though if true the extraction method and solvent choice will have likely 
impacted protein structure (see section 6.1.3).  
Overall, studies reporting red algae based bioactives specific to bone tissue are very limited. 
One notable exception to this is a red algal based compound called floridoside, which is a 
glycerol glycoside metabolite of Laurencia undulata (Ryu et al. 2015). Floridoside was  shown 
to promote differentiation, increased ALP levels, mineralisation and expression of factors 
including type 1 collagen, Runx-2 and Osterix (Ryu et al. 2015). Before this study, floridoside 
had not been investigated for its highly promising osteogenic potential, thus highlighting the 
importance of testing novel extracts.  Furthermore, this compound is also produced by other 
species of red algae such as Galdieria sulphuraria (Martinez-Garcia & van der Maarel 2016) 
and Mastocarpus stellatus (Courtois et al. 2008), and may therefore also be present in the 
red algae described in this chapter. However, chemical analysis is needed to determine this.  
 
6.1.2.5 Psolus squamatus 
 
P. squamatus is a species of deep sea sponge which is typically found at more than 200 m 
depth along continental slopes (found at approximately 2000 m in this study), but may also 
appear attached to stones in shallower water areas. This species, like the rest of those in this 
chapter, has a fairly ubiquitous distribution, found in waters off Mexico, Norway, British 
Columbia and the British Isles (Southward et al. 2006). The vast majority of published 
research mentioning P. squamatus is concerned with describing its distribution in different 
areas, whilst to date there have been no published reports of bioactives or chemical analysis 
of extracts from this species. As such, no comparisons can be made to the activity described 
in this thesis and speculation on active components is limited. Normally, deep sea sampling 
is limited by the difficulty and cost associated with collecting more sample material (Van 
Dover 2011), or due to issues of conservation (Davies et al. 2007). However, as mentioned P. 
squamatus is a fairly common species with a ubiquitous distribution in both shallow and 
deep-water habitats. Therefore, sourcing fresh sample material should be easier than with 





bioactivity has been associated with a molecule or compound it could then be reproduced 
(depending on its complexity), making further sampling unnecessary and addressing 
concerns about species depletion. Therefore, P. squamatus remains an interesting extract 
able to stimulate hBMSC differentiation, mineralisation and operculum growth, which 
warrants further study.  
 
6.1.3 Considerations for bioactive composition 
The main limitation of this project is that the specific active component(s) for each extract 
has not been identified. When screening such large numbers of extracts, chemical analysis is 
not feasible –and often unnecessary, as many do not display significant osteogenic activity. 
Therefore, chemical analysis of the promising bioactive powder extracts will be the focus of 
future work. This is detailed further in section 6.3, but will involve determining overall extract 
composition, fractionation, repeat bioactivity screening and then eventual characterisation 
of each compound.  
Although beyond the original scope of this research project, some preliminary chemical 
analysis has been conducted and includes Gas Chromatography – Flame Ionisation Detector 
(GC-FID) to test for fatty acids, which was completed for all samples mentioned in this 
chapter (along with others, see appendix 9 and 11) and mass spectrometry analysis for 
extracts from Irish samples of P. cartilagineum, UK and Irish samples of C. secundatum and 
C. pallidum (see appendix 10 and 12). Fatty acid analysis showed no obvious positive results, 
with only relatively weak peaks seen for all powder extracts. Furthermore, these peaks did 
not correlate with any FAME standards, suggesting they were either impurities, or that fatty 
acids present were at a concentration below the detection limit of the system. Mass 
spectrometry data were more interesting, showing a large number of peaks for each extract 
tested. Taking extract 615 from C. pallidum (009) as an example, approximately 17 peaks 
were evident (as shown in appendix 12). This indicates that powder extracts are a complex 
mix, containing a number of components which may contribute to the overall activity 
described in chapters 4 and 5.  
Initial treatment of samples at the Marine Institute included the use of dichloromethane and 
methanol. Powder extracts were left over from these extractions and therefore anything 
removed by these solvents will not have been present in the final extract. DCM and methanol 
are likely to have extracted a wide range of organics from the original sample material, as 





polarity organics, whilst methanol is a polar protic solvent (Lagowski 1978). Their pairing was 
likely used to dissolve as much organic material as possible, as anything missed by DCM may 
have dissolved in methanol – such as remaining polar organic compounds. Of the material 
left over as a powder extract for dissolution at QUB, use of water and 0.1 M NaOH solvents 
will have probably removed different organic material. Water, with its high polarity, is an 
efficient solvent for organics such as alcohols, some amines, acids, esters, ketones and 
aldehydes (Marcus 1998). As such, the active component(s) extracted with water, as for 
Punctaria sp., is difficult to determine. Alternatively, NaOH is best known for its ability to 
dissolve carboxylic acids and phenols, through the formation of polar carboxylate or 
phenoxide groups. For algae, this again supports the idea of the bioactive component being 
proteinaceous, whilst phenols are also a common constituent of extracts from these 
eukaryotes. Furthermore, previous studies have reported that extracts from algae which 
contain high phenol levels are able to promote osteogenic activities both in vitro  (Surget et 
al. 2017) and in vivo (Park et al. 2012). 
Another important consideration is the effect of solvent choice on the chemical structure of 
organic molecules/compounds. Of particular importance to this work is the impact of alkaline 
treatment, as even at a 0.1 M concentration NaOH is likely to have influenced the structure 
of different components within each extract, particularly proteins and polysaccharides. 
Proteins are most likely to have been denatured, except perhaps more robust glycoproteins, 
creating smaller proteinaceous molecules – whilst polysaccharides will probably have been 
affected similarly. One relevant study extracted polysaccharides from the red algae Gracilaria 
corticata, finding that alkali pre-treatment reduced the yield and molecular weight of cold 
water extracted polymers; due to degradation of the polysaccharide backbone (Mazumder 
et al. 2002). Despite these concerns, use of alkali extraction was still deemed to be a useful 
extraction method for this study. This was based on other studies’ use of 0.1 M NaOH - which 
found it to be an effective extraction solvent, particularly for ensuring a high protein yield 
(Shen et al. 2008; P. A. Harnedy & FitzGerald 2013b; P. a. Harnedy & FitzGerald 2013). Finally, 
it is important to note that molecular content changes greatly based on the extraction 
method used. Therefore, the test solutions detailed in this work are likely to be very different 
from those of other studies, such as that of Valentão et al. (2010);  which used an aqueous 
rather than alkaline extraction to produce extracts from lyophilized P. cartilagineum material 
– meaning extracted components of the two may be very different and inferences on 






6.1.4 Future potential 
Of those marine derived osteogenic bioactives described to date, fucoidan and nacre show 
good pre-clinical potential. Approximate maximum/minimum in vitro (proliferation, 
differentiation and mineralisation) and in vivo effects of both extracts have been summarised 
in table 6.1, along with the same measures for powder extracts described in this chapter. 
Such summation is difficult, considering the variability between studies in terms of cell type, 
seeding densities, other experimental conditions, types of each extract and in vivo models 
used, to name but a few variables. Despite this, noting the approximate maximum or 
minimum percentage change gives a good indication of fucoidan, nacre and powder extracts 
general effects.  
Overall, powder extracts compare favourably with both fucoidan and nacre, arguably 
outperforming them in some measures of activity. Proliferative effects of the 5 powder 
extracts are the most variable, ranging from approximate effects on cell number of -50 to 
+120%. Comparatively, only one nacre related study reported a greater effect, showing 
MC3T3-E1 cell viability to be increased 150% upon treatment with P. fucata mantle gene 3 
(Wang et al. 2011b); though other studies testing water soluble nacre fractions reported no 
significant increases of cell viability or proliferation. Comparatively, fucoidan performed 
more consistently, increasing cell viability/proliferation in the range of 20-80%. Measures of 
cell differentiation and mineralisation were more comparable between the three groups 
whereby, ALP activity was increased in all studies, ranging from 100-150% for all powders 
tested, between 20 and >200% for nacre-based extracts and between 30 and >200% for 
fucoidan. As with ALP activity, mineralisation levels were increased in all studies, with powder 
extracts and nacre showing the greatest overall increases – which often exceeded 200%, 
whilst fucoidan ranged between 40 and 190%.  
In vivo activity is even more difficult to compare between studies than in vitro work, as those 
models used vary greatly in their reported measures. Considering its in vitro potential there 
are a surprising lack of studies testing fucoidan in vivo, with most work testing scaffolds 
incorporated with fucoidan for their in vitro osteogenicity (Puvaneswary et al. 2016; 
Venkatesan et al. 2014; S Igondjo Tchen Changotade et al. 2008). One study did test the 
sulphated polysaccharide in a bone-growth mouse model, but found no bone formation after 
5 or 8 weeks (Pereira et al. 2014). Comparatively, nacre has been tested more 
comprehensively and is known to fuse directly with bone when implanted in both rats (Liao 
et al. 2002) and sheep (Atlan 1999; Berland et al. 2005), whilst one trial was even conducted 





of bioactive discovery, this trial was undertaken before significant in vitro and animal model 
testing and showed that nacre was able to stimulate healing in bone maxillary defects of 8 
female patients; fuelling interest in nacreous and other marine-organism derived extracts. 
Comparing either fucoidan or nacres in vivo potential to that of powder extracts tested in 
zebrafish is difficult. However, powder extracts showed an excellent ability to increase the 
operculum area of juvenile fish. For example, C. pallidum extract has shown the greatest 
promotion of operculum area of those molecules/compounds/extracts tested in the model 
system to date. This may indicate that upon further in vivo testing, as with nacre, powders 








Table 6.1: summary of the effect of fucoidan, nacre or powder extracts on in vitro proliferation, 
differentiation and mineralisation of osteoblast relevant cells, as well as in vivo measures. The 
approximate maximum percentage increase or decrease reported for each measure is shown, 
along with the citation for each study. Green indicates an increase in activity and red a decrease. 








Due to the incidence and cost associated with treating musculoskeletal conditions there has 
been a drive to find novel treatment options from natural sources, as in other areas of 
medicine. This work sought to address this need, by screening marine-organism derived 
extracts for their osteogenic potential, specifically to find an anabolic bioactive that might 
one day be used to promote bone formation in patients; such as those suffering from 
osteoporosis. Other studies have conducted similar work, but due to the sheer number and 
variety of marine species research in this area remains in its infancy; meaning discovery 
potential is high. Furthermore, published studies do not always characterise activity fully – 
for example by leaving out the response of primary cells or not testing extracts/compounds 
in vivo. Whilst impractical to include all measures of in vitro and in vivo activity, this study 
adopted a comprehensive approach, investigating; cytotoxicity, proliferation, differentiation 
and mineralisation in vitro (using a hFOB cell line and primary hBMSCs), as well as bone 
formation and regeneration in vivo (using zebrafish). 
Throughout this work over 100 extracts were screened, with the majority showing little to 
no promising activity. However, powder extracts were identified as a potential source of 
bioactives towards the end of the screening process. Subsequent work demonstrated an 
effective extraction method and the ability of powder extracts to stimulate the activity of 
hBMSCs. This osteogenic potential was retained in vivo upon testing using larval zebrafish, 
with many extracts stimulating increases in operculum area. Main conclusions for each body 




• hFOB use was justified for screening work and an effective seeding 
density of 1 x 104 was chosen.  
• Limitations with PicoGreen assay as a measure of cell proliferation were 
described and crystal violet assay was chosen as replacement.  
• Effective use of crystal violet assay was developed and described.  
• Solvent toxicity: Tween20 was toxic at all concentrations, above 0.1% 
DMSO caused dose-dependent decreases in cell proliferation, ethanol 
was less toxic - though concentrations exceeding 0.5% reduced some 
measures of cell activity.  
• 0.1% DMSO and 0.5 or 1% ethanol were chosen for future work.  
• hBMSCs were chosen to better describe in vitro bioactivity, ethical 
approval was granted for their use and cells were derived from 8 donor 
tissue samples. A 2 x 104 seeding density was chosen for future work 
using these primary cells.  
•  






























• Use of PBS during alkaline phosphatase activity was shown to stop 
detection of ALP activity, likely due to binding of phosphate within the 
buffer to the active site of the enzyme.  
• Various solvent concentrations were tested in the ALP assay, to 
determine effects on activity for both hFOBs and hBMSCs. hBMSCs were 
shown to have the best ALP expression overall.  
• hFOB ability to mineralise was again lower than that of hBMSCs and 
therefore hBSMCs were chosen for future mineralisation work.  
• Various media recipes were tested using the mineralisation assay, with 
50 µg/ml A-2-P, 10 mM β-glycerophosphate and 0.01 µM 
dexamethasone the most effective for hBMSCs. 
Overall: a total of 101 marine-organism derived extracts were tested for their 
osteogenic activity in this project. Many of these extracts were repeat tested, 
often over a range of different concentrations and sometimes using more than 
one solvent.  
Batch of 43 extracts dissolved in DMSO (0.1% concentration): 
• DMSO dissolved extracts were non-toxic, whilst many decreased hFOB 
cell death levels (day 1).  
• In general, DMSO extracts only caused small responses in terms of hFOB 
metabolic activity (day 1), proliferation (day 4, 7) and hBMSC 
differentiation (day 7). Some significant effects were observed, but 
these were not large enough to warrant further investigation.  
Batch of 25 extracts dissolved in ethanol (0.5% concentration): 
• Extract 324 was toxic, but remaining extracts were similar in value to 
control – with only small significant increases/decreases in hFOB cell 
death seen (day 1).  
• No ethanol dissolved extracts notably increased hFOB proliferation, 
though several caused large decreases (day 1). Similarly, of those 
extracts tested, none caused a significant increase in hBMSC 
differentiation (day 7), though several large and significant decreases in 
activity were seen.  
Powder extracts: 
• No toxicity data was presented, as fine particulate matter in powder 
extracts affected results – due to the sensitivity of the LDH assay.  
• hFOB proliferation data (day 1, 4, 7) was presented for 10 powder 
extracts, many of which caused significant increases in cell number. 






























Overall: a total of 17 powder extracts were tested (for at least one activity 
measure) in this section, using hBMSCs. Results were presented for cell 
proliferation, differentiation and mineralisation.  
 
Proliferation: 
• Of those extracts which increased proliferation, those from P. 
lyngbyanum (333), P. cartilagineum (334), C. secundatum (614 ‘in-
house’) and Punctaria sp.(621) were most significant.  
• Remaining extracts either had a limited effect on proliferation or 
decreased it. Of those that caused decreases, extracts from S. muticum 
(840) and C. spongiosus (632) were most significant.  
Differentiation: 
• The majority of extracts caused at least a small increase in ALP activity at 
one concentration, with lower concentrations being particularly active.  
• Large significant increases were seen with extracts from C. secundatum 
(614), Punctaria sp.(621), C. spongiosus (632), C. pallidum (615), B. 
fruticulosa (294) and P. squamatus (1358).  
Mineralisation: 
• Most extracts caused a promotion of hBMSC mineralisation, especially 
at higher concentrations and later timepoints of day 21.  
• Exceptions to this were C. secundatum (614), C. spongiosus (632) and S. 
muticum (840), which had no significant effect on mineralisation levels.  
• ‘In-house’ extractions of P. cartilagineum (334) and C. secundatum  
(614) caused the greatest consistent increase in mineralisation level of 
those extracts tested.   
 
Powder extract potential   Chapter 4 
Overall: a total of 11 powder extracts, dissolved in either water or saline (0.1 M 
NaOH extraction) solution, were tested using an operculum bone growth or 
caudal fin regeneration system.  
 
Operculum bone growth: 
• A preliminary test confirmed that saline solution was not toxic to 
zebrafish larvae at up to 10% concentration.  
• Most powder extracts caused an increase of operculum area, many of 
which were large. Higher extract concentrations had the best effect, 
often exceeding growth seen with the calcitriol positive control.  

















The work presented in this thesis represents the first stage of drug discovery, providing the 
first reported evidence of osteogenic activity in extracts from a range of marine organisms, 
specifically four species of red algae, one species of brown algae and a species of deep sea 
sponge. Further work is now needed to elucidate the bioactive component of each extract 
and understand the mechanisms of in vitro and in vivo activity. Taking Plocamium as an 
example, extracts from this genus promoted a 2-fold proliferation and an 8-fold 
mineralisation increase, compared to control, with as little as 7 µg/ml treatment 
concentration; whilst in vivo operculum growth response was also excellent. Such potent 
activity indicates that this extract, along with others, contains bioactives that may be useful 
in stimulating bone growth in humans. Though this has yet to be confirmed through trials, if 
true such a treatment would likely help to promote bone growth in those suffering from 
conditions such as osteoporosis; allowing increases in bone mineral density, a better quality 
of life and reduced costs for NHS services.   
• Both water and saline dissolved extracts showed potential, though 
activity sometimes differed between the two for extracts from the same 
species – indicating different bioactives were present in each.  
• Extracts from Osmundea sp. (625), S. muticum (840, saline) and P. 
squamatus (1358, saline) showed limited activity.  
Caudal fin regeneration: 
• 12 extracts were tested in the caudal fin regeneration system.  
• Of those extracts tested, there were no significant effects on the degree 
of regeneration or osteogenesis in regenerated caudal fins.  
• Pixel intensity analysis was the only measure to show significant extract 
effects. C. pallidum (615, saline) extract caused a significant reduction in 
low intensity and promotion of high intensity pixels – indicating 
increased bone mineral density. C. secundatum (614, water) extract had 
the opposite effect, indicating reduced bone mineral density.  
• The caudal fin regeneration system was thought to be less sensitive than 
the operculum system, whilst the use of IP injection meant the effective 
concentration over the growth period was also reduced for adults 





6.3 Future work 
Directly related to this project: 
• Chemical analysis: each extract should be tested again via mass spectrometry 
(including negative ionization), using more concentrated solutions to gain a better 
idea of how complex each extract is. Extracts should then be fractionated, using a 
technique such as preparative high performance liquid chromatography (HPLC), 
allowing retesting of each fraction to confirm osteogenic activity. Compounds in each 
active fraction could then be identified, i.e. using mass spectrometry.  
• More extensive re-extraction from fresh algal samples is required to ensure 
reproducibility.  
• After chemical analysis has been completed the mechanisms of action for osteogenic 
activity should be investigated, including gene expression analysis for osteocalcin, 
osteopontin, bone sialoprotein and Cbfa-1/Runx2.  
• Further in vivo testing could include use of several zebrafish based systems/assays to 
further understanding of extract effects in vivo. For example, mutant/transgenic lines 
are available which express pathologies similar to human musculoskeletal 
conditions, such as osteoporosis and osteogenesis imperfecta (Laizé et al. 2014). 
These lines could be used to directly test if extracts are able to alleviate or rescue 
these pathologies. Furthermore, transgenic lines are a powerful reporter of 
osteogenic activity, such as those lines bred to express fluorescent markers like green 
fluorescent protein (GFP) and mCherry at sites of bone formation (Knopf et al. 2011). 
These could give a visual and quantifiable measure of different aspects of osteoblast 
development stimulated by each extract, such as expression of key markers like 
Runx2 and osteocalcin. Finally, one especially interesting method is an ex-vivo model 
using zebrafish scales from sp7:luciferase transgenic adults, where SP7 (osterix) was 
used as an approximation of osteoblast activity (de Vrieze et al. 2015). This model 
showed good conservation of activity from known bioactives and also allowed 
discovery of novel compounds. Furthermore, fish only needed to be anesthetised to 
remove scales rather than killed, whilst scales were easily cultured over a 3-day 
period in 96 well plates – using media to sustain zebrafish osteoblasts. This ex-vivo 
scale based assay therefore represents a good potential option for cheap, rapid and 
accurate screening of many compounds, which could be utilised in future screening 





• Further screening based on phylogenetic analysis. The genera Plocamium and 
Ceramium both had two species which showed activity, indicating other related 
species may also contain bioactives. This work should also include a seasonal and 
geographical component, to see how activity varies based on sample site location; 
following on from the brief investigation of this with P. cartilagineum and C. 
secundatum extracts.   
• Algal extracts often have some degree of antioxidant capabilities and therefore 
powder extracts could be tested for this, for example using the DPPH assay in vitro 
and in zebrafish through exposure to a stressor such as heavy metals or UV radiation.  
 
Recommendations for the field: 
• A greater focus on in vivo testing for promising extracts, to ensure activity is 
maintained within a whole organism.  
• Greater use of hBMSCs, as these give a better indication of how cells will respond 
within the human body.  
• Investigations into the effect of extracts (such as those of this work and similar 
studies) on cell senescence. Cell senescence and osteoporosis are both age related 
and therefore an extract which can reduce senescence, whilst also promoting 
osteogenicity, could be very clinically relevant.  
(Hwang et al. 2016; Y.-S. Cho et al. 2009) (Kim et al. 2015; Pereira et al. 2014)(Chaturvedi et 
al. 2013; Wang et al. 2011a; Moutahir-Belqasmi et al. n.d.; Kim et al. 2012; Brion et al. 2015; 
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         97 Lisburn Road 
         Belfast BT9 7BL 
Patient Information Sheet  
            
Evaluation of Osteogenic Potential of Marine Extracts 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the information below carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not to take part.  
 
About the Study 
We are testing extracts of marine creatures to identify new drugs which might 
have the potential to aid bone healing. An important step in testing these 
extracts is seeing how they affect cells in the laboratory, such as if they grow 
and develop better and to ensure the extracts do not damage the cells. The 
best cells to use for these experiments are cells from human bone marrow 
which have the potential to become osteoblasts. These cells are responsible 
for making bone.  
We are asking you to donate a sample of bone marrow for these laboratory 
experiments to test a number of marine extracts we have collected. As this is 
a common type of research study used in our laboratory, we are also asking 
for your permission to keep any unused cells for future similar studies. If you 
do not consent to this, your cells will be safely disposed of when the experiment 
is completed. 
 
Why have I been chosen? 
Patients who require spinal surgery involving the placement of metal screws 







Do I have to take part? 
No. It is up to you whether to take part or not. If you decide to participate you 
will be asked to sign a consent form. You may withdraw from the study at any 
time by contacting the researcher named at the bottom of this information 
sheet. You do not have to give a reason. If you decide not to take part, this will 
not affect the treatment you receive. 
 
What will happen to me if I take part? 
If you decide to take part in the study you will be asked to sign a consent form 
to allow the surgeon to collect a bone marrow sample during your surgery. 
During the routine placement of screws the bone marrow cavity of the spinal 
vertebrae (bones) is accessed. If you agree to participate approximately 6-8 
mls of bone marrow will be collected through the hole already made for screw 
insertion. The screw will then be inserted as usual. No further access into the 
bone marrow cavity will be necessary. Your surgery will then continue as 
normal.   
 
What is required of me? 
If you decide to participate in the study you will be asked to sign a consent 
form to allow your surgeon to take a bone marrow sample during your surgery. 
No further participation is required by you for this study. You should follow your 
consultant’s instructions as normal following your surgery. 
 
What are the possible risks of taking part? 
There are no additional risks to you above those usually associated with your 
surgery. 
 
What are the possible benefits of taking part? 
Taking part in this study will have no clinical benefit to you and will not affect 
your treatment. The information we get from this study may help us to treat 
patients in the future more effectively.  
 
Confidentiality- who will have access to the data? 
It will be necessary to obtain general information from your hospital notes. This 
information will be accessed only by your clinical team and will be fully 
anonymised before being passed to members of the research team. No 
information that can identify you such as name, address or hospital no will be 






What will happen to my tissue at the end of the research? 
With your consent your tissue may be used for future similar experiments. If 
you do not consent to this then it will only be used for this experiment and when 
the testing is completed, your sample will be destroyed. 
 
What will happen to the results of the research? 
The results will be published in a scientific journal. You will not be identified by 
name in any publication. 
 
Who is organising and funding the research? 
The research is funded by the School of Nursing and Midwifery, Queen’s 
University Belfast in association with NHS R&D Office and a Beaufort Marine 
Research Award with the support of the Marine Institute, Ireland.  
 
Who has reviewed the study? 
The research has been approved by North East-Tyne and Wear South and by 
research governance at Queen’s University Belfast and Belfast Health and 
Social Services Trust. 
 
Contact for further information   
Research: Dr Susan Clarke PhD 02890 97 2171  
 




















Appendix 4 – donor information table 
Donor 
number  
Age BMI  Gender Drugs Co-
morbid 
conditions 
00 1 20 21.3 Male Inhaler Asthma  
00 2 51 24 Male N/A N/A 
00 3 22 24.8 Female N/A N/A 
00 4 38 23.7 Male anti-
epilepsy 
N/A 
00 5 21 28.5 Male N/A N/A 
00 6 38 24.5 Male N/A N/A 
00 7 29 24.7 Male N/A N/A 

















Inclusion: age 18-65, able to consent for self 
Exclusion: rheumatoid arthritis, osteoporosis, other metabolic bone 
diseases, or taking bisphosphonates, long term steroid use and statins 
Table 8.1: containing basic information for each of the 8 bone marrow donors of this study. 
Included is donor number, age, BMI, gender, drugs taken and any co-morbid conditions. Some 
information, such as the date of marrow collection, has been excluded – to ensure the anonymity 






Appendix 5 – ALP assay optimisation 
  
Figure 8.1: results from an alkaline phosphatase assay performed on hFOBs, split for 
convenience between a) and b). Cells were plated at a 1x104 cells/cm2 density, given 24 hours 
to attach and then cultured for 7 days in either complete or osteogenic media. Subsequently, 
cells were lysed via addition of a PBS or Tris buffer containing 0.1 or 0.2% Triton X-100, and 
either kept at room temperature or subjected to 2, 3 or 4 cycles of freeze thaw. Results are 
presented as the mean +/- standard deviation of duplicate values (n=2 or 3), *p<0.05 for 





Appendix 6 – Summary of tested extracts/fractions 
Table 8.2: table showing the extracts tested (ID number), their common name and the 
corresponding genera/species/description of each. A (1) or (2) indicates both extracts were 




Common name Genera/Species/description 
   
 DMSO dissolved extracts  
MR-01 Red algae Bonnemaisonia hamifera 
MR-02 Coastal sponge Porifera demospongiae 
MR-03 Brown algae Bifurcaria bifurcata 
MR-04 Coastal sponge Porifera; Order Poecilosclerida 
MR-05(1) Coastal sea squirt Chordata; Class Ascidiacea 
MR-06 Coastal sponge Halichondria panicea 
MR-07 Red algae Anotrichium barbatum 
MR-08 Star fish Asterias rubens 
MR-09(2) Coastal sea squirt Chordata; Class Ascidiacea 
MR-10 Coastal sponge Haliclona indistincta 
MR-11 Red algae Griffithsia corallinoides 
MR-12 Red algae Bonnemaisonia hamifera 
MR-13 Coastal sponge Porifera; Order Poecilosclerida 
MR-14 Coastal sponge Dictyoceratid sponge 
MR-15 Green algae Ulva linza 
MR-16 Brown algae Cystoseira tamariscifolia 
MR-17 Red algae Polysiphonia elongata 
MR-18 Brown algae Sargassum muticum 
MR-19 Coastal sponge Porifera; Family Suberitidae  
MR-20 Brown algae Desmarestia aculeata 
MR-21 Red algae Polysiphonia stricta 
MR-22 Coastal sponge Polymastia boletiformis 
MR-23 Brown algae Sargassum muticum 
MR-24 Coastal sponge Suberites ficus 





MR-26(1) Tunicate Ascidian; Family Styelidae 
MR-27 Coastal sponge Haliclona simulans 
MR-28(2) Tunicate Ascidian; Family Styelidae 
MR-29 Coastal sponge Haliclona indistincta 
MR-30 Brown algae Cystoseira baccata 
MR-31 Brown algae Desmarestia viridis 
MR-32 Brown algae Desmarestia ligulata 
MR-33 Coral Soft coral 
MR-34 Hydrozoan Hydrozoan 
MR-35 Coastal sponge Sea fan; Paramuricea 
MR-36 Sea star Sea star 
MR-37 Brittle star N/A 
MR-38 Brown algae Cystoseira foeniculacea 
MR-39 Brown algae Cystoseira nodicaulis 
MR-40 Deep sea sponge Lissodendoryx diversichela 
MR-41 Sea cucumber N/A 
MR-42 Sea fan N/A 
 Ethanol dissolved extracts  
87 Star fish N/A 
79 Sea fan N/A 
35 Deep sea sponge Haliclona simulans 
199 Soft coral Soft coral 
146 Sea star Sea star 
1448 Sea star Cushion star fish 
1544 Sea star N/A 
1095 Sea star Sea star 
1133 Sea pen Sea pen 
1359 Sea star Cushion sea star 
1083 Sea fan Phanophathes sp. 
12 Red algae Corallina elongata 
279 Algae (griffithsia) Griffithsia corallinoides 
B1295 Sea star Cushion sea star 








B1693 Deep sea sponge Haliclona indistincta 
614 Red algae Ceramium secundatum 
324 Brown algae Bifurcaria bifurcata 
294 Red algae Boergeseniella fructiculosa 
333 Red algae Plocamium cartilagineum 
625 Red algae Osmundea sp. 
621 Brown algae Ectocarpales (Puncatria) 
632 Sponge Cladostephus spongiosus 
B13568 Coral N/A 













Figure 8.2: cytotoxicity results (LDH assay) for hBMSCs (donor:002, passage:5). Treatments include 
powder extracts dissolved in saline (614, 333 and 625) or water [(621(w) and 625 (w)] solution at 
a range of concentrations. Cells were given a 24 h attachment period, 24 h with treatment and 
then supernatant was collected for testing. Results are presented as the mean+/- standard 
deviation (n=3). C+ve (red) shows the absorbance values for 100% cell death. All values are 
corrected for background absorbance by subtracting appropriate negative control values, run on 
the same plate. Kit positive control confirmed the assay worked on each plate as expected. 
Controls included complete media (C. plain) and complete media with saline solution (1-10%) or 
water (1/5%). Statistical significance: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 







Appendix 8 – operculum system mortality tables   
Note: in chapter 5 results for similar taxa or water/saline treatments of the same extract 
were grouped together. However, this does not reflect the order in which extracts were 














Treatment Treatment Losses/exculsions Total losses
(water) level 24 48 72 Pic day % of population
840 (water) 580 µg/ml 10 100
840 (water) 290 µg/ml 10 100
840 (water) 58 µg/ml 6 60
294 (water) 5% 1 10
294 (water) 0.04% 1 10
C (negative) 10% dH2O 1 10
C (ethanol) 0.1%
C (vitamin D) 10 pg/ml 1 1 20




Treatment Treatment Losses/exculsions Total losses
(Water) level 24 48 72 Pic day % of population
632 400 µg/ml 4 26.7
632 200 µg/ml 1 6.7
1358 160 µg/ml 1 6.7
1358 1.3 µg/ml 1 6.7
1358 0.65 µg/ml 1 6.7
C (negative) 10% dH2O
C (ethanol) 0.1% 1 6.7
C (vitamin D) 10 pg/ml 1 6.7
Mortality (hours with treatment)
No mortality
Table 8.3: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 632 water (C. 
spongiosus) and 1358 water (P. squamatus). For all treatments n=15. See figures 5.15 and 5.16.  
 
Table 8.4: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts.  Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 840 water (S. 

























Treatment Treatment Losses/exculsions Total losses
(saline) level 24 48 72 Pic day % of population
840 760 µg/ml 7 3 100
840 380 µg/ml 2 6 1 90
1358 830 µg/ml 1 10
1358 166 µg/ml 2 20
1358 33 µg/ml 1 10
632 640 µg/ml 1 10
632 320 µg/ml 1 10
C (negative) 10% saline
C (ethanol) 0.1%
C (vitamin D) 10 pg/ml 1 10
Mortality (hours with treatment)
No mortality
No mortality
Treatment Treatment Losses/exculsions Total losses
(water) level 24 48 72 Pic day % of population
614 340 µg/ml 1 6.7
614 140 µg/ml 2 13.3
614 1.4 µg/ml 1 6.7
333 1% 1 6.7
333 0.2% 2 13.3
C (negative) 10% dH2O
C (ethanol) 0.1% 1 6.7
C (vitamin D) 10 pg/ml
Mortality (hours with treatment)
No mortality
No mortality
Table 8.5: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 614 water (C. 
secundatum) and 333 water (P. lyngbyanum). For all treatments n=15. See figures 5.9 and 5.6.  
 
Table 8.6: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 840 saline (S. 
muticum), 1358 saline (P. squamatus), 632 saline (C. spongiosus). For all treatments n=10. See 























Treatment Treatment Losses/exculsions Total losses
(saline) level 24 48 72 Pic day % of population
333 820 µg/ml 1 1 13.3
333 410 µg/ml 1 1 13.3
614  N/A 0
C (negative) 10% saline 0
C (ethanol) 0.15% 0
C (vitamin D) 15 pg/ml 1 6.7
No mortality
Mortality (hours with treatment)
No mortality in any treatment
No mortality
Treatment Treatment Losses/exculsions Total losses
(saline) level 24 48 72 Pic day % of population
334 UK 22 µg/ml 1 6.7
614 Ire 525 µg/ml 1 6.7
614 Ire 105 µg/ml 1 6.7
C (negative) 5% saline 1 6.7
C (ethanol) 0.15% 0
C (vitamin D) 15 pg/ml 0
No mortality
Mortality (hours with treatment)
No mortality
Table 8.7: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 615 water (C. 
pallidum) and 621 water (Punctaria sp.). For all treatments n=15. See figures 5.8 and 5.13.  
 
Table 8.8: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extracts 333 saline (P. 
lyngbyanum) and 614 saline (C. secundatum). For all treatments n=15. See figures 5.9 and 5.6.  
 
Table 8.9: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of UK and Ireland-derived 
extracts 334 saline (P. cartilagineum) and 614 saline (C. secundatum). For all treatments n=15. See 
figures 5.10 and 5.7.  
 
Treatment Treatment Losses/exculsions Total losses
(water) level 24 48 72 Pic day % of population
615 1500 µg/ml 1 1 13.3
615 750 µg/ml 1 6.7
615 150 µg/ml 11 73.3
615 30 µg/ml 1 1 1 20.0
621  N/A
C (negative) 10% dH2O 1 2 1 26.7
C (ethanol) 0.2%
C (vitamin D) 20 pg/ml 1 6.7
No mortality in any treatment
No mortality


















Treatment Treatment Losses/exculsions Total losses
level 24 48 72 Pic day % of population
625 saline 1600 µg/ml 11 1 80
625 saline 800 µg/ml 9 60
625 saline 32 µg/ml 1 6.7
625 water 1200 µg/ml 6 1 1 53.3
625 water 600 µg/ml 1 1 13.3
625 water 120 µg/ml 1 6.7
C (negative) 10% saline
C (ethanol) 0.15%
C (vitamin D) 15 pg/ml 1 6.7
No mortality
Mortality (hours with treatment)
No mortality
Treatment Treatment Losses/exculsions Total losses
(saline) level 24 48 72 Pic day % of population
294 1400 µg/ml 7 2 6 100
294 700 µg/ml 6 40
615 1600 µg/ml 2 13 100.0
615 800 µg/ml 1 1 13.3
C (negative) 10% saline 0
C (ethanol) 0.15% 0
C (vitamin D) 15 pg/ml 0
No mortality
Mortality (hours with treatment)
No mortality
No mortality
Table 8.10: mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extract 294 saline (B. 
fruticulosa) and 615 saline (C. pallidum). For all treatments n=15. See figures 5.11 and 5.8.  
 
Table 8.11 mortality table showing the death of larval zebrafish (tested in the operculum area 
system) during the three-day exposure period to extracts. Mortality is shown at 24, 48 and 72 
hours, as well any losses on the picture day (due to damage during placement for imaging) or 
exclusions of obvious outliers (underlined). Total losses as a % of population are also shown. 
Control treatments are included, as well as varying concentrations of extract 625 in either saline 

















1 P. squamatus 1358 water 
2 P. squamatus 1358 saline 
3 P. cartilagineum 334 Ire saline 
4 P. cartilagineum 334 UK water 
5 P. cartilagineum 334 UK saline 
6 P. cartilagineum 334 Ire water 
7 P. lyngbyanum 333 saline 
8 C. spongiosus 632 water 
9 C. spongiosus 632 saline 
10 C. secundatum 614 saline 
11 C. secundatum 614 water 
12 C. secundatum 614 UK water 
13 C. secundatum 614 Ire water 
14 C. secundatum 614 UK saline 
15 C. secundatum 614 Ire saline 
16 B. fruticulosa 294 saline 
17 S. muticum 840 saline 
18 S. muticum 840 water 
19 Osmundea sp. 625 saline 
20 Punctaria sp. 621 water 
21 C. pallidum 615 water 







Table 8.12: full list of samples analysed via GC-FID. Included is the order they were tested in 
(analysis no.), the species/genus name for each extract along with their extract ID and whether 
the sample was dissolved in water or saline solution. Concentration has not been included as 
extracts were tested in their pure form and concentration was only determined for extracts in 
solution (i.e. culture media or zebrafish water). However, for each extract concentration is likely 







Appendix 10 – samples analysed via mass spec 
  
Analysis no. Species/genus Extract ID Solvent
6 P. cartilagineum 334 Ire Saline
7 C. secundatum 614 Ire Saline
8 C. secundatum 614 UK Saline
9 C. pallidum 615 water
Table 8.13: samples analysed via mass spec in positive ionisation mode. Included is the order they 
were tested in (analysis no.), the species/genus name for each extract along with their extract ID 






Appendix 11 – example GC-FID analysis 
As GC-FID analysis is thought to have only shown impurities, rather than identifiable fatty 


















mode) analysis for 
4 samples: see 
table 7.12. 
 
